Fahrleitner-Pammer Astrid |

Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen

Dimai, HP; Reichardt, B; Zitt, E; Concin, H; Malle, O; Fahrleitner-Pammer, A; Brozek, W Thirty Years of Hip Fracture Incidence in Austria; is the Worst Over?
J BONE MINER RES. 2022; 37: 139-140.-Annual Meeting of the American-Society-for-Bone-and-Mineral-Research (ASBMR); OCT 01-04, 2021; San Diego, CA. [Poster]
Web of Science

 

Fahrleitner-Paammer, A Knochenbruch im Alter
Bezirksärztefortbildung Feldbach ; Mar 29,2022; Feldbach. 2022. [Oral Communication]

 

Fahrleitner-Pammer, A Implantologie und Zahnmedizin.
ÖGI ; Nov 13, 2022; MUG. 2022. [Oral Communication]

 

Fahrleitner-Pammer, A; Starke kncohen für ein langes Leben
Bezirksärztefortbildung ; Jun, 08,2022; Deutschlandsberg. 2022. [Keynote lecture]

 

Fahrleitner-Pammer, A; Osteoporosetherapie- Aus der Praxis für die Praxis
Bezirksärztefortbildung - ÄK Burgenland; Mar 03,2022; Burg Hochschleining. 2022. [Keynote lecture]

 

Fahrleitner-Pammer, A; Osteoporose in der Praxis
Bezirksärztefortbildung Mürzzuschlag ; Mar 10, 2022; Murau. 2022. [Keynote lecture]

 

Fink, A; Fahrleitner-Pammer, A; Seibert, FJ; Puchwein, P; Leithner, A; Bernhardt, GA Retrospektive Studie zum Management von osteoporotischen Hüftfrakturen
Abstractband 1. Österreichischer Kongress für Orthopädie & Traumatologie. 2022; 227--1. Österreichischer Kongress für Orthopädie & Traumatologie; MAY 12-14, 2022; Graz, AUSTRIA. [Oral Communication]

 

Puchwein, P; Fahrleitner-Pammer A Let this fracture be the last
Netzwerktreffen Traumazentren Steiermark ; APR 26, 2022; Graz, AUSTRIA. 2022. [Oral Communication]

 

Bytyqi, K; Baumann, PM; Hochfellner, D; Aberer, F; Simic, A; Treiber, G; Pottler, T; Holl, B; Fahrleitner-Pammer, A; Beck, P; Mader, J Feasibility to use a continuous glucose monitoring system to manage diabetes during hospitalisation
WIEN KLIN WOCHENSCHR. 2021; 133(SUPPL 6):211-212.-49. Jahrestagung ÖDG; NOV 18-20; Salzburg, AUSTRIA. [Poster]
Web of Science

 

Dimai, HP; Reichardt, B; Zitt, E; Concin, H; Malle, O; Fahrleitner-Pammer, A; Svedbom, A; Brozek, W THIRTY YEARS OF HIP FRACTURE IN AUSTRIA; IS THE WORST OVER?
OSTEOPOROSIS INT. 2021; 32(SUPPL 1):S370-S371. [Poster]
Web of Science

 

Hochfellner, DA; Baumann, PM; Aberer, F; Simic, A; Bytyqi, L; Pottler, T; Holl, B; Fahrleitner-Pammer, A; Pieber, TR; Beck, P; Mader, J Basal-bolus Insulin Therapy through an electronic Decision Support System for stationary glycemic Control with Insulin degludec
WIEN KLIN WOCHENSCHR. 2021; 133(SUPPL 6):209-209. [Poster]
Web of Science

 

Langdahl, B; Hofbauer, LC; Ferrari, SL; Wang, Z; Fahrleitner-Pammer, A; Gielen, E; Lakatos, P; Czerwinski, E; Jodar-Gimeno, E; Timoshanko, J; Oates, M; Libanati, C ROMOSOZUMAB EFFICACY AND SAFETY IN EUROPEAN PATIENTS: A SUBANALYSIS OF THE PHASE 3, RANDOMISED FRAME STUDY
OSTEOPOROSIS INT. 2021; 32(SUPPL 1): S45-S46.
Web of Science

 

Malle, O; Borgstroem, F; Svedbom, A; Fahrleitner-Pammer, A; Dimai, SV; Dimai HP Impact on quality of life by osteoporosis treatment after fragility fracture.
Post-hoc analysis of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS), not published yet. 2021; -29. Osteoporoseforum; OKT 14-16, 2021; St. Wolfgang, AUSTRIA. [Poster]

 

Starchl, C; Amrein, K, Dimai, H, Fahrleitner-Pammer, A Osteoporosetherapie in der Covid-Pandemie
Osteologie 2021; Mar; 18-20,2021; Bremen . 2021. [Oral Communication]
FullText

 

Starchl, C; Dimai, H.P.; Amrein, K; Mader, J; Geiger, S; Fahrleitner-Pammer, A. Teriparatide after 38 months of treatment still effective and safe A case report.
ÖGKM-Osteoporoseforum; OKT 14-16, 2021; St. Wolfgang, AUSTRIA. 2021. [Poster]

 

Tmava-Berisha, A; Scherkl, M; Fahrleitner-Pammer, A; Holl, AK; Reininghaus, E.Z.; Amrein K; Kognition und psychiatrische Manifestationen bei chronischem Hypoparathyreoidismus.
1. Impulstagung „Psychische Gesundheit sichtbar machen“; 21.06.2021; Universitätsklinik für Psychiatrie und Psychotherapeutische Medizin, Graz, AUSTRIA;. 2021. [Poster]

 

Fahrleitner-Pammer, A Study Club "Kiefernekrosen-Nutzen und Risiken der antiresorptiven Therapie".
ZFP-ÖZÄK; Feb 6,2020; Billrothgasse 4 . 2020. [Keynote lecture]

 

Fahrleitner-Pammer, A Was tun wenn der Knochen brüchig wird?
Bezirksärztefortbildung Hartberg; Mar 4, 2020; Im museum Hartberg . 2020. [Oral Communication]

 

Haberl, HC; Pottler, T; Hochfellner, D; Aberer, F; Ziko, H; Simic, A; Bytyqi, L; Baumann, P; Samonigg, J; Beck, P; Fahrleitner-Pammer, A; Mader, JK Evaluation of the Sensor Performance of a blinded, professional continuous Glucose Measurement System in hospitalized Female Patients with Type 2 Diabetes.
WIEN KLIN WOCHENSCHR. 2020; 132: S360-S360.-Jahrestagung der österreichischen Diabetesgesellschaft ; [Poster]
Web of Science

 

Haberl, HC; Pottler, T; Hochfellner, DA; Aberer, F; Ziko, H; Bytyqi, L; Baumann, P; Samonigg, J; Beck, P; Fahrleitner-Pammer, A; Mader, JK Assessment of sensor performance of a blinded professional continuous glucose monitoring system in hospitalised patients with type 2 diabetes.
DIABETOLOGIA. 2020; 63(SUPPL 1):S348-S349.-56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD); SEP 21-25, 2020; ELECTR NETWORK. [Poster]
Web of Science

 

Malle, OM; Fahrleitner-Pammer, AF; Dimai, HP IMPACT OF OSTEOPOROSIS TREATMENT ON QUALITY OF LIFE (QOL) AFTER FRAGILITY FRACTURE
OSTEOPOROSIS INT. 2020; 31(SUPPL 1):S429-S429. [Poster]
Web of Science

 

Schatzl, S; Tmava-Berisha, A; Scherkl, M; Kaser, S; Mader, JK; Fahrleitner-Pammer, A; Amrein,K The HypAUS study - First results of an Austrian prospective hypoparathyroidism registry.
22nd European Congress of Endocrinology. 2020; -European Congress of Endocrinology; SEP 5-9, 2020; Bristol, UNITED KINGDOM. [Poster]

 

Verheyen, N; Schmid, J; Kolesnik, E; Bencic, D; Kattnig, L; Scherr, D; Manninger, M; Fruhwald, F; Obermayer-Pietsch, B; Fahrleitner-Pammer, A; Zirlik, A; von Lewinski, D; Ablasser, K Prevalence and determinants of bone disease in patients with chronic heart failure-a prospective cohort study.
WIEN KLIN WOCHENSCHR. 2020; 132: S234-S235. [Poster]
Web of Science FullText

 

Bencic, D; Schmid, J; Fuchsjager, M; Fahrleitner-Pammer, A; Obermayer-Pietsch, B; Pieber, T; Kolesnik, E; Zirlik, A; Fruhwald, F; von Lewinski, D; Ablasser, K; Verheyen, N; Tomaschitz, A; Scherr, D Association between plasma sodium and bone disease in patients with chronic heart failure: a prospective cohort study
J BONE MINER RES. 2019; 34: 357-357.-Annual Meeting of the American-Society-for-Bone-and Mineral Research; SEP 20-23, 2019; Orlando, FL. [Poster]
Web of Science

 

Dimai, HP; Paixao, T; Bertalan, Z; Ljuhar, R; Goetz, C; Ljuhar, D; Nehrer, S; Fahrleitner-Pammer, A Artificial Intelligence (AI) Can Detect Bone Marrow Lesions (BMLs) on Plain Radiographs
J BONE MINER RES. 2019; 34: 199-199.-Annual Meeting of the American-Society-for-Bone-and Mineral Research; SEP 20-23, 2019; Orlando, FL. [Poster]
Web of Science

 

Dimai, HP; Paixao, T; Bertalan, Z; Ljuhar, R; Goetz, C; Ljuhar, D; Nehrer, S; Fahrleitner-Pammer, A; Kurth, A DETECTING BONE MARROW LESIONS ON PLAIN RADIOGRAPHS USING ARTIFICIAL INTELLIGENCE (AI): DATA FROM THE OSTEOARTHRITIS INITIATIVE (OAI) STUDY
OSTEOPOROSIS INT. 2019; 30: S488-S488.-World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO); APR 04-07, 2019; Paris, FRANCE. [Oral Communication]
Web of Science

 

Fahrleitner-Pammer, A; Update Osteologie und Hyperlipidämie
Bezirksärztefortbildung Graz Umgebung; Jan 17th 2019; Unterpremstätten. 2019. [Keynote lecture]

 

Fahrleitner-Pammer, A; Rheumatologie und Knochen - warum jeder Patient individuell therapiert werden muss
Interne Rheumafortbildung; Feb, 11 2019; Graz Austria. 2019. [Keynote lecture]

 

Fahrleitner-Pammer,A; Die Analyse der FRAME und ARCH Studie
Advisory board meeting Wien ; 26.01.2019; Wien. 2019. [Oral Communication]

 

Fahrleitner-Pammer,A, Rheumapatienten & Knochenstoffwechsel
Bezirksärzte Graz; 11.02.2019; Graz. 2019. [Keynote lecture]

 

Geusens, P; Kendler, D; Fahrleitner-Pammer, A; Lopez-Romero, P; Marin, F THE DISTRIBUTION OF PREVALENT AND INCIDENT VERTEBRAL FRACTURES IN THE TERIPARATIDE VERSUS RISEDRONATE "VERO" CLINICAL TRIAL
ANN RHEUM DIS. 2019; 78: 929-930.-Annual European Congress of Rheumatology (EULAR); JUN 12-15, 2019; Madrid, SPAIN. Doi: 10.1136/annrheumdis-2019-eular.808 [Oral Communication] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Malle, O; Bergthaler, M; Muller, C; Krisper, P; Dimai, HP; Kirsch, A; Rosenkranz, A; Pieber, T; Obermayer-Pietsch, B; Fahrleitner-Pammer, A USEFULNESS OF TRABECULAR BONE SCORE IN DIALYSIS PATIENTS
OSTEOPOROSIS INT. 2019; 30: S535-S536.-World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO); APR 04-07, 2019; Paris, FRANCE. [Poster]
Web of Science

 

Malle, O; Bergthaler, M; Muller, C; Krisper, P; Dimai, HP; Kirsch, A; Rosenkranz, A; Pieber, T; Obermayer-Pietsch, B; Fahrleitner-Pammer, A Usefulness of the Trabecular Bone Score in dialysis patients
n/a. 2019; -Osteoporoseforum 2019; MAY 9-11, 2019; St. Wolfgang, AUSTRIA. [Oral Communication]

 

Bertalan, Z; Ljuhar, R; Nehrer, S; Ljuhar, D; Fahrleitner-Pammer, A; Dimai, HP COMBINED FRACTAL- AND ENTROPY-BASED ANALYSIS OF BONE TEXTURE PREDICTS INCIDENT OSTEOARTHRITIS OF THE KNEE: DATA FROM THE MULTICENTER OSTEOARTHRITIS STUDY (MOST)
OSTEOPOROSIS INT. 2018; 29: S245-S245.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; APR 19-22, 2018; Krakow, POLAND. [Oral Communication]
Web of Science

 

Bertalan, Z; Ljuhar, R; Norman, B; Ljuhar, D; Fahrleitner-Pammer, A; Dimai, HP; Nehrer, S COMBINING FRACTAL- AND ENTROPY-BASED BONE TEXTURE ANALYSIS FOR THE PREDICTION OF OSTEOARTHRITIS: DATA FROM THE MULTICENTER OSTEOARTHRITIS STUDY (MOST)
OSTEOARTHR CARTILAGE. 2018; 26: S49-S49.-OARSI World Congress on Osteoarthritis - Promoting Clinical and Basic Research in Osteoarthritis; APR 26-29, 2018; Liverpool, ENGLAND. Doi: 10.1016/j.joca.2018.02.112 [Oral Communication]
Web of Science FullText FullText_MUG

 

Body, JJ; Marin, F; Geusens, P; Zerbini, C; Fahrleitner-Pammer, A; Moericke, R; Casado, E; Stepan, J; Minisola, S; Lespessailles, E; Lopez-Romero, P; Kendler, D Efficacy of Teriparatide Compared With Risedronate on FRAX (R)-defined Major Osteoporotic Fractures: A Post-hoc Analysis of the VERO Clinical Trial
J BONE MINER RES. 2018; 33: 113-113.-Annual Meeting of the American-Society-for-Bone-and-Mineral-Research; SEP 28-OCT 01, 2018; Montreal, CANADA. [Oral Communication]
Web of Science

 

Fahrleitner-Pammer, A Prolia beim älteren Patienten
UKH _ Morgenfortbildung; 30.10.2018; Graz Austria. 2018. [Keynote lecture]

 

Fahrleitner-Pammer, A; Vero - Anabole Therapie bei schwerer Osteoporose
Qualitätszirkel Orthopäden Steiermark ; Apr 3rd 2018; Graz Austria. 2018. [Oral Communication]

 

Fahrleitner-Pammer, A; Osteoporose -ein schleichendes Ungeheuer
Bzirksärztefortbildung in Tobelbad; Nov 8th 2018; Tobelbad. 2018. [Keynote lecture]

 

Fahrleitner-Pammer, A; Transplantationsosteoporose
Osteologie Tagung 2018 ; March 07th - 10th 2018; Dresden , Germany . 2018. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Prolia - Update
Klinikfortbildung LKH Oberwart ; November 5th 2018 ; Oberwart. 2018. [Keynote lecture]

 

Fahrleitner-Pammer, A; Osteoporose Management im Alter
Bezirksärztefortbildung Graz Umgebung; 22.03.2018; Graz Umgebung. 2018. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; Antikörpertherapie bei Hyperlipidämie und Osteoporose
Bezirksärztefortbildung Kapfenberg ; Nov 6th 2018 ; Kapfenberg . 2018. [Keynote lecture]

 

Fahrleitner-Pammer, A; Interaktiver Workshop, hochgradige Osteoporose
Osteologie 2018; March 07th - 10th 2018; Dresden , Germany . 2018. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; CKD-MBD Update 2018
Osteologie 2018 ; March 07th - 10th 2018; Dresden , Germany . 2018. [Keynote lecture]
FullText

 

Fahrleitner-Pammer A; Theardie bei CKD - MBD
Bezirksärztefortbildung ; Jan 30th 2018; Vienna. 2018. [Oral Communication]

 

Fahrleitner-Pammer,A; Preventing the first fracture
Sales training EliLilly ; 16.-18.Jan 2018; Pöllau . 2018. [Oral Communication]

 

Foessl, I; Kotzbeck, P; Francic, V; Haudum, C; Gruselj-Strele, A; Piswanger-Sölkner, CJ; Dobnig, H; Fahrleitner-Pammer, A; Obermayer-Pietsch, B microRNA profiles in diabetic octogenarians with and without historical and prospective hip fractures
20th European Congress of Endocrinology; MAY 19-22, 2018; Barcelona, SPAIN. 2018. [Poster]
FullText

 

Foessl, I; Kotzbeck, P; Francic, V; Haudum, C; Gruselj-Strele, A; Piswanger-Sölkner, CJ; Dobnig, H; Fahrleitner-Pammer, A; Obermayer-Pietsch, B Bone-specific microRNA profiles in elderly diabetes patients with and without prevalent and prospective hip fractures.
ECTS 2018; MAY 26-29, 2018; Valencia, SPAIN. 2018. [Poster]
FullText

 

Foessl, I; Kotzbeck, P; Francic, V; Haudum, C; Gruselj-Strele, A; Piswanger-Sölkner, CJ; Dobnig, H; Fahrleitner-Pammer, A; Obermayer-Pietsch, B; microRNA profiles in diabetic octogenarians with and without historical and prospective hip fractures.
23. Jahrestagung der ÖGES. 2018; APR 5-6, 2017; Linz, AUSTRIA. [Oral Communication]

 

Hadji, P; Marin, F; Kendler, D; Geusens, P; Russo, L; Malouf, J; Lakatos, P; Minisola, S; Lopez-Romero, P; Fahrleitner-Pammer, A Patient Characteristics and Fracture Outcomes in Patients Previously Treated With Bisphosphonates or Treatment-naive in the Teriparatide versus Risedronate VERO Clinical Trial
J BONE MINER RES. 2018; 33: 286-286.-Annual Meeting of the American-Society-for-Bone-and-Mineral-Research; SEP 28-OCT 01, 2018; Montreal, CANADA. [Poster]
Web of Science

 

Ljuhar, R; Bertalan, Z; Nehrer, S; Norman, B; Dimai, HP; Fahrleitner-Pammer, A; Ljuhar, D COMBINING FRACTAL- AND ENTROPY-BASED BONE TEXTURE ANALYSIS FOR THE PREDICTION OF OSTEOARTHRITIS: DATA FROM THE MULTICENTER OSTEOARTHRITIS STUDY (MOST)
ANN RHEUM DIS. 2018; 77: 787-787.-Congress of the European-League-Against-Rheumatism (EULAR); JUN 13-16, 2018; Amsterdam, NETHERLANDS. Doi: 10.1136/annrheumdis-2018-eular.1118 [Oral Communication]
Web of Science FullText FullText_MUG

 

Malle, O; Bergthaler, M; Müller, C; Krisper, P; Dimai, HP; Kirsch, A; Rosenkranz, A; Pieber, T; Obermayer-Pietsch, O; Fahrleitner-Pammer, A Usefulness of the Trabecular Bone Score in dialysis patients
J BONE MINER RES. 2018; 33: 101-101.-Annual Meeting of the American-Society-for-Bone-and-Mineral-Research; SEP 28-OCT 01, 2018; Montreal, CANADA. [Poster]
Web of Science

 

Malle, O; Borgstroem, F; Fahrleitner-Pammer, A; Svedbom, A; Dimai, SV; Dimai, HP Treatment of Osteoporosis
Austrian Bone Conference; OKT 28-29, 2018; Vienna, AUSTRIA. 2018. [Oral Communication]

 

Malle, O; Borgstroem, F; Svedbom, A; Fahrleitner-Pammer, A; Dimai, SV; Dimai, HP Treatment gap after fracture in osteoporosis patients: results of the austrian arm of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)
J BONE MINER RES. 2018; 33: 276-276.-Annual Meeting of the American-Society-for-Bone-and-Mineral-Research; SEP 28-OCT 01, 2018; Montreal, CANADA. [Poster]
Web of Science

 

Malle, O; Borgstroem, F; Svedbom, A; Fahrleitner-Pammer, A; Dimai, SV; Dimai, HP Treatment gap after fracture in osteoporosis patients: results of the austrian arm of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS).
OSTEOPOROSIS INT. 2018; 29: S292-S292.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; APR 19-22, 2018; Krakow, POLAND. [Poster]
Web of Science

 

Minisola, S; Marin, F; Kendler, D; Geusens, P; Zerbini, C; Russo, L; Greenspan, S; Casado, E; Fahrleitner-Pammer, A; Stepan, J; Lespessailles, E; Moericke, R; Bagur, A; Lakatos, P; Lopez-Romero, P; Body, JJ VITAMIN D STATUS AND EFFECTS OF 25-HYDROXYVITAMIN D (25OHD) SERUM LEVELS ON THE RISK OF FRACTURES IN THE TERIPARATIDE VS. RISEDRONATE: VERO CLINICAL TRIAL
OSTEOPOROSIS INT. 2018; 29: S259-S260.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; APR 19-22, 2018; Krakow, POLAND. [Oral Communication]
Web of Science

 

Ulm, S; Fahrleitner-Pammer, A; Pieber, T; Dobnig, H; Sourij, H; Amrein, K Quality of Life and Health Competence in Patients with Diabetes mellitus and other endocrine Diseases
WIEN KLIN WOCHENSCHR. 2018; 130: 360-360. [Poster]
Web of Science

 

Ulm, S; Fahrleitner-Pammer, T; Pieber, T; Dobnig, H; Sourij, H; Amrein, K Lebensqualität und Gesundheitskompetenz bei Diabetes mellitus, sowie weiteren endokrinen Erkrankungen.
46. ÖDG Jahrestagung; 15-17 NOV, 2018; Salzburg, AUSTRIA. 2018. [Poster]

 

Bertalan, Z; Ljuhar, R; Nehrer, S; Ljuhar, D; Fahrleitner-Pammer, A; Dimai, HP Combining fractal- and entropy-based bone texture analysis for the prediction of Osteoarthritis: data from the Multicenter Osteoarthritis study (MOST).
J BONE MINER RES. 2017; 32: S81-S82. [Poster]
Web of Science FullText

 

David W Dempster,1 Nadia Daizadeh,2 Astrid Fahrleitner-Pammer,3 Jens-Erik Beck Jensen,4 David Kendler,5 Ivo Valter,6 Rachel B Wagman,2 Susan Yue,2 Jacques P Brown7 Effect of 10 Years of Denosumab Treatment on Bone Histology and Histomorphometry in the FREEDOM Extension Study
Proceeding of Osteoporosis. 2017; -ANZBMS-IFMRS; 17th - 21st June 2017; Brisbane, Australia. [Oral Communication]

 

Dempster, DW; Daizadeh, N; Fahrleitner-Pammer, A; Jensen, JEB; Kendler, D; Valter, I; Wagman, RB; Yue, S; Brown, JP EFFECT OF 10 YEARS OF DENOSUMAB TREATMENT ON BONE HISTOLOGY AND HISTOMORPHOMETRY IN THE FREEDOM EXTENSION STUDY
OSTEOPOROSIS INT. .. 2017; 28: S63-S64.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; MAR 23-26, 2017; Florence, ITALY. [Poster]
Web of Science

 

Dimai, HP; Krisper, P; Wagner, D; Fahrleitner-Pammer, A TERIPARATIDE TREATMENT IN A HEART TRANSPLANT PATIENT WITH CHRONIC KIDNEY DISEASE AND LOW-TURNOVER BONE DISEASE: A CASE REPORT
OSTEOPOROSIS INT. 2017; 28: S405-S406.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; MAR 23-26, 2017; Florence, ITALY. [Poster]
Web of Science

 

Dimai, HP; Ljuhar, R; Ljuhar, D; Norman, B; Haftner, T; Nehrer, S; Fahrleitner-Pammer, A Fractal-based Assessment of Bone-antiresorptive Treatment Effects at the Lumbar Spine Using Conventional Radiographs; Results from a Pilot Study in a Sub-cohort of Postmenopausal Women who Participated in the FREEDOM Pivotal Trial and its Extension Phase
J BONE MINER RES. 2017; 32: S356-S356. [Poster]
Web of Science FullText

 

Fahrleitner-Pammer, A Metabolische Knochenstoffwechselstörungen
Interne Fortbildung BHB Marschallgasse ; 9.Mar 2017; Graz . 2017. [Oral Communication]

 

Fahrleitner-Pammer, A; Bone diseases in diabetes, Transplantation and renal failure
International Bone Conference ; June 03th - 4th 2017; Madrid Spain . 2017. [Keynote lecture]

 

Fahrleitner-Pammer, A; Die Osteoporose als internistische Erkrankung
Fortbildung KH Wels ; 08. Mar. 2017; Wels . 2017. [Oral Communication]

 

Fahrleitner-Pammer; A Fatal Attraction - why tumor cells are homing to bone
XXVI. Tagung der AGO ; 27.-29.April 2017; Salzburg . 2017. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A, Diagnose und Therapie der Osteoporose - wenn antiresorptiv nicht reicht
Bezirksärztefortbildung Anif Salzburg ; Oct 17Th 2017; salzburg . 2017. [Oral Communication]

 

Fahrleitner-Pammer, A; When Antiresorptives are not enough
Morning meeting Melbourne University Hospital ; June 14th 2017; Melbourne . 2017. [Oral Communication]

 

Fahrleitner-Pammer, A; Metabolische Knochenstoffwechselstörung
Osteoporose Workshop 2017 ; 3. Mai 2017; Ludersdorf . 2017. [Oral Communication]

 

Fahrleitner-Pammer, A; Osteoporose - Zielgerichtete Therapie durch gute Diagnostik und Therapie
Synlab - Fortbildung Hamburg ; Sep 6th 2017; Hamburg . 2017. [Oral Communication]

 

Fahrleitner-Pammer, A; How to treat our patients right
Dinner Meeting - waterfront Sydney ; June 15Th 2017; Sydney . 2017. [Keynote lecture]

 

Fahrleitner-Pammer, A; Osteoanabole Therapie im Wandel der Zeit
25. Osteoporoseforum ; Apr 20. - 22. 2017; St. Wolfgang Österreish . 2017. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Sequenztherapie bei Osteoporose
Osteologie 2017 ; 21th - 24th March , 2017; Erlangen . 2017. [Oral Communication]

 

Fahrleitner-Pammer, A; MOA - Antiresorptiveas versus Anabolics
Lunch meeting - brisbane University Hospital Brisbane ; 16th June 2017 ; Brisbane , Australia . 2017. [Keynote lecture]

 

Fahrleitner-Pammer, A; Metabolic Bone Disease
International Bone Academy Madrid ; 2nd- 3rd June 2017 ; Madrid , Spain, . 2017. [Oral Communication]

 

Fahrleitner-Pammer, A; Who to decide who to treat with anabolic versus antiresorptives
Dinner meeting, ; June 14th 2017; Melbourne, Australia. 2017. [Oral Communication]

 

Fahrleitner-Pammer, A; MOA of Teriparatide
Lunch Meeting Geelong ; Hospital meeting Geelong ; Geelong Australia . 2017. [Oral Communication]

 

Fahrleitner-Pammer A, Kendler DL, Zerbini C, Russo L, Greenspan S, Zikan V, Bagur A, Malouf J, Lakatos P, Lespessailles E, Minisola S, Body JJ, Geusens P, Moericke R, López-Romero P, Marin F Effects of 24 Months Treatment of Teriparatide Compared with Risedronate on New Fractures in Postmenopausal Women with Severe Osteoporosis:A Randomized, Double-Dummy, Clinical Trial(VERO Trial)
Proceeding of Osteoporosis . 2017; -ANZBMS-IFMRS; 17th - 21st June 2017; Brisbane Australia . [Oral Communication]

 

Fahrleitner-Pammer,A Frakturmanagement - interdisziplinär.
Morgenfortbildung Orthopädie ; Oct 11th 2017; UKIM, graz, austria. 2017. [Keynote lecture]

 

Fahrleitner-Pammer,A; Recent Evidence on the Mechanisms of Action of Osteoporosis Drugs with Histomorphometry
ANZBMS-IFMRS; June 19th 2017 ; Brisbane, Australia. 2017. [Keynote lecture]

 

Fahrleitner-Pammer,A; Wenn antitresorptiv nicht reicht - TBS zeigt uns wann?
Gynäkologie Stammtisch ; 5Th April 2017; Graz . 2017. [Oral Communication]

 

Fahrleitner-Pammer,A; Bone Academy Graz - Damit aus einem Sturz kein schwerer Fall wird
Bone Academy 2017 Graz ; Sep 20th 2017 ; graz. 2017. [Keynote lecture]

 

Fahrleitner-Pammer,A; Osteoporosetherapie bis ins hohe Alter
Männerfortbildung zur Osteoporose - KLIMAx; 14.01.2017; Wien . 2017. [Oral Communication]

 

Fahrleitner-Pammer,A; Hypophasphatasie die heimliche Krankheit
25. Osteoporoseforum ; 20. - 22.05.2017; St. Wolfgang . 2017. [Oral Communication]
FullText

 

Fahrleitner-Pammer,A; MOA of Teriparatide
Lunch meeting Sydney memorial Meeting ; June 15Th 2017; Sydney, Australia. 2017. [Keynote lecture]

 

Fahrleitner-Pammer,A; CKD-MBD - Indikationen zur Beckenkammbiopsie
Fortbildung LKH Bruck ; 13. Mar 2017; LKH Bruck . 2017. [Oral Communication]

 

Fahrleitner-Pammer,A; Sequenztherapie in der Osteoporose
4. nationaler Osteoporose Workshop; 27. - 28.01.2017; Wien . 2017. [Oral Communication]

 

Fahrleitner-Pammer,A; Long-term management of osteoporosis
44th European Calcified Tissue Society Congress; May 13th-16th 2017; Salzburg . 2017. [Oral Communication]
FullText

 

Fahrleitner-Pammer,A; Therapie der Osteoporose -State of the art
Medizin im Museum ; Oct 14th 2018 ; Wien . 2017. [Oral Communication]

 

Geusens, P; Marin, F; Kendler, DL; Russo, L; Zerbini, CAF; Greenspan, S; Minisola, S; Bagur, A; Lakatos, P; Casado, E; Fahrleitner-Pammer, A; Stepan, J; Lespessailles, E; Moericke, R; Body, JJ; Lopez-Romero, P Teriparatide Compared with Risedronate and the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.
J BONE MINER RES. 2017; 32: S22-S22. [Oral Communication]
Web of Science FullText

 

Kendler, DL; Zerbini, C; Russo, L; Greenspan, S; Zikan, V; Bagur, A; Malouf, J; Lakatos, P; Fahrleitner-Pammer, A; Lespessailles, E; Minisola, S; Body, JJ; Geusens, P; Moericke, R; Lopez-Romero, P; Marin, F EFFECTS OF 24 MONTHS TREATMENT OF TERIPARATIDE COMPARED WITH RISEDRONATE ON NEW FRACTURES IN POSTMENOPAUSAL WOMEN WITH SEVERE OSTEOPOROSIS: A RANDOMIZED, DOUBLE-DUMMY, CLINICAL TRIAL
OSTEOPOROSIS INT. .. 2017; 28: S69-S70.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; MAR 23-26, 2017; Florence, ITALY. [Poster]
Web of Science

 

Ljuhar, R; Dimai, HP; Ljuhar, D; Hladuvka, J; Mai, MBT; Canhao, H; Branco, J; Rodrigues, AM; Gouveia, N; Fahrleitner-Pammer, A; Nehrer, S A NOVEL COMBINATION OF BONE MICRO-ARCHITECTURE DESCRIPTORS FOR THE IDENTIFICATION OF OSTEOARTHRITIS
RHEUMATOLOGY. 2017; 56: 163-163.-Rheumatology Conference; APR 25-27, 2017; Birmingham, ENGLAND. [Oral Communication]
Web of Science

 

Ljuhar, R; Haftner, T; Bertalan, Z; Ljuhar, D; Fahrleitner-Pammer, A; Dimai, HP; Nehrer, S A NOVEL METHOD FOR IDENTIFYING RADIOGRAPHIC BASELINE RISK OF OSTEOARTHRITIS USING AN ANISOTROPY-BASED TEXTURE ANALYSIS ALGORITHM: DATA FROM THE OSTEOARTHRITIS INITIATIVE
ANN RHEUM DIS. 2017; 76: 1423-1423.-Annual European Congress of Rheumatology; JUN 14-17, 2017; Madrid, SPAIN. Doi: 10.1136/annrheumdis-2017-eular.5860 [Poster]
Web of Science FullText FullText_MUG

 

Ljuhar, R; Haftner, T; Ljuhar, D; Norman, B; Fahrleitner-Pammer, A; Dimai, HP; Hladuvka, J; Nehrer, S A NOVEL METHOD FOR IDENTIFYING RADIOGRAPHIC BASELINE RISK OF OSTEOARTHRITIS USING AN ANISOTROPY-BASED TEXTURE ANALYSIS ALGORITHM: DATA FROM THE OSTEOARTHRITIS INITIATIVE
OSTEOARTHR CARTILAGE. .. 2017; 25: S263-S263.-World Congress of the Osteoarthritis-Research-Society-International (OARSI) on Osteoarthritis; APR 27-30, 2017; Las Vegas, NV. Doi: 10.1016/j.joca.2017.02.443 [Poster]
Web of Science FullText FullText_MUG

 

Malle, O; Maurer, D; Wagner, D; Schnedl, C; Amrein, S; Pieber, TR; Fahrleitner- Pammer, A; Dimai, HP; Dobnig, D; Amrein, K MORPHOMETRISCHE PARAMETER VON MUSKEL UND KNOCHEN BEI KRITISCH KRANKEN - POSTHOC-ANALYSE DER VITdAL-ICU STUDIE
Wiener Klinische Wochenschrift Supplement. 2017. 2017; -Wiener Intensivmedizinische Tage 2017; FEB 15-18, 2017; Vienna, Austria. [Oral Communication]

 

Paschalis, E; Krege, J; Gamsjaeger, S; Eriksen, E; Burr, D; Disch, D; Stepan, J; Fahrleitner-Pammer, A; Klaushofer, K; Pavo, I DEXA areal BMD Measurement Underestimates the Bone Forming Effects of Teriparatide.
J BONE MINER RES. 2017; 32: S272-S272. [Poster]
Web of Science FullText

 

Zach, M; Fahrleitner-Pammer, A; Dimai, HP; Trummer, C; Pieber, TR; Amrein, K EINSCHRÄNKUNG VON LEBENSQUALITÄT UND ARBEITSFÄHIGKEIT BEI HYPOPARATHYREOIDISMUS
Journal für Klinische Endokrinologie und Stoffwechsel - Austrian Journal of Clinical Endocrinology and Metabolism - Supplement. 2017; -Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel (ÖGES); MAR 22-24, 2017; Linz, AUSTRIA. [Oral Communication]

 

Zerbini, CAF; Geusens, P; Lespessailles, E; Body, JJ; Casado, E; Stepan, J; Kendler, DL; Russo, L; Greenspan, SL; Minisola, S; Bagur, A; Lakatos, P; Fahrleitner-Pammer, A; Moricke, R; Lopez-Romero, P; Marin, F Teriparatide Compared with Risedronate and the Risk of Clinical Vertebral Fractures: 2-Year Results of a Randomized, Double-Dummy Clinical Trial
ARTHRITIS RHEUMATOL. .. 2017; 69: [Poster]
Web of Science

 

Amrein, K; Schnedl, C; Verheyen, N; Schwetz, V; Pieber, TR.; Fahrleitner-Pammer, A; Dobnig H FGF-23 as a novel predictor of hospital mortality in critically ill patients
Endocrine Reviews, Supplement. 2016; -ENDO16; APR 1-4, 2016; Boston, USA. [Poster]

 

Bone, H; Brandi, ML; Brown, J; Chapurlat, R; Cummings, S; Czerwinski, E; Fahrleitner-Pamer, A; Kendler, D; Lippinur, K; Reginster, JY; Vittinghoff, E; Daizadeh, N; Wang, A; Dakin, P; Wagman, R; Papapoulos, S Ten Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results from the FREEDOM Extension Trial
J RHEUMATOL. 2016; 43(6):1209-1209.-Canadian-Rheumatology-Association Meeting; FEB 17-20, 2016; Alberta, CANADA. [Oral Communication]
Web of Science

 

Bone, HG; Brandi, ML; Brown, JP; Chapurlat, R; Cummings, SR; Czerwinski, E; Fahrleitner-Pammer, A; Kendler, DL; Lippuner, K; Reginster, JY; Vittinghoff, E; Daizadeh, NS; Wang, A; Dakin, P; Wagman, RB; Papapoulos, SE TEN YEARS OF DENOSUMAB (DMAB) TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FREEDOM EXTENSION TRIAL
OSTEOPOROSIS INT. 2016; 27: S135-S136.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; APR 14-17, 2016; Malaga, SPAIN. [Oral Communication]
Web of Science

 

Fahrleitner-Pammer,; Neues in der Osteologie - ASBMR Update
Fortbildungsabend KH der Elisabthinen ; Sep 29th 2016; Klagenfurt. 2016. [Oral Communication]

 

Fahrleitner-Pammer, A, When anabolic treatment is not enough
24. osteoporoseforum ; 21. - 23.04 2016; St. Wolfgang . 2016. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; Der Knochen als interdisziplinäres Organ
Bezirksärztefortbildung ; 24.11.2016 ; Skybar Graz. 2016. [Oral Communication]

 

Fahrleitner-Pammer, A; Knochenstoffwechsel von Adynam bis Anabol
29. Gynäkologische Winterfortbildung ; 21. - 28.01.2016; Lech . 2016. [Oral Communication]

 

Fahrleitner-Pammer; A TBS - die Bedeutung in der Ostgeologie für den operativ tätigen Osteologen
Qualitätszirkel; 05.07.2016; Graz. 2016. [Oral Communication]

 

Fahrleitner-pammer, A; 3. Nationaler Osteoporose Workshop
3. Nationaler Osteoporose Workshop ; 11.03. - 12.03.2016; Baden bei Wien. 2016. [Keynote lecture]

 

Fahrleitner-Pammer, A; Die Knochenbruchkrankheit
Orthopädenfachgruppensitzung ; Nov, 11,2016; Graz . 2016. [Oral Communication]

 

Fahrleitner-Pammer, A; Warum braucht das Skelett Densoumab?
Urologische Fortbildung LKH Oberwart ; Nov 21st, 2016; Oberwart . 2016. [Oral Communication]

 

Fahrleitner-Pammer, A; Mangement des primären Hyperparathyreodismus
Ärztetage Grado ; May 22Th - 28th 2016; Grado, Italy. 2016. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Management der Osteoporose - Update 2016
; May, 23th 2016; Bad Aussee. 2016. [Keynote lecture]

 

Fahrleitner-Pammer, A; Hypophosphatasie
Proceedimgs of Hypophospahtasie. 2016; -Internationales Advisorybord; 20.04.2018 ; Wien . [Oral Communication]

 

Fahrleitner-Pammer, A; Update in der Osteologie
Ärztekammer Fortbildung ; September 26th 2016; Graz. 2016. [Oral Communication]

 

Fahrleitner-Pammer, A; Hypophosphatasie
Wiener Rathaustag; 14.10.2016; Wien. 2016. [Oral Communication]

 

Fahrleitner-Pammer, A; OsteoporoseWorkshop national
3: iNTERDISZIPLINÄRER oSTEOPOROSE wORKSHOP ; 11.03-13.03.2016; Wien. 2016. [Keynote lecture]

 

Fahrleitner-Pammer; A, Update in Diagnosis and therapy in postmenopausal osteoporosis
Refresher in gynaecology ; Nov, 10th,2016; Vienna. 2016. [Oral Communication]

 

Fahrleitner-Pammer; A, Why antiresorptive therapy is sometimes not enough
National osteoporosis Society ; Nov 4th- 7th,2016; Birmingham, UK . 2016. [Oral Communication]

 

Fahrleitner-Pammer; A: Treatment goals in Osteoporosis
Efort Symposium ; June 1st - 4th ; Geneve . 2016. [Oral Communication]
FullText

 

Fahrleitner-Pammer,A; Hormone für den Knochen
29. Gynäkologische Fortbildungstage ; 21. - 28.01.2016; LECH . 2016. [Oral Communication]

 

Fahrleitner-Pammer,A; Der RANKL Antikörper als Schlüssel zur logisch/biologischen Therapieoption in der Osteologie und Onkologie.
Fachgruppentagung Urologen ; 05.10.2016; Graz . 2016. [Oral Communication]

 

Fahrleitner-Pammer,A; Was gibt's Neues in der Osteoporose
Fortbildung BHB Eggenberg ; 04.02.2016; Graz. 2016. [Oral Communication]

 

Fahrleitner-Pammer,A; Die AVA-Studie - Implication in der täglichen Routine
MediaMed Consulting; 07.10.2016; Wien. 2016. [Oral Communication]

 

Fahrleitner-Pammer,A; Warum Antiresorptiv nicht immer reicht
Bezirksärztefortbildung LKH Feldbach; 20.10.2016; Feldbach . 2016. [Oral Communication]

 

Fahrleitner-Pammer,A; Hot Topics in der Osteologie
Menopause Andropause - Anti-Aging 2016 ; 7. - 10- Dezember 2016 ; Wien . 2016. [Oral Communication]

 

Fahrleitner-Pammer,A; Morbus Cushing - die endokrine Adipositas
Ärztetage Grado; may 22Th - 28th 2016; Grado, italy. 2016. [Oral Communication]
FullText

 

Fahrleitner-Pammer,A; Warum braucht das weibliche Skelett Denosumab?
Gynäkologie Stammtisch ; 02.11.2016; Graz . 2016. [Oral Communication]

 

Fahrleitner-Pammer,A; Hands on on osteoporose
Bezirksärztefortbildung; 03.02.2016; Bad Waltersdorf. 2016. [Oral Communication]

 

Fahrleitner-Pammer,A; Warum Antiresorptiv nicht immer reicht
Klinischer Roundtable; 20.10.2016; LKH Feldbach . 2016. [Oral Communication]

 

Fahrleitner-Pammer,A; Damit aus einem leichten Sturz kein schwerer Fall wird
Bone Academy; 20.10.2016; Graz . 2016. [Oral Communication]

 

Gilg, MM; Wibmer, C; Amrein, K; Fahrleitner-Pammer, A; Berghold, A; Ferstl-Rohrbacher, A; Maurer-Ertl, W; Gerger, A; Leithner, A; Pichler, M; Szkandera, J Serum sclerostin levels in renal cell carcinoma patients with bone metastases.
Abstracts of EMSOS 2016. 2016; -29th Annual Meeting of the European Musculo-Skeletal Oncology Society; MAY 25-27, 2016; La Baule, FRANCE. [Poster]

 

Kern, K; Schwetz, V; Trummer, C; Dimai, HP; Fahrleitner-Pammer, A; Obermayer-Pietsch, B; Pieber, TE; Amrein, K Hypoparathyreoidismus - retrospektive Beobachtungsstudie
Osteologie 2016; 25:1-56. 2016; -OSTEOLOGIE 2016; MAR 3-5; Essen, GERMANY. [Poster]

 

Ljuhar, R, Dimai,HP; Fahrleitner-Pammer.A; Ljuhar, D; Norman, B; Hladuvka, J. A novel method for the assessment of Joint space width and subchondral bone micro architecture.
Osteologie. 2016; 1/2016(1):A4-A5.-Osteologie ; 03. - 05. März 2016; ESSEN, Deutschland. [Oral Communication]
FullText

 

Ljuhar, R; Norman, B; Ljuhar, D; Haftner, T; Hladuvka, J; Canhao, H; Branco, J; Rodrigues, A; Gouveia, N; Nehrer, S; Fahrleitner-Pammer, A; Dimai, HP A NOVEL METHOD FOR THE ASSESSMENT OF KNEE JOINT SPACE WIDTH AND SUBCHONDRAL BONE MICRO ARCHITECTURE
OSTEOARTHR CARTILAGE. 2016; 24: S379-S379. Doi: 10.1016/j.joca.2016.01.677 [Oral Communication]
Web of Science FullText FullText_MUG

 

Ljuhar, R; Norman, B; Ljuhar, D; Haftner, T; Hladuvka, J; Mai, PBT; Canhao, H; Branco, J; Rodrigues, AM; Gouveia, N; Nehrer, S; Fahrleitner-Pammer, A; Dimai, HP A CLINICAL STUDY TO EXAMINE THRESHOLDS OF JOINT SPACE WIDTH AND JOINT SPACE AREA FOR IDENTIFICATION OF KNEE OSTEOARTHRITIS
OSTEOPOROSIS INT. 2016; 27: S488-S489.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; APR 14-17, 2016; Malaga, SPAIN. [Oral Communication]
Web of Science

 

Ljuhar, R; Norman, B; Ljuhar, D; Haftner, T; Hladuvka, J; Mai, PBT; Canhao, H; Branco, J; Rodrigues, AM; Gouveia, N; Nehrer, S; Fahrleitner-Pammer, A; Dimai, HP A NOVEL FEATURE SELECTION ALGORITHM BASED ON BONE MICROARCHITECTURE ANALYSIS TO IDENTIFY OSTEOARTHRITIS
OSTEOPOROSIS INT. 2016; 27: S426-S427.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; APR 14-17, 2016; Malaga, SPAIN. [Oral Communication]
Web of Science

 

Muschitz, C; Kocijan, R; Haschka, J; Pahr, D; Hans, D; Kaider, A; Fahrleitner-Pammer, A; Resch, H; TBS reflects trabecular microarchitecture in premenopausal women and similarly aged men with low traumatic fractures.
Osteologie. 2016; 1/2016(1):V18-V18.-Osteologie; 03. - 05. März 2016; ESSEN, Deutschland. [Oral Communication]
FullText

 

Muschitz, CM; Kocijan, R; Haschka, J; Pahr, DP; Kaider, AK; Hans, DH; Fahrleitner-Pammer, A; Resch, HR TBS REFLECTS TRABECULAR MICROARCHITECTURE IN PREMENOPAUSAL WOMEN AND SIMILARLY AGED MEN WITH LOW TRAUMATIC FRACTURES
OSTEOPOROSIS INT. .. 2016; 27: S80-S81.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; APR 14-17, 2016; Malaga, SPAIN. [Poster]
Web of Science

 

Trummer, C; Kern, M; Schwetz, V; Wolf, G; Bradatsch, A; Fahrleitner-Pammer, A; Pieber, TR; Dobnig, H; Amrein, K Hypoparathyroidism - results from a large Austrian cohort.
DACH-Tagung 2016 der DGE, ÖGES und SGED; MAY 26-28, 2016; Munich, GERMANY. 2016. [Poster]

 

Verheyen, N; Dimai, HP; Fahrleitner-Pammer, A; Pilz, S; Tomaschitz, A; High bone turnover is independently related with left ventricular stiffness in primary hyperparathyroidism - the EPATH Trial.
Osteologie. 2016; 1/2016(1):A5-A6.-Osteologie ; 03. - 05. März 2016; ESSEN, Deutschland. [Oral Communication]
FullText

 

Verheyen, N; Dimai, HP; Fahrleitner-Pammer, A; Pilz,S; Tomaschitz, A; Effects of mineral corticoid receptor antagonism on markers of bone turnover in patients with primary hyperparathyroidism- the EPATH Trial
Osteologie. 2016; 1/2016(1):A35-A35.-Osteologie; 03. - 05. März 2016; Essen, Deutschland. [Poster]
FullText

 

Verheyen, N; Grubler, M; Fahrleitner-Pammer, A; Pilz, S; Tomaschitz, A; Marz, W Plasma parathyroid hormone is independently associated with atrial fibrillation - Insights from the LURIC study
WIEN KLIN WOCHENSCHR. 2016; 128: S307-S308. [Poster]
Web of Science

 

Verheyen, N; Meinitzer, A; Ablasser, K; Fahrleitner-Pammer, A; Brussee, H; Pilz, S; Tomaschitz, A Serum kynurenine, quinolinic acid and cardiac stiffness parameters: the eplerenone in primary hyperparathyroidism study
WIEN KLIN WOCHENSCHR. 2016; 128: S308-S308. [Poster]
Web of Science

 

Wetzel, J; Pilz, S; Gruebler, M; Fahrleitner-Pammer, A; Dimai, HP; Von Lewinski, D; Kolesnik, E; Perl, S; Weinrauch, V; Maerz, W; Belyavskiy, E; Pieske, B; Brussee, H; Tomaschitz, A; Verheyen, N Parathyroid hormone is independently associated with systolic blood pressure, pulse wave velocity and left ventricular mass index in patients with primary hyperparathyroidism
EUR HEART J. 2016; 37: 417-417.-Congress of the European-Society-of-Cardiology (ESC); AUG 27-31, 2016; Rome, ITALY. [Poster]
Web of Science

 

Bilezkian, JP; Benhamou, CL; Lin, CJF; Brown, JP; Fahrleitner-Pammer, A; Franek, E; Gilchrist, N; Simon, JA; Valter, I; Peters, K Denosumab restores cortical bone loss at the distal radius associated with aging and reduces wrist fracture risk: analyses from the FREEDOM extension cross-over group
AUSTRALAS J AGEING. . 2015; 34: 65-65. [Oral Communication]
Web of Science

 

Fahrleitner-Pammer, A Reparieren statt konservieren
Ortopädenschulung; 17.Jänner 2015; Schloss Pichlarn Irdning. 2015. [Keynote lecture]

 

Fahrleitner-Pammer, A Schwangerschaft und Osteoporose
29. Gynäkologie Winterfortbildung; 24. - 31.01.2015; Oberlech, Vorarlberg. 2015. [Oral Communication]

 

Fahrleitner-Pammer, A Auch Männer brauchen Schutz
Osteologie; 12.-14 März 2015; Berlin, Germany. 2015. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A Schilddrüse und Schwangerschaft
29. Gynäkologie Wintertagung; 24. - 31.01.2015; Oberlech, Vorarlberg. 2015. [Oral Communication]

 

Fahrleitner-Pammer, A; When Anabolics are not enough
Osteoporos International. 2015; 26(Suppl ):256-256.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; 26th and 29th March 2015; Milan Italy. [Oral Communication]

 

Fahrleitner-Pammer, A; Amrein, K; Prenner, G; Dimai, HP; Wagner, D; EFFECTS OF TESTOSTERONE REPLACEMENT THERAPY IN HYPOGONADAL CARDIAC TRANSPLANT PATIENTS
Osteoporosis International. 2015; 26(Suppl ):70-497.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; 26th and 29th March 2015; Milan, ITALY. [Poster]

 

Fahrleitner-Pammer,A Parathormon - die zwei Gesichter
GSAAM; April 30-May 02; München, Gasteig. 2015. [Oral Communication]

 

Fahrleitner-Pammer,A; Bilezikian, JP; Benhamou, CL; Lin, CJF; Brown, J.P; Daizadeh, NS; Ebeling, P; Franek, E; Gilchrist, N; Miller, PD; Simon, JA; Valter, I; Zerbini, CAF; Libanati, C; Denosumab reversiert altersbedingten kortikalen Knochenverlust am distalen Radius und senkt das Frakturrisiko: Analysen der Freedom -Verlängerungsstudie
Osteologie . 2015; 2015(1):A7-A8.-Osteologie; 12.-14. März 2015; Berlin, Germany. [Oral Communication]
FullText

 

Maurer-Ertl, W; Friesenbichler, J; Maier, M; Pirker-Frühauf, U; Wagner, D; Pieber, T; Leithner, A; Fahrleitner-Pammer, A; Amrein, K Mangan im Knochen und Serum: Vergleich osteoporotischer versus nicht osteoporotischer Knochen.
Jatros Orthopädie & Rheumatologie 2015 . 2015; 20(5):117-117.-32. Jahrestagung der Österreichischen Gesellschaft für Orthopädie und orthopädische Chirurgie; OCT 29-31, 2015; Vienna, AUSTRIA. [Oral Communication]

 

Mueller, C; Krisper,P; Beckmann, B.B; Orthmayr, M.O; Rosenkranz, A; Pieber,T; Fahrleitner-Pammer, A; Knochengesundheit bei dialysepflichtiger Niereninsuffizienz
Osteologie 2015;24:1-62. 2015; 1: -Osteology ; 12th - 14th March 2015; Berlin, Germany. [Poster]
FullText

 

Mueller, C; Krisper,P; Dimai, HP; Amrein, K; Beckmann,BB; Orthmayr, MO; Kirsch, A; Rosenkranz, A; Fahrleitner-Pammer, A. BONE HEALTH IN DIALYSIS PATIENTS
OSTEOPOROSIS International. 2015; 26(suppl ):70-380.-WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; 26th and 29th March 2015; Milan, ITALY. [Oral Communication]
FullText

 

Verheyen, N; A. Fahrleitner-Pammer, C. Catena, E. Belyavskiy, J Martensen, J. Wetzel, M. Gaksch, M.R. Grübler, A. Meinitzer, B. Pieske, S. Pilz, A. Tomaschitz Effects of Mineralocorticoid Receptor Antagonism on Markers of Bone Turnover in Patients with Primary Hyperparathyroidism – the EPATH Trial.
J Bone Miner Res 30 (Suppl 1). 2015; -ASBMR Annual Meeting; OKT 9-12, 2015; Seattle, USA. [Poster]

 

Verheyen, N; Fahrleitner-Pammer, A; Catena, C; Belyavskiy, E; Martensen, J; Wetzel, J; Gaksch, M; Grübler, MR; Meinitzer, A; Pieske, B; Pilz, S; Tomaschitz, A High Bone Turnover is Independently Related with Left Ventricular Stiffness in Primary Hyperparathyroidism – the EPATH Trial.
J Bone Miner Res 30 (Suppl 1). 2015; -ASBMR Annual Meeting; OKT 9-12, 2015; Seattle, USA. [Poster]

 

Verheyen, N; Fahrleitner-Pammer, A; Gaksch, M; Grübler, MR; Schmid, J; Wetzel, J; Martensen, J; Belyavskiy, E; Kraigher-Krainer, E; Pieske, B; Pilz, S; Tomaschitz, A Gender Differences in the Biochemical Profile of Primary Hyperparathyroidism - the EPATH Study
J MINER STOFFWECHS 2014; 21 (SONDERHEFT 1). 2015; -Wissenschaftliche Herbsttagung der ÖGKM; NOV 14-15, 2014; Vienna, Austria. [Poster]

 

Verheyen, N; Fahrleitner-Pammer, A; Pilz, S; Tomaschitz, A Association of Plasma Parathyroid Hormone with Nighttime Blood Pressure in Primary Hyperparathyroidism
25th European Meeting on Hypertension and Cardiovascular Protection; JUN 12-15, 2015; Milano. 2015. [Oral Communication]

 

Verheyen, N; Wetzel, J; Martensen, J; Belyavskiy, E; Schmidt, A; Colantonio, C; Catena, C; Gaksch, M; Grübler, MR; Kraigher-Krainer, E; Pieske, B; Meinitzer, A; Rus-Machan, J; Fahrleitner-Pammer, A; Pilz, S; Tomaschitz, A 9B.05: ASSOCIATION OF PLASMA PARATHYROID HORMONE WITH NIGHTTIME BLOOD PRESSURE IN PRIMARY HYPERPARATHYROIDISM-THE "EPLERENONE IN PRIMARY HYPERPARATHYROIDISM" TRIAL.
J Hypertens. . 2015; 33 Suppl 1(10):e121-e121. Doi: 10.1097/01.hjh.0000467677.24307.ad [Oral Communication]
Web of Science PubMed FullText FullText_MUG

 

Amrein K, Drexler C, Oczko S, Sareban N, Sipurzynski S, Pieber TR, Lanzer G, Wagner D, Fahrleitner-Pammer A The effect of granulocyte colony-stimulating factor in adults undergoing autologous peripheral blood stem cell collection
Bone Abstracts. 2014; 3: 101--European Calcified Tissue Society Conference; May 17-20,2014; Prag Tschechien. [Poster]
FullText

 

Amrein K, Muschitz C, Wagner D, Pieber TR, Resch H, Dimai HP, Fahrleitner-Pammer A; Baseline data of the DEVIDE-study: DEnosumab vs Intravenous Ibandronate: a 2-year retrospective head to head real life study
Bone Abstracts . 2014; 3: PP327--European Calcified Tissue Society Conference ; May 17-20,2014; Prag Tschechien. [Poster]
FullText

 

Amrein, K; Oczko, S; Sareban, N; Drexler, C; Sipurzynski, S; Pieber,T; Lanter, G; Wagner,D; Fahrleitner-Pammer,A; Bone turnover after the administration of granulocyte colony-stimulation factor for mobilization of peripheral blood stem cells
Osteology 2014. 2014; 23 (Suppl1) : 47--Osteology ; Mar 13th - 15th 2014; München, Germany. [Poster]
FullText

 

Amrein, K; Schnedl,C; Bisping, E; Zajic, P; Dobnig, H; Pieber, T; Dimai, H; Fahrleitner-Pammer, A; Wagner, D; FGF23 in critical illness
Osteologie 2014;. 2014; 23 (Suppl 1) : -Osteology ; Mar 13th - 15th 2014; München, Germany. [Poster]
FullText

 

Bilezikian, JP; Benhamou, CL; Lin, CJF; Brown, JP; Daizadeh, NS; Ebeling, PR; Fahrleitner-Pammer, A; Franek, E; Gilchrist, N; Miller, PD; Simon, JA; Valter, I; Zerbini, CAF; Libanati, C Denosumab Restores Cortical Bone Loss at the Distal Radius Associated with Aging and Reduces Wrist Fracture Risk. Analyses from the Cross-over Group in the Extension of Denosumab Pivotal Fracture Trial
ARTHRITIS RHEUMATOL. . 2014; 66: S788-S789. [Poster]
Web of Science

 

Fahrleitner-Pammer. A; How to treat patients with severe osteoporosis
Jishuitan Forum 2014; April 25-27, 2014; Peking China. 2014. [Oral Communication]

 

Fahrleitner-Pammer, A; From structure to patient
Japanese Osteoporosis Society; Oct 22 - 25, 2014; Tokyo. 2014. [Keynote lecture]

 

Fahrleitner-Pammer, A; The role of bone biopsy; indication, performance and interpretation
Japanese Osteoporosis Society ; Oct 22 - 25, 2014; Tokyo. 2014. [Keynote lecture]

 

Fahrleitner-Pammer, A; Teriparatide in severely ill patients
Launch Symposium Forsteo - China; Apr 24 - 26, 2014; Peking China. 2014. [Keynote lecture]

 

Fahrleitner-Pammer, A; Inflammation and Bone
colloques cliniques du Service des Maladies Osseuses; Mar28th 2014; Genf, Schweiz. 2014. [Keynote lecture]

 

Fahrleitner-Pammer, A; Die Beckenkammbiopsie, Indikation, Durchführung und Interpretation.
45. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin ; 25. - 27. SEPTEMBER 2014; Salzburg. 2014. [Oral Communication]

 

Fahrleitner-Pammer A; Physiologisch therapieren im klinischen Alltag
22. Osteoporoseforum ; May 8-10 2014; St. Wolfgang Austria. 2014. [Oral Communication]
FullText

 

Fahrleitner-Pammer,a, How does the fragile osteoporosis patient look like in daily routine?
MEME - Netwoking on osteoporosis, ; Nov 20th ; Oslo Norway. 2014. [Oral Communication]

 

Fahrleitner-Pammer,A; Dear adyname Knochen
Wiener Rathaustag - Osteoporose; 30.10.2014; Wien. 2014. [Oral Communication]

 

Fahrleitner-Pammer,A; Osteoporosetherapie - according DVO Guidelines
Bezirksärztemeeting ; 21.03.2014; Oberwart . 2014. [Keynote lecture]

 

Fahrleitner-Pammer,A; Rheuma meets Bone
clinical Roundtable; 27.03.2014; Bern Schweiz. 2014. [Keynote lecture]

 

Fahrleitner-Pammer,A; Bone is a prey to inflammation
clinical roundtable ; 28.12.2014; Lousanne Schweiz. 2014. [Keynote lecture]

 

Fahrleitner-Pammer,A; Denosumab- gezielt anders
www.medacad.org/osteoporose2014/. 2014; -22. Osteoporoseforum ; May 8-10,2014; St. Wolfgang, Austria. [Oral Communication]

 

Fahrleitner-Pammer,A; Osteoporose im Wandel der Zeit
Klinische Fortbildung; 21.03.2014; Oberwart. 2014. [Keynote lecture]

 

Fahrleitner-Pammer,A; Welcher Patient profitiert von einer Teriparatide Therapie?
Osteologie 2014; May 13th-15th 2014; Muenchen . 2014. [Oral Communication]
FullText

 

Fahrleitner-Pammer,A; Bone is a prey to inflammation
Swiss Rheumatology society 2014 ; 26 - 27.03.2014; Zürich - Schweiz. 2014. [Keynote lecture]

 

Fahrleitner-Pammer,A; Die Osteoporose eine internistische Erkrankung?
Gynäkologische Wintertagung 2014; 26.01. - 31.01.2014; Oberlech. 2014. [Keynote lecture]

 

Fahrleitner-Pammer,A; Knochenschwund bei Männern mit ProstataCA: Wann und wie therapieren?
Osteologie 2014; März 13th-15th,2014; München, Gasteig. 2014. [Oral Communication]

 

Fahrleitner-Pammer,A; Rheuma trifft Knochen
Schweizerfortbildungstage ; Mar 26th-28Th,2014; Zürch. 2014. [Keynote lecture]

 

Fahrleitner-Pammer,A; State of the art Therapie der Osteoporose 2014
Bezirksärztefortbildung; 15. Jänner 2014; Graz. 2014. [Keynote lecture]

 

Fahrleitner-Pammer,A; Muschitz, C; Wagner, D; Amrein, K; Pieber, TR; Resch, H; Dimai, HP; DEVIDE-Study: Denosumab versus Intavenous Ibandronate - a 24 months retrospective head to head real life study - Baseline Data
Osteologie 2014; . 2014; 23 (Suppl1) : 37-37.-Osteologie; mar 13th - 15th 2014; München, Germany. [Poster]
FullText

 

Filzmaier, P; Malliga, D-E; Zirngast, B; Schwarz, M; Dacar, D; Dapunt, O; Fahrleitner-Pammer, A; Osteoprotegerin als möglicher Risikofaktor einer KHK.
Wissenschaftliches Programm der 55. Tagung der Österreichischen Gesellschaft für Chirurgie. 2014; -55. Tagung der Österreichischen Gesellschaft für Chirurgie; JUN 25-27, 2014; Graz, AUSTRIA. [Oral Communication]

 

Gaksch, M; Mader, JK; Grogorenz, J; Kienreich, K; Verheyen, N; Grübler, M; Fahrleitner-Pammer, A; Schmid, J; Pieske, B; Pilz, S; Tomaschitz, A; Pieber; TR. Resting Heart Rate Is Associated with HbA1c Levels: The Styrian Hypertension Study.
Diabetes. 2014; 63(Supp.1):A633-A633.-74th Scientific Sessions of the American Diabetes Association (ADA); JUN 13-17, 2014 ; San Francisco, CA, USA.

 

Hadji, P; Fahrleitner-Pammer,A; Tepie, MF; Möller, G; Zhang, E; Papaioannou, N; Baseline-Daten einer prospektiven Beobachtungsstudie zum Einnahme-Berhalten von Medikamenten bei Frauen mit PMO, die Denosumab erhalten.
Osteologie. 2014; 23(Suppl1):34-35.-Osteologie; Mar 13th - 15th 2014; München, Germany. [Poster]
FullText

 

Hadji, P; Papaioannou, NA; Gielen, E; Tepie, MF; Zhang, E; Kalouche-Khalil, L; Fahrleitner-Pammer, A 12-MONTH PERSISTENCE WITH DENOSUMAB (DMAB) IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS (PMO): INTERIM RESULTS OF A 24-MONTH PROSPECTIVE OBSERVATIONAL STUDY IN GERMANY, AUSTRIA, GREECE AND BELGIUM
OSTEOPOROSIS INT. 2014; 25: S181-S182.-World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; APR 02-05, 2014; Seville, SPAIN. [Oral Communication]
Web of Science

 

Schnedl C, Bisping E, Zajic P, Dimai HP, Wagner D, Pieber TR, Fahrleitner-Pammer A, Amrein K Bone turnover and FGF-23 levels in vitamin D-deficient critically ill patients with and without acute kidney injury
Bone Abstracts (2014) 3 PP74 | DOI:10.1530/boneabs.3.PP74 . 2014; 3: 74--European Calcified Tissue Society Conference; May 17-20,2014; Prag Tschechien. [Poster]
FullText

 

Tomaschitz, A; Verheyen, N; Gaksch, M; Grübler, MR; Wetzel, J; Belyavskyi, E; Colantonio, C; Kraigher-Krainer, E; März, W; Grammer, T; Meinitzer, A; Rus-Machan, J; Fahrleitner-Pammer, A; Pieske, B; Pilz, S Ambulatory Blood Pressure Monitoring and Kynurenic Acid in Female Patients with Primary Hyperparathyroidism - the EPATH Study.
Journal of Hypertension. 2014; -ESH/ISH Joint Meeting; June 13-16, 2014; Athens, Greece. [Oral Communication]

 

Tomaschitz, A; Verheyen, N; Gaksch, M; Grübler, MR; Wetzel, J; Belyavskyi, E; Colantonio, C; Kraigher-Krainer, E; März, W; Grammer, T; Meinitzer, A; Rus-Machan, J; Fahrleitner-Pammer, A;Pieske, B; Pilz, S Associations of Tryptophan Metabolism with Systolic and Diastolic Left Ventricular Function in Patients with Primary Hyperparathyroidism
Journal of Hypertension. 2014; -ESH/ISH Joint Meeting; June 13-16, 2014; Athens, Greece. [Oral Communication]

 

Verheyen, N; Gaksch, M; Grogorenz, J; Grübler, M; Kienreich, K; Schmid, J; Wetzel, J; Belyavskiy, E; Colantonio, C; Kraigher-Krainer, E; Schmidt, A; van Ballegooijen, AJ; Fahrleitner-Pammer, A; Pieske, B; Tomaschitz, A; Pilz, S Association of Plasma Parathyroid Hormone with Nighttime Blood Pressure in Hypertensive Patients – Insights from The Styrian Hypertension Study
Journal of Hypertension. 2014; -ESH/ISH Joint Meeting; June 13-16, 2014; Athens, Greece. [Poster]

 

Verheyen, N; Gaksch, M; Grogorenz, J; Grübler, MR; Kienreich, K; Schmid, J; Wetzel, J; Belyavskyi, E; Colantonio, C; Kraigher-Krainer, E; Schmidt, A; van Ballegooijen, H; Fahrleitner-Pammer, A; Pieske, B; Tomaschitz, A; Pilz, S. Association of plasma parathyroid hormone with nighttime blood pressure in hypertensive patients – Insights from the Styrian Hypertension Study
Journal für Hypertonie - Austrian Journal of Hypertension 2014; 18 (3), 110-128. 2014; -Jahrestagung Nephrologie & Hypertensiologie; 18-20 SEPT, 2014; Baden (NÖ), AUSTRIA. [Poster]

 

Verheyen, N; Gaksch, M; Grogorenz, J; Kienreich, K; Grübler, MR; Schmid, J; Wetzel, J; Belyavskiy, E; Colantonio, C; Kraigher-Krainer, E; Maerz, W; Meinitzer, A; Fahrleitner-Pammer, A; Pieske, B; Pilz, S; Tomaschitz, A Differences In 24-Hours Ambulatory Blood Pressure Readings Between Hypertensives With And Without Primary Hyperparathyroidism – A Case Control Study
Journal of Hypertension. 2014; -ESH/ISH Joint Meeting; June 13-16, 2014; Athens, Greece. [Poster]

 

Verheyen, N; Tomaschitz, A; Pilz, S; Fahrleitner-Pammer, A; Gaksch, M; Grübler, M; Belyavskiy; Kraigher-Krainer, E; Pieske, B;März, W The Relationship Between the Aldosterone-to-Renin Ratio and Markers of Bone Turnover - the LURIC Study
Putting the A back into RAAS satellite meeting; June 10-12, 2014; Thira, Santorini, Greece. 2014. [Oral Communication]

 

Amrein, K; Dobnig, H; Fenzl, KH; Pieber, TR; Tomaschitz, A; Wagner, D; Fahrleitner-Pammer, A Assoziation von Sclerostin mit Parametern des Quantitativen Knochenultraschalls und Knochen-umbaumarkern
Osteologie, 2013 (Suppl 1). 2013; -Osteologie 2013; MAR 6-9, 2013; Weimar, GERMANY. [Poster]

 

D. Wagner, H. Dobnig, T. Pieber, A. R. Rosenkranz, A. Fahrleitner Teriparatide Treatment in a Cardiac Transplant Patient with Adynamic Bone Disease and Renal Failure – Improvement of Bone Histomorphometric Indices and Bone mineral Density
Supplement 1. 2013; -Osteologie 2013; MAR 6-9; Weimar, GERMANY. [Poster]

 

Fahrleitner-Pammer, A; Reconstruction - Teriparatide
Brazilian Orthopedic Society; sep 26-29,2013; sao Paoulo, Brazil. 2013. [Keynote lecture]

 

Fahrleitner-Pammer, A; PTH als Regulator des Knochenstoffwechsels
Endokriner Kreis; 07.-09.06.2013; Vienna. 2013. [Oral Communication]

 

Fahrleitner-Pammer, A; Therapiedauer, Sequenztherapie, Therapiesicherheit
Osteoporoseseminar am Hafnersee; 14.-15.03.2013; Hafnersee, Austria. 2013. [Oral Communication]

 

Fahrleitner-Pammer, A; Osteoporose - kein Schicksal nur eine Erkrankung
Bezirksärztefortbildung Leibnitz; Nov 7th 2013; Schloss Lobau . 2013. [Keynote lecture]

 

Fahrleitner-Pammer, A; Rheuma meets Bone
Scientific event - Pfizer _Lilly ; Feb 6th 2013; Graz. 2013. [Oral Communication]

 

Fahrleitner-Pammer, A; Why do we need osteoporosis therapy beyond antiresorptives?
Osteoporosis guidelines confronting NICE; 24.10. - 26.10.2013; London UK. 2013. [Keynote lecture]

 

Fahrleitner-Pammer, A; Anabolic treatment - who when why
Orthopedic circle Klagenfurt; Jan, 15, 2013; Klagenfurt. 2013. [Keynote lecture]

 

Fahrleitner-Pammer, A; Rheumatische Erkrankungen und Osteoporose
Grazer Rheumatag; 10.mai 2013; 2013. [Oral Communication]

 

Fahrleitner-Pammer, A; Prolia - die Therapie mit dem kortikalem Plus
Bone Academy Bad Ischl; 09. Sep. 2013; Bad Ischl. 2013. [Keynote lecture]

 

Fahrleitner-Pammer, A; What to do if antiresorptive Therapy is not enough
Swiss Rheumatology Society ; 12 - 14 th September 2013; Interlaken Switzerland. 2013. [Oral Communication]

 

Fahrleitner-Pammer, A; Osteoporose - kein Schicksal nur eine Erkrankung
Fortbildung am Punkt; Mar 15,2013; Linz. 2013. [Oral Communication]

 

Fahrleitner-Pammer, A; Hoffnung für den kortikalen Knochen
Bezirksärztefortbildung Leoben; 21.06.2013; Leoben. 2013. [Oral Communication]

 

Fahrleitner-Pammer. A; If antiresorptive therapy is not enough
Life science event ; 26.-28.06.2013; Graz. 2013. [Keynote lecture]

 

Fahrleitner-Pammer, A; Muschitz, C; Resch, H; Wagner, D; Amrein, K; Pilz, S; Tomaschitz, A; Pieber, T; Dimai, HP DEVIDE-study: DEnosumab Versus Intravenous ibanDronate - a 24 months respective head to head real life study.
J Bone Miner Res. 2013; Supplement 1(MO0381):-ASBMR; Oct 4th - 7th 2013; Baltimore, USA. [Poster]
FullText

 

Fahrleitner-Pammer,A Teriparatide and Fractur healing
Calcified Tissue - Volume 1. 2013; 1: 212-212.-European Calcified Tissue Society ; 18.-22.05.2013; Lisbon. [Oral Communication]

 

Fahrleitner-Pammer,A Compliance and awareness of patients with osteoporosis
Brazil Orthopedics society ; Sep 26-29,2013; Sao Paoulo, Brazil. 2013. [Keynote lecture]

 

Fahrleitner-Pammer,A; Reparieren statt konservieren
www.uog.com. 2013; -Orthopäden Tagung 2013 ; 11th to 13 th September 2013; Krems. [Oral Communication]

 

Fahrleitner-Pammer,A; Teriparatide und Frakturheilung
21. Osteoporoseforum; 25.-27.04.2013; St. Wolfgang. 2013. [Oral Communication]
FullText

 

Fahrleitner-Pammer,A; Oseoporose eine unterdiagnostizierte und untertherapierte Erkrankung
Menopause Tagung ; 04. - 07. 12.2013; Wien. 2013. [Oral Communication]
FullText

 

Fahrleitner-Pammer,A; Osteoporosetherapie im täglichen Leben
Kongress für Allgemeinmedizin; 27.11. - 30.11.2012; Graz. 2013. [Oral Communication]
FullText

 

Fahrleitner-Pammer,A; Der kranke Knochen
Bezirksärztefortbildung ; 12.06.2013; Fürstenfeld. 2013. [Keynote lecture]

 

Gaksch, M; Grübler, MR; Kienreich, K; Tomaschitz, A; Ritz, E; Verheyen, N; Fahrleitner-Pammer, A; Schmid, J; Pieske, B; März, W; Pieber, TR; Pilz, S; Aldosterone is associated with parathyroid hormone in patients with arterial hypertension: The Styrian Hypertension Study
EYES (European Young Endocrine Scientists) 1st meeting; OCT 11-13, 2013; Rotterdam, the Netherlands. 2013. [Oral Communication]
FullText

 

Gaksch, M; Kienreich, K; Tomaschitz, A; Verheyen, N; Grübler, M; Fahrleitner-Pammer, A; Schmid, J; Pieske, B; Pilz, S. HbA1c levels are associated with resting heart rate: The Styrian Hypertension Study.
http://www.oedg.org/pdf/1311_JT_Hauptprogramm.pdf. 2013; -41. Jahrestagung der ÖDG; NOV 21-23, 2013; Salzburg, AUSTRIA. [Poster]

 

Gaksch, M; Pilz, S; Piecha, G; Ritz, E; Meinitzer, A; Pieske, B; Wiecek, A; Haas, J; Kienreich, K; März, W; Verheyen, N; Fahrleitner-Pammer, A; Kraigher-Krainer, E; Drechsler, C; Tomaschitz, A Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications - The Graz Endocrine Causes of Hypertension (GECOH) Study
PIPA 3 (Progress in Primary Aldosteronism); JUL 3-5, 2013; Munich, Germany. 2013. [Oral Communication]
FullText

 

Grübler, M; Kienreich, K; Tomaschitz, A; Verheyen, N; Gaksch, M; Fahrleitner-Pammer, A; Schmid, J; Pieske, B; Pieber, TR; Pilz, S. Aldosterone to renin ratio is associated with QTc changes in patients with arterial hypertension: The Styrian Hypertension Study
http://www.atcardio.at/fileadmin/images/Kardio_Salzburg_2013_HP_Web_02.pdf. 2013; -Jahretagung der ÖKG 2013; JUN 5-8, 2013; Salzburg, AUSTRIA. [Poster]

 

Grubler, M; Kienreich, K; Tomaschitz, A; Verheyen, N; Gaksch, M; Fahrleitner-Pammer, A; Schmid, J; Pieske, B; Pieber, TR; Pilz, S; Aldosterone to renin ratio is associated with 24 hour ambulatory blood pressure in essential hypertensives: the Styrian Hypertension study.
EUR HEART J. 2013; 34: 1051-1051.-Congress of the European-Society-of-Cardiology (ESC); AUG 31-SEP 04, 2013; Amsterdam, NETHERLANDS. [Poster]
Web of Science

 

Grübler, M; Kienreich, K; Tomaschitz, A; Verheyen, N; Gaksch, M; Fahrleitner-Pammer, A; Schmid, J; Pieske, B; Pieber, TR; Pilz, S. Aldosterone to renin ratio is associated with 24 hour ambulatory blood pressure in essential hypertensives: The Styrian Hypertension Study
http://www.atcardio.at/fileadmin/images/Kardio_Salzburg_2013_HP_Web_02.pdf. 2013; -Jahrestagung der ÖKG 2013; JUN 5-8, 2013; Salzburg, AUSTRIA. [Poster]

 

Grubler, MR; Verheyen, N; Pilz, S; Kienreich, K; Gaksch, M; Schmid, J; Rus-Machan, J; Fahrleitner-Pammer, A; Kraigher-Krainer, E; Pieske, B; Marz, W; Tomaschitz, A Is Resting Heart Rate Really Associated With Cardiovascular Mortality?
CIRCULATION. 2013; 128(22): [Poster]
Web of Science FullText

 

Grubler, MR; Verheyen, N; Tomaschitz, A; Kienreich, K; Gaksch, M; Bersuch, LA; Fahrleitner-Pammer, A; Schmid, J; Marz, W; Pieske, B; Pilz, S Nocturnal Diastolic Blood Pressure is Associated With 24 Hour Urinary Albumin in Essential Hypertensive Patients
CIRCULATION. 2013; 128(22): [Oral Communication]
Web of Science FullText

 

Hofbauer, LC; Fahrleitner-Pammer, A; Ho, PR; Hawkins, F; Roux, C; Micaelo, M; Minisola, S; Papaioannou, NA; Stone, M; Wark, J; Zillikens, MC; Ferreira, I; Siddhanti, S; Wagman, RB; Brown, JP; EFFICACY AND SAFETY OF DENOSUMAB VS. RISEDRONATE IN POSTMENOPAUSAL WOMEN SUBOPTIMALLY ADHERENT TO ALENDRONATE: RESULTS FROM A RANDOMIZED OPEN-LABEL STUDY.
OSTEOPOROSIS INT. 2013; 24: S218-S219.-European Congress on Osteoporosis and Osteoarthritis (ESCEO-IOF); APR 17-20, 2013; Rome, ITALY. [Oral Communication]
Web of Science

 

Klemmer, AS; Mikschofsky, C; Hausleitner, A; Fruhwald, F; Schnedl, C; Stojakovic, T; Pieber, TR; Fahrleitner-Pammer, A; Amrein, K KNOCHENDICHTE UND KÖRPERZUSAMMENSETZUNG BEI CHRONISCHER HERZINSUFFIZIENZ UND VITAMIN D-MANGEL
Journal für Klinische Endokrinologie und Stoffwechsel. 2013; Sonderheft 1(6). 2013; -18. Jahrestagung der ÖGES; APR 18-19; Linz, AUSTRIA. [Oral Communication]

 

Malliga, DE; Zirngast, B; Cohnert, T; Schwarz, M; Tsybrovskyy, O; Fahrleitner-Pammer, A; Amrein, K Osteoprotegerin is higher in more advanced peripheral arterial disease
Osteologie 2013; 22 (Suppl 1): S1-S57. 2013; -Osteologie 2013; MAR 6-9, 2013; Weimar, GERMANY. [Poster]

 

Mikschofsky, C; Hausleitner, A; Fruhwald, F; Klemmer, AS; Schnedl, C; Pieber, TR; Stojakovic, T; Fahrleitner-Pammer, A; Amrein, K Vitamin D-Mangel und chronische Herzinsuffizienz: eine schlechte Kombination für den Knochen
Osteologie, 2013 (Suppl 1). 2013; -Osteologie 2013; MAR 6-9, 2013; Weimar, GERMANY. [Poster]

 

Mikschofsky, C; Hausleitner, A; Fruhwald, F; Klemmer, AS; Schnedl, C; Stojakovic, T; Pieber, TR; Fahrleitner-Pammer, A; Amrein, K Prävalenz einer erniedrigten Knochendichte bei chronischer Herzinsuffizienz
Kardiologie 2013; MAR 1-2, 2013; Innsbruck, AUSTRIA. 2013. [Poster]

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Lung, S; Resch, H; OVERLAPPING AND FOLLOW-U P OF ALENDRONATE TO TERIPARATIDE TREATMENT RESULTS IN MAINTENANCE OF EXCESS BMD GAIN.
OSTEOPOROSIS INT. 2013; 24: S93-S93.-European Congress on Osteoporosis and Osteoarthritis (ESCEO-IOF); APR 17-20, 2013; Rome, ITALY. [Oral Communication]
Web of Science

 

Muschitz,S; Kocijan,R; Schima, W; Haschka, A; Zendeli, A; Fahrleitner-Pammer, A; Resch,H Overlapping and Follow-up of Alendronate in Teriparatide Results in Continuing Volumetric Bone Mass Increase measured by Quantitative Computed Tomography
JBMR 3013; Supplement 1. 2013; (SA0377):-ASBMR; Oct 4th - 7th 2013; Baltimore, USA. [Oral Communication]
FullText

 

Oczko, S; Sareban, N; Drexler, C; Sipurzynski, S; Fahrleitner-Pammer, A; Pieber, T.R.; Dobnig, H; Lanzer, G; Amrein, K THE ACUTE EFFECT OF GRANULOCYTE COLONY-STIMULATING FACTOR ON BONE TURNOVER
Transfusion Medicine and Hemotherapy. 2013; -46. Jahrestagung DGTI; SEP, 24-27, 2013; Münster, GERMANY. [Poster]

 

Papaioannou, N; Fahrleitner-Pammer,A; Tepie, MF; Moeller,G; Zhang,E; Hadji,P Baseline characteristics of a prospective observational study in Germany Austria, Greece and Belgium to evaluate medictaion-taking behavior of postmenopausal (PMO) patients receiving denosumab (dmab) in clinical practice
JBMR Supplement 1. 2013; (SA0392):-ASBMR; Oct 4th - 7th 2013; Baltimore, USA. [Poster]
FullText

 

Roux, C; Fahrleitner-Pammer, A; Ho, PR; Hawkins, F; Hofbauer, LC; Micaelo, M; Minisola, S; Papaioannou, N; Stone, M; Wark, J; Zillikens, MC; Ferreira, I; Siddhanti, S; Wagman, RB; Brown, JP DENOSUMAB VERSUS RISEDRONATE: EFFICACY AND SAFETY IN POSTMENOPAUSAL WOMEN SUBOPTIMALLY ADHERENT TO ALENDRONATE THERAPY IN A RANDOMIZED OPEN-LABEL STUDY
ANN RHEUM DIS. 2013; 72: 306-306.-ASBMR; Oct 2013; Minneapolis. [Oral Communication]
Web of Science

 

Tomaschitz, A; Grammer, T; Verheyen, N; Pilz, S; Rus-Machan, J; Meinitzer, A; Ritz, E; Pieske, P; Kienreich, K; Fahrleitner- Pammer, A; Kraigher-Krainer, E; Boehm, B.O.; März. W Amino acid status and risk of heart failure death
http://www.atcardio.at/fileadmin/images/Kardio_Salzburg_2013_HP_Web_02.pdf. 2013; -Jahrestagung der ÖKG 2013 ; JUN 5-8, 2013; Salzburg, AUSTRIA. [Poster]

 

Tomaschitz, A; Meinitzer, A; Pieske, B; März, W; Fahrleitner-Pammer, A; Grammer, T; Kraigher-Krainer, E; Toplak, H; Pilz, S. Association of Tryptophan Metabolism with Metabolic Traits in Hypertensive Patients
http://www.oedg.org/pdf/1311_JT_Hauptprogramm.pdf. 2013; -41. Jahrestagung der ÖDG; 21.-23. November 2013; Salburg, AUSTRIA. [Poster]

 

Verheyen, N; Grubler, M; Pilz, S; Kienreich, K; Gaksch, M; Schmid, J; Bersuch, LA; Pieske, B; Kraigher-Krainer, E; Fahrleitner-Pammer, A; Boehm, BO; Marz, W; Tomaschitz, A Serum Parathyroid Hormone is Independently Associated With Atrial Fibrillation: Insights From the LURIC Study
CIRCULATION. 2013; 128(22): [Poster]
Web of Science FullText

 

Wagner, D; Pilz, S; Tomaschitz, A, Pieber, T; Dimai, HP, Amrein, K; Fahrleitner-Pammer, A; Testosterone Replacement on Top of Bisphosphonate therapy has an additional Benefit on Bone Mass, Libido and Sexual Activities in Male Cardiac Transplant Patients: A 5 year Prospective Controlled Study.
Calcified Tissue. 2013; 1: 221-221.-European Calcified Tissue Society ; 18.-22.05.2013; Lisbon. [Oral Communication]

 

Wagner D, Werkgartner G, Rosenkranz AR, Mischinger HJ, Fahrleitner-Pammer A Treatment with intravenous ibandronate does not affect renal function - a 24 months prospective controlled trial on renal function
Osteologie Supplement 1. 2013; -Osteologie; MAR 6-9; Weimar, Germany. [Poster]

 

Wagner,D; Werkgartner,G; Mischinger, HJ; Rosenkranz, AR; Fenzl, K; Fahrleitner-Pammer Treatment with intravenous ibandronate does not affect renal function - a 24 month prospective controlled study on renal function.
JBMR . 2013; Supplement 1(SA0438):-ASBMR; Oct 4th - 7th 2013; Baltimore, USA. [Poster]

 

Werkgartner, G; Fahrleitner-Pammer, A; Roller-Wirnsberger, R; Kniepeiss, D; Wagner, D LONG TERM QUALITY OF LIFE OF LIVER TRANSPLANT RECIPIENTS BEYOND SIXTY YEARS OF AGE
TRANSPL INT. . 2013; 26: 189-189. [Poster]
Web of Science

 

Fahrleitner-Pammer Immer nur hemmen ist zuwenig
Qualitätszirkel Leoben; 14.08.2012; St. Michael. 2012. [Keynote lecture]

 

Fahrleitner-Pammer Teriparatide- why, when, who
Forsteo Launch Belgium; June, 14th 2012; Bruessel, Belgium. 2012. [Keynote lecture]

 

Fahrleitner-Pammer, A Kortikal versus trabekulär
Jännertagung Amgen Österreich; 10.01.2012; Fuschl, österreich. 2012. [Keynote lecture]

 

Fahrleitner-Pammer, A; Sinn und Unsinn der gepaarten Beckenkammbiopsie
20. Osteoporoseforum ; 10-12.Mai 2012; St. Wolfgang . 2012. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Der lebendige Knochen
Bezirksärztefortbildung St-Peter; 16.02.2012; Graz. 2012. [Keynote lecture]

 

Fahrleitner-Pammer, A; Immer nur hemmen ist zu wenig
Bezirksärztefortbildung Velden; June 15th; Velden Österreich. 2012. [Keynote lecture]

 

Fahrleitner-Pammer, A; Vitamin D - die Bedeutung in der Geriatrie
Geriatrie Diplomkurs; June, 15Th - 16th; Graz Austria. 2012. [Oral Communication]

 

Fahrleitner-Pammer; A Versorgungssituation der Osteoporose in Österreich
Osteologie 2012;21:1-58. 2012; 1/2012(1019):A3-A27.-Osteologie 2012; 29.03. - 31.03.2012; Basel, CH. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Wenn antiresorptive Therapie nicht reicht
Krankenhausfortbildung LKH Steyr; June 5th 2012; Steyr, Österreich. 2012. [Keynote lecture]

 

Fahrleitner-Pammer; Astrid Denosumab in der Osteologie
Amgen Science Lounge; 14.03.2012; Wien. 2012. [Keynote lecture]

 

Fahrleitner-Pammer,A; Nur hemmen ist zu wenig...
Bezirksärztefortbildung Deutschlandsberg ; 29.02.2012; Deutschlandsberg. 2012. [Keynote lecture]

 

Fahrleitner-Pammer,A; Prolia die Innovation in der Osteoporosetherapie
Bezirksärztefortbildung Mürzzuschlag; 19.04.2012; Mürzzuschlag. 2012. [Keynote lecture]

 

Fahrleitner-Pammer,A; Der kranke Knochen
Interne Fortbildung LKH Wolfsberg; 25.09.2012; Wolfsberg. 2012. [Keynote lecture]

 

Fahrleitner-Pammer,A; Osteoporose kein Schicksal, nur eine Erkrankung
osteoporose Workshop; 13.-14.04.2012; Bad Erlach. 2012. [Keynote lecture]

 

Fahrleitner-Pammer;a; Alternativtherapien in der Osteoporose
Interne Fortbildung BHB 1; 14.08.2012; Graz. 2012. [Keynote lecture]

 

Fahrleitner-Pammer,A; Fenzl, K; Wagner, D; Muschitz, C; Amrein, K; Pieber, T; Obermayer-Pietsch, B; Dimai, HP. Three-monthly i.v. Ibandronate following log-term treatment with oral alendronate; results from a two-year prospective open-labeled Study
Osteology. 2012; 1/2012: A44-A44.-Osteologie 2012; 29.03. - 31.03.2012; Basel, CH. [Poster]
FullText

 

Fahrleitner-Pammer,A; Wagner,D; Dobnig,H; Dimai, HP; Amrein, K; Muschitz, C; Beham-Schmid, C; Sereinigg, M; Stiegler,P; Pieber, T. Paired Bone Biopsies: How valid are they?A prospective controlled study!
Osteology. 2012; 1/2012: A33-A33.-Osteologie 2012; 29.03. - 31.03.2012; Basel, CH. [Poster]
FullText

 

Hausleitner, A; Fruhwald, F; Mikschofsky, C; Klemmer, AS; Schnedl, C; Stojakovic, T; Pieber, TR; Astrid Fahrleitner-Pammer, A; Amrein, K Prävalenz einer erniedrigten Knochendichte bei Herzinsuffizienz
Abstractband Herzinsuffizienz Dreiländertreffen 2012. 2012; -Herzinsuffizienz Dreiländertreffen; SEP 27-29; Innsbruck, AUSTRIA. [Poster]

 

Kocijan, R; Muschitz, C; Amrein, K; Fahrleitner-Pammer, A; Pietschmann, P; Haschka, J; Dinu, S; Resch, H; Serum sclerostin levels, bone turnover markers and body composition in mild, moderate and severe osteogenesis imperfecta.
BONE. 2012; 51(6):S10-S11.-International Conference on Progress in Bone and Mineral Research / Annual Autumn Conference of the Austrian-Society-for-Bone-and-Mineral-Research including a Symposium on Calcium Sensing Receptor; NOV 29-DEC 01, 2012; Vienna, AUSTRIA. Doi: 10.1016/j.bone.2012.08.029 [Oral Communication]
Web of Science FullText FullText_MUG

 

Muschitz, C; Fahrleitner-Pammer, A; Kocijan, R; Bittighofer, C; Trubrich, A; Kuehne, F; Waneck, R; Resch, H; TERIPARATIDE AND ANTIRESORPTIVE COMBINATION TREATMENT SUBSEQUENT TO 9 MONTHS OF TERIPARATIDE MONOTHERAPY.
OSTEOPOROSIS INT. 2012; 23: S106-S107.-IOF-ECCEO European Congress on Osteoporosis and Osteoarthritis / 2nd IOF-ESCEO Pre-Clinical Symposium; MAR 21-24, 2012; Bordeaux, FRANCE. [Oral Communication]
Web of Science

 

Muschitz, C; Haschka, J; Kocijan, R; Bitighofer, C; Trubrich, A; Fahrleitner-Pammer, A; Resch, H; TREATMENT WITH PTH 1-84 IN MALE PATIENTS WITH SEVERE OSTEOPOROSIS - RESULTS FROM A PROSPECTIVE 24 MONTH OPEN-LABEL TRIAL.
OSTEOPOROSIS INT. 2012; 23: S107-S107.-IOF-ECCEO European Congress on Osteoporosis and Osteoarthritis / 2nd IOF-ESCEO Pre-Clinical Symposium; MAR 21-24, 2012; Bordeaux, FRANCE. [Oral Communication]
Web of Science

 

Muschitz, C; Haschka, J; Kocijan, R; Bittighofer, C; Trubrich, A; Fahrleitner-Pammer, A; Resch, H; Treatment with PTH 1-84 in male patients with severe osteoporosis - results from a prospective 24 month open-label trial.
BONE. 2012; 50: S154-S154.-39th Annual Congress of the European-Calcified-Tissue-Society (ECTS); MAY 19-23, 2012; Stockholm, SWEDEN. Doi: 10.1016/j.bone.2012.02.481 [Oral Communication]
Web of Science FullText FullText_MUG

 

Muschitz, C; Haschka, J; Kocijan, R; Fahrleitner-Pammer, A; Nirnberger, G; Resch, H TREATMENT WITH PTH 1-84 IN MALE PATIENTS WITH SEVERE OSTEOPOROSIS RESULTS FROM A PROSPECTIVE 24 MONTH OPEN-LABEL TRIAL
OSTEOPOROSIS INT. 2012; 23: 696-696.-IOF Regionals 2nd Middle East and Africa Osteoporosis Meeting / 6th Pan Arab Osteoporosis Congress (PAOC); SEP 27-OCT 01, 2012; JORDAN. [Oral Communication]
Web of Science

 

Muschitz, C; Haschka, J; Kocijan, R; Fahrleitner-Pammer, A; Resch, H. Treatment with PTH 1-84 in male patients with severe osteoporosis-results from a prospective 24 month open-label trial
Osteology. 2012; 1/2012: A42-A43.-Osteologie 2012; 29.03. - 31.03.2012; Basel, CH. [Poster]
FullText

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Lung, S; Resch, H; Overlapping and follow-up of alendronate to teriparatide treatment results in maintenance of excess BMD gain.
BONE. 2012; 51(6):S10-S10.-International Conference on Progress in Bone and Mineral Research / Annual Autumn Conference of the Austrian-Society-for-Bone-and-Mineral-Research including a Symposium on Calcium Sensing Receptor; NOV 29-DEC 01, 2012; Vienna, AUSTRIA. Doi: 10.1016/j.bone.2012.08.028 [Keynote lecture]
Web of Science FullText FullText_MUG

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Pavo, I; Lung, S; Resch, H ANTIRESORPTIVES OVERLAPPING ONGOING TERIPARATIDE TREATMENT RESULT IN ADDITIONAL INCREASES IN BONE MINERAL DENSITY
OSTEOPOROSIS INT. 2012; 23: 695-695.-IOF Regionals 2nd Middle East and Africa Osteoporosis Meeting / 6th Pan Arab Osteoporosis Congress (PAOC); SEP 27-OCT 01, 2012; JORDAN. [Oral Communication]
Web of Science

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Pavo, I; Resch, H OVERLAPPING AND FOLLOW-UP OF ALENDRONATE TO TERIPARATIDE TREATMENT RESULTS IN MAINTENANCE OF EXCESS BMD GAIN
OSTEOPOROSIS INT. . 2012; 23: 697-697.-IOF Regionals 2nd Middle East and Africa Osteoporosis Meeting / 6th Pan Arab Osteoporosis Congress (PAOC); SEP 27-OCT 01, 2012; JORDAN. [Oral Communication]
Web of Science

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Resch, H OVERLAPPING AND FOLLOW-UP OF ALENDRONATE TO TERIPARATIDE TREATMENT RESULTS IN MAINTENANCE OF EXCESS BMD GAIN
OSTEOPOROSIS INT. . 2012; 23: S750-S751.-IOF Regionals - 3rd Asia-Pacific Osteoporosis Meeting; DEC 13-16, 2012; Kuala Lumpur, MALAYSIA. [Poster]
Web of Science

 

Muschitz, C; Kocijan, R; Kuehne, F; Haschka, J; Bittighofer, C; Trubrich, A; Fahrleitner-Pammer, A; Resch, H; Teriparatide and antiresorptive combination treatment subsequent to 9 months of teriparatide monotherapy.
BONE. 2012; 50: S41-S41.-39th Annual Congress of the European-Calcified-Tissue-Society (ECTS); MAY 19-23, 2012; Stockholm, SWEDEN. Doi: 10.1016/j.bone.2012.02.107 [Oral Communication]
Web of Science FullText FullText_MUG

 

Muschitz, C; Kocijan, R; Kuehne, F; Haschka, J; Bittighofer, C; Trubrich, A; Fahrleitner-Pammer, A; Resch, H; The discriminatory capacity of clinical risk factors and bmd measurements at different skeletal sites for detect-ing patients with vertebral fractures.
BONE. 2012; 50: S147-S147.-39th Annual Congress of the European-Calcified-Tissue-Society (ECTS); MAY 19-23, 2012; Stockholm, SWEDEN. Doi: 10.1016/j.bone.2012.02.457 [Oral Communication]
Web of Science FullText FullText_MUG

 

Muschitz, C; Kocijan,R; Christina,B; Haschka,J; Trubrich, A; Resch, H. Teriparatide and Antiresorptive Combination Treatment subsequent to 9 months of Teriparatide Monotherapy
Osteology. 2012; 1/2012: A11-A11.-Osteologie 2012; 29.03. - 31.03.2012; Basel, CH. (ISBN: 1019-1291 ) [Oral Communication]
FullText

 

Sampl, E; Dobnig,H; Obermayer-Pietsch, B; Dimai, HP; Seibert, FJ; Pieber, T; Fahrleitner-Pammer, A. Verbesserung der Sekundärprävention bei Patienten nach osteoporotischer Fraktur: 2-jahresdaten eines interdisziplinären Netzwerkes.
Osteology. 2012; 1/2012: A34-A34.-Osteologie 2012; 29.03. - 31.03.2012; Basel, CH. [Poster]
FullText

 

Schweighofer, N; Lerchbaum, E; Gugatschka, M; Walter-Finell, D; Fahrleitner-Pammer, A; Dobnig, H; Pieber, TR; Renner, W; Obermayer-Pietsch, B Morphogenetic Gene Meis1 and Bone Characteristics in 1975 patients.
European Journal of Human Genetics. 2012; 20(supl 1):240-240.-European Human Genetics Conference 2012; JUN 23-26, 2012; Nuremberg, Germany. [Poster]

 

Schweighofer, N; Lerchbaum, E; Gugatschka, M; Walter-Finell, D; Fahrleitner-Pammer, A; Dobnig, H; Pieber, TR; Renner, W; Obermayer-Pietsch, B Genetische Variationen im Gen Meis1 und Knochendichte.
Journal für Klinische Endokrinologie und Stoffwechsel. 2012; 5(1):14-14.-ÖGES Jahrestagung; APR 19-20, 2012; Graz, AUSTRIA. [Poster]

 

Stepan, JJ; Dobnig, H; Fahrleitner-Pammer, A; Ma, YFL; Zeng, QQ; Wan, XH; Marin, F; Pavo, I; EFFECTS OF TERIPARATIDE ON CORTICAL HISTOMORPHOMETRIC VARIBLES IN PATIENTS RECEIVING LONG-TERM ALENDRONATE THERAPY.
OSTEOPOROSIS INT. 2012; 23: S132-S132.-IOF-ECCEO European Congress on Osteoporosis and Osteoarthritis / 2nd IOF-ESCEO Pre-Clinical Symposium; MAR 21-24, 2012; Bordeaux, FRANCE. [Oral Communication]
Web of Science

 

Tomaschitz A; Meinitzer, A; Pieske, P; Kienreich, K; März, W; Ritz, E; Fahrleitner-Pammer, A; Grammer, T; Kraigher-Krainer, E; Colantonio, C; Toplak, H; Drechsle, C; Verheyen, N; Pilz, S Associations of Tryptophan Metabolism with Metabolic Traits in Hypertensive Patients: the Graz Endocrine Causes of Hypertension (GECOH) Study
Abstraktband. 2012; -Biomarkers in Heart Failuren with Preserved Ejection Fraction - International Symposium; OCT 13-15, 2012; Graz, AUSTRIA. [Poster]

 

Tomaschitz, A; Fahrleitner-Pammer, A; Pieske, B; Verheyen, N; Amrein, K; Ritz, E; Kienreich, K; Horina, JH; Schmidt, A, Kraigher-Krainer, E; Colantonio, C; Meinitzer, A; Pilz, S Effect of Eplerenone on Parathyroid Hormone Levels in Patients with Primary Hyperparathyroidism - a Randomized, Double-blind, Placebo-controlled Trial: Rationale and Design
Abstraktband. 2012; -Biomarkers in Heart Failuren with Preserved Ejection Fraction - International Symposium; OCT 13-15, 2012; Graz, AUSTRIA. [Poster]

 

Tomaschitz, A; Meinitzer, M; Pilz, S; Kienreich, K; Genser, B; Drechsler, C; Grammer, T; Krane, V; Ritz, E; Kleber, ME; Pieske, B; Fahrleitner-Pammer, A; Wanner, C; Boehm, BO; März, W Homoarginine, Kidney Function and Related 10-year Cardiovascular Mortality Risk
Abstraktband. 2012; -Biomarkers in Heart Failuren with Preserved Ejection Fraction - International Symposium; OCT 13-15, 2012; Graz, AUSTRIA. [Poster]

 

Tomaschitz A; Piecha, G; Ritz, E; Meinitzer, A; Pieske, P; Fahrleitner-Pammer, A; März, W; Kienreich, K; Grammer, T; Verheyen, N; Pilz, S Marinobufagenin in arterial hypertension: a promising biomarker for cardiovascular and renal diseases? Cross-sectional relations from the Graz Endocrine Causes of Hypertension (GECOH) Study
Abstract-Band . 2012; -Biomarkers in Heart Failuren with Preserved Ejection Fraction - International Symposium; OCT 13-15, 2012; Graz, AUSTRIA. [Poster]

 

Tomaschitz, A; Pilz, S; Pieske, B; Ritz, E; März, W; Meinitzer, A; Dobnig, H; Amrein, K; Kienreich, K; Kraigher-Krainer, E; Colantonio, C; Wagner, D; Fahrleitner-Pammer, A Circulating Aldosterone and Mortality in Female Nursing Home Residents
Abstraktband. 2012; -Biomarkers in Heart Failuren with Preserved Ejection Fraction - International Symposium; OCT 13-15, 2012; Graz, AUSTRIA. [Poster]

 

Trummer, O; Schwetz, V; Lerchbaum, E; Fahrleitner-Pammer, A; Pieber, T; Obermayer-Pietsch, B; Gugatschka, M; Renner, W; Dobnig, H. Vitamin-d-insuffizienz-Genotypen, Vitamin D, knochendichte und Frakturen
Osteologie. 2012; 1/2012: A49-A50.-Osteology 2012; 29.03. - 31.03.2012; Basel, CH. [Poster]
FullText

 

Wagner, D; Kniepeiss, D; Stiegler, P; Zitta, S; Muller, H; Meinitzer, A; Fahrleitner-Pammer, A; Rosenkranz, AR THE ASSESSMENT OF GFR AFTER ORTHOTOPIC LIVER TRANSPLANTATION USING CYSTATIN C AND CREATININE-BASED EQUATIONS
J HEPATOL. 2012; 56: S96-S96.-47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL); APR 18-22, 2012; Barcelona, SPAIN. Doi: 10.1016/S0168-8278(12)60242-6 [Poster]
Web of Science FullText FullText_MUG

 

Wagner, D; Knoepeiss, D; Amrein, K; Dimai, HP; Iberer, F; Tscheliessnigg, Ferlitsch, A; fahrleitner-Pammer, A. Vitamin D3 and survival in patients with end stage liver cirrhosis.
Osteology. 2012; 1/2012: A49-A49.-Osteology; 29.03. - 31.03.2012; Basel, CH. [Poster]
FullText

 

Wagner,D; Kniepeiss,D; Amrein, K; Dimai,HP; Iberer, F; Tscheliessnigg, KH; Pieber, T; Fahrleitner-Pammer, A. Vitamin D deficiency and HCV recurrence after liver transplantation.
Osteology. 2012; 1/2012: A49-A49.-Osteologie 2012; 29.03. - 31.03.2012; Basel, CH. [Poster]
FullText

 

Wagner,D; Prenner,G; Dobnig H, Pieber,TR, Obermayer-Pietsch, BM; Tomaschitz, A; Pilz, S; Fahrleitner-Pammer, A. Testosterone Replacement on Top of Bisphosphonate Therapy Has an Additional Benefit on Bone Mass, Libido and Sexual Activity in Male Cardiac Transplant Patients: A 5-Year Prospective Controlled Study
Journal of Endocrinology and Metabolism. 2012; 49: 332-332.-American Endocrine Society ; June 11th-15th; Houston Texas. [Poster]

 

Amrein, K; Amrein, S; Schnedl, C; Drexler, C; Dimai, HP; Dobnig, H; Tomaschitz, A; Pieber, TR; Fahrleitner-Pammer, A Sclerostin and Its Association with Age, Gender, Body Composition, Physical Activity and Bone Mineral Content in Healthy Adults
J MINER STOFFWECHS 2011; 18 (SUPPLEMENTUM 3). 2011; -Wissenschaftliche Herbsttagung der Österreichischen Gesellschaft zur Erforschung des Knochens und Mineralstoffwechsels (ÖGEKM); NOV 25-26, 2011; Vienna, AUSTRIA. [Poster]

 

Amrein, K; Dimai, HP; Dobnig, H; Fahrleitner-Pammer, A POSTOPERATIVE HYPOPARATHYROIDISM, LOW BONE TURNOVER AND INCREASE IN BONE MINERAL DENSITY DESPITE THYROXINE SUPPRESSIVE THERAPY IN A PREMENOPAUSAL WOMAN
OSTEOPOROSIS INT. 2011; 22: 182-183. [Poster]
Web of Science

 

Amrein, K; Fahrleitner-Pammer, A; Amrein, S; Drexler, C; Dimai, H; Pieber, TR; Tomaschitz, A; Dobnig, H Sclerostin Is Associated with Age, BMI and Bone Mineral Content, but Not Gender or Physical Activity in Healthy Adults
J Bone Miner Res. 2011; 26(Supp):-ASBMR; Sep 16th-20th 2011; San Diego, CA USA. [Poster]

 

Amrein, K; Pieber, T; Fahrleitner-Pammer, A; Amegah-Sakotnik, A; Urbanic, T; Mader, JK; Wagner, D; Zollner-Schwetz, I; Putz-Bankuti, C; Langmann A 2011 - The Gender Gap Continues
Endocr Rev 32: P3-202 . 2011; -The Endocrine Society's 93rd Annual Meeting; JUN 4-7, 2011; Boston, USA. [Poster]

 

Amrein, K; Putz-Bankuti, C; Amegah-Sakotnik, A; Urbanic, T; Mader, JK, Wagner, D; Pieber, TR; Prandl, E; Sareban, N; Zollner-Schwetz, I; Amrein, S; Langmann, A; Fahrleitner-Pammer, A Gender Disparity in editorial boards of major medical journals
Abstracts ÖGGSM – Österreichische Gesellschaft für geschlechtsspezifische Medizin Jahrestagung2011; -ÖGGSM – Österreichische Gesellschaft für geschlechtsspezifische Medizin Jahrestagung; APR 8-9, 2011 ; Vienna, AUSTRIA . [Oral Communication]

 

Amrein, K; Putz-Bankuti, C; Amegah-Sakotnik, A; Urbanic, T; Mader, JK; Wagner, D; Pieber, TR; Zollner-Schwetz, I; Fahrleitner-Pammer, A WOMEN IN ACADEMIC MEDICINE
J Klin Endokrinol Stoffw2011; -ÖGES Jahrestagung; MAY 12-13, 2011; Vienna, AUSTRIA . [Poster]

 

Amrein, K; Sourij, H; Pieber, TR; Dimai, HP; Fahrleitner-Pammer, A; Schnedl, C; Dobnig, H Critical Illness and Metabolic Bone Disease
Osteologie 2011 - Abstractband2011; -Osteologie Jahrestagung; MAR 23-26, 2011; Fürth, GERMANY. [Poster]

 

Amrein, K; Worm, H; Köhler, G; Mader, JK; Pieber, T; Fahrleitner-Pammer, A Moxibustion warning for diabetic patients
J Klin Endokrinol Stoffw2011; -ÖGES Jahrestagung; MAY 12-13, 2011; Vienna, AUSTRIA. [Poster]

 

Dimai, H; Chandran, M; Svedbom, A; Thaler, H; Amrein, K; Fahrleitner-Pammer, A; Zwettler, E; Borgstrom, F INCIDENCE OF HUMERAL FRACTURES IN AUSTRIA BETWEEN 1989 AND 2008
OSTEOPOROSIS INT. 2011; 22: 306-307.-European Congress on Osteoporosis & Osteoarthritis (ECCEO11-IOF); MAR 23-26, 2011; Valencia, SPAIN. [Poster]
Web of Science

 

Dimai, HP; Svedbom, A; Chandran, M; Amrein, K; Fahrleitner-Pammer, A; Zwettler, E; Borgstrom, F Epidemiology of humeral fractures in Austria between 1989 and 2008
BONE. . 2011; 48: S190-S191.-3rd Joint Meeting of the European Calcified Tissue Society & the International Bone and Mineral Society; MAY 7-11, 2011; Doi: 10.1016/j.bone.2011.03.449 [Poster]
Web of Science FullText FullText_MUG

 

Fahrleitner-Pammer, A osteoporosetherapie 2011 - die neue "Freiheit"
Bezirksärztefortbildung St. Michael; 03.03.2011; Leoben. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; Osteoporose Workshop in Traunkirchen
Osteoporose Workshop in Traunkirchen; 29.-30.06.2011; Traunkirchen OÖ. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; .....nur hemmen ist zuwenig
Meet the expert ; Herbsttagung der ÖGKM; Wien, Austria. 2011. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Prolia, die innovative Osteoporosetherapie
Bezirksärsztefortbildung ; 02.03.2011; Weiz. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; Therapiemanagement 2011
Bezirksärztefortbildung Wolfsberg; 18.01.2011; Wolfsberg. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; Prolia - eine Innovation in der Osteologie
Bezirksärztefortbildung Liezen; 17.02.2011; Bad Mitterndorf. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; Bone Quality and Denosumab
Trinationales Ad-Board ; 27.01.2011; Vienna. 2011. [Oral Communication]

 

Fahrleitner-Pammer, A; Innovation der Osteoporosetherapie
Fortbildung im KH der Elisabethinen; 01.03.2011; KH der Elisabethinen Klagenfurt. 2011. [Oral Communication]

 

Fahrleitner-Pammer; A Osteoporosetherapie beim geriatrischen Patienten
Bone Academy 2011; 12.11.2011; Wien. 2011. [Keynote lecture]

 

fahrleitner-Pammer, A; Sinn und Unsinn der Osteoporosetherapie
Bezirksärztefortbildung ; 25.05.2011; lassnitzhöhe. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; Sequenztherapie in der osteoporose
Osteology. 2011; 1/2011(20):1-81.-Osteologie; 23 - 26.03.2011; Fuerth, Deutschland. [Oral Communication]

 

Fahrleitner-Pammer, A; The Patient with severe osteoporosis - how to treat!
International Bone Conference Bruessel; Oct 7th - 8 th, 2011; Bruessel; Belgium. 2011. [Oral Communication]

 

Fahrleitner-Pammer, A; Osteoporose: Versorgungssituation in Österreich
DVO - Meeting München; 8th October 2011; München, Germany. 2011. [Oral Communication]

 

Fahrleitner-Pammer, A; Nur hemmen ist zuwenig
Bezirksärztefortbildung ; 23.11.2011; Villach. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; Die gepaarte Beckenkammbiopsie - Sinn oder Unsinn?
Osteology2011; 1/2011(20):1-81.-Osteologie 2011; 23 - 26.03.2011; Fuerth, Deutschland. [Oral Communication]

 

Fahrleitner-Pammer, A; Aclasta - innovative Therapie für Alle
Spitalsärztefortbildung im LKH Bruck; 22.06.2011; Bruck an der Mur. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; Roche Satellitensymposium
19.Osteoporoseforum ; 19. - 21.Mai, 2011; St. Wolfgang,. 2011. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; Prolia und Nierenfunktion
Fortbilldung Nephrologie und Hämodialyse; 13.04.2011; Graz. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; Osteoporosetherapie bei Niereninsuffizienz
11. Wiener Internationaler Geriatriekongress; May, 12-14, 2011; Vienna, Austria. 2011. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Sinn und Unsinn der Osteoporosetherapie
Osteoporosewochenende Salzburg ; 11. - 13. März 2011; Salzburg, Austria. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; Sekundäre Osteoporose
Bezirksärztefortbildung graz Umgebung; 25.01.2011; unterpremstätten. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; kortikal versus trabekular Bone under Denosumab
; 03.02.2011; Vienna. 2011. [Oral Communication]

 

Fahrleitner-Pammer, A; Kein Schicksal , eine Erkrankung!
Intensiv Workshop ; 13.05.2011 - 14.05.2011; Asia Linsberg resort. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; Osteoporose Workshop in Radstadt Sinn und Unsinn der Osteoporosetherapie
Osteoporose Workshop in Radstadt Sinn und Unsinn der Osteoporosetherapie; 21. 24.06.2011; Radstadt. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; Aclasta - innovative Therapie für Alle.
Spitalsärztefortbildung im LKH Leoben; 22.06.2011; LKH Leoben. 2011. [Keynote lecture]

 

Fahrleitner-Pammer. A; Sicher effizient und nachhaltig!
Diplomfortbildung LKH West ; 22.03-2011; Graz. 2011. [Keynote lecture]

 

Fahrleitner-Pammer; A, Prolia, eine innovative Therapieoption im der Osteoporose
Bezirksärztefortbildung St. Michael; 10.03.2011; St. Michael. 2011. [Keynote lecture]

 

Fahrleitner-Pammer; A, Prolia - die Innovation in der Osteoporosetherapie
Bezirksärztefortbildung in Weiz; 09. 03. 2011; Weiz. 2011. [Oral Communication]

 

Fahrleitner-Pammer; A, Osteoporose - sicher, effizient und nachhaltihg therapieren
Osteoporosewochenende Salzburg; 12. - 14. 03. 2011; Salzburg. 2011. [Keynote lecture]

 

Fahrleitner-Pammer; A, Prolia - eine Innovation in der Osteoporosetherapie
Interne Fortbildung im KH der Elisabethinen ; 08.03.2011; Klagenfurt. 2011. [Keynote lecture]

 

Fahrleitner-Pammer; A, MEET THE EXPERT
Osteoporosewochenende Salzbug ; 12. - 14. 03. 2011; Salzburg, Austria. 2011. [Keynote lecture]

 

Fahrleitner-Pammer, A; Dobnig, H; Stepan, J; Petto, H; Pavo, I Increase of Serum PINP Is Associated with Trabecular Microstructural Improvement in Patients on Teriparatide Pretreated with Alendronate
J Bone Miner Res. 2011; 26(Supp):-ASBMR; Sep 16th-20th 2011; San Diego, CA USA. [Oral Communication]

 

Fahrleitner-Pammer, A; Fenzl, K; Wagner, D; Muschitz, C; Amrein, K; Pieber, T; Obermayer-Pietsch, B; Dimai, H Three-Monthly i.v. Ibandronate Following Long-Term Treatment With Oral Alendronate; Results From a Two-Year Prospective Open-Labeled Study
J Bone Miner Res. 2011; 26(Supp):-ASBMR; Sep 16th-20th 2011; San Diego, CA USA. [Poster]

 

Fahrleitner-Pammer, Astrid Therapieeffekte auf kortikalen und trabekulären Knochen - wie valide sind Biopsie Daten
Advisory Board Wien; 18.11.2011; Wien. 2011. [Oral Communication]

 

Fahrleitner-Pammer,A; The European FORSTEO Observational Study (EFOS): Final Results
Osteoporosis International (Suppl1)2011; 32(132):45-45.-ECTS ; May 7th-10th 2011; Athens, Greece. [Oral Communication]
FullText

 

Fahrleitner-Pammer,A; Der Frakturpatient - was tun bei schwerer Osteoporose?
Österreichische Jahrestagung für Unfallchirurgie; Oct 6Th - 8Th , 2011; Salzburg, Österreich. 2011. [Oral Communication]

 

Fahrleitner-Pammer,A; Die Problematik der sekundären Osteoporose
Spitalsärztefortbildung; 30.11.2011; Hartberg. 2011. [Keynote lecture]

 

Fahrleitner-Pammer,A; Teriparatid kann mehr, Daten vom ASBMR 2011 und der EFOS Studie
Wissenschaftlicher Herbsttagung der ÖGKM; 25.-26.11.2011; Wien, Austria. 2011. [Keynote lecture]
FullText

 

Fahrleitner-Pammer,A; Osteoporose UPDATE
bezirksäerztefortbildung; 08.06.2011; Zeltweg. 2011. [Keynote lecture]

 

Fahrleitner-Pammer,A; Warum brechen Knochen?
Minimed; 31.03.2011; graz. 2011. [Keynote lecture]

 

Fahrleitner-Pammer,A; Treatment of patients with severe osteoporosis - The EFOS Study
Clinical conference on bone metabolism; 26.10.2011; Stockhol, Sweden. 2011. [Keynote lecture]

 

Fahrleitner-Pammer,A; Treatment of patients with severe osteoporosis - The EFOS Study
Experts in the Bone Field; 26.10.2011; Götheburg, Sweden. 2011. [Keynote lecture]

 

Fahrleitner-Pammer,A; Renale Osteopathie, Diagnostik und Therapiemöglichkeiten
Gemeinsame Jahrestagung ÖGH und ÖGN; Nov 4-5,2011; Gmunden. 2011. [Oral Communication]
FullText

 

Fahrleitner-Pammer,A; Amgen Satellit
19. Osteoporoseforum ; 19.-21. Mai 2011; St. Wolfgang,. 2011. [Keynote lecture]
FullText

 

Friedl C, Rosenkranz AR, Fahrleitner-Pammer A Die chronische Niereninsuffizienz (CKD) ist ein häufig unerkanntes Gesundheitsrisiko.
Jahrestagung der ÖGN und ÖGH; NOV, 4-5, 2011; Gmunden, Österreich. 2011. [Oral Communication]

 

Friedl C, Rosenkranz AR, Fahrleitner-Pammer A Chronic Kidney Disease-Mineral and Bone Disorder in a Cohort of Internal Inpatients: A Prospective Analysis.
Annual Meeting of the American Society of Nephrology; Nov 9-13, 2011 ; Philadelphia. 2011. [Poster]

 

Friedl C, Rosenkranz AR, Fahrleitner-Pammer A. Die chronische Niereninsuffizienz (CKD) ist ein häufig unerkanntes Gesundheitsrisiko.
Kongress für Nephrologie; SEP 10-13, 2011; Berlin, GERMANY. 2011. [Poster]

 

Friedl C, Rosenkranz AR, Piswanger-Sölkner JC, Stiegler C, Pieber T, Fahrleitner-Pammer A Chronische Niereninsuffizienz (CKD), Kochen- und Mineralstoffwechsel bei internistischen Akutpatienten: Eine prospektive Analyse
Kongress für Nephrologie ; SEP 10-13, 2011; Berlin. 2011. [Poster]

 

Friedl C, Rosenkranz AR, Piswanger-Sölkner JC, Stiegler C, Pieber T, Fahrleitner-Pammer A Chronische Niereninsuffizienz (CKD), Kochen- und Mineralstoffwechsel bei internistischen Akutpatienten: Eine prospektive Analyse.
Jahrestagung der ÖGN und ÖGH, Gmunden, Österreich; Nov 4-5, 2011; Gmunden. 2011. [Oral Communication]

 

Jan Stepan, Charles University, Czech Republic; Harald Dobnig, Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Austria; Astrid Fahrleitner-Pammer, Medical University Graz, Austria; Yanfei Ma, Eli Lilly and Company, USA; Qing Zeng, Eli Lilly and Company, USA; Xiaohai Wan, Lilly USA, LLC, USA; Fernando Marin, Eli Lilly and Company, Spain; Imre Pavo, Eli Lilly and Company, Austria Effects of Teriparatide on Cortical Histomorphometric Variables in Patients Receiving Long-Term Alendronate Therapy
J Bone Miner Res 26(Suppl 1) 2011, . 2011; 26(1):322-322.-ASBMR 2011; Sep 16th-20th 2011; San Diego, CA USA. [Oral Communication]
FullText

 

Muschitz, C; Haschka, J; Kocijan, R; Fahrleitner-Pammer, A; Nirnberger, G; Trubrich, A; Bittighofer, C; Resch, H Treatment with PTH 1-84 in Male Patients with Severe Osteoporosis – Results from a Prospective 24 Month Open-Label Trial
J Bone Miner Res. 2011; 26(Supp):-ASBMR; Sep 16th-20th 2011; San Diego, CA USA. [Poster]

 

Muschitz, C; Haschka, J; Kocijan, R; Trubrich, A; Fahrleitner-Pammer, A; Nirnberger, G; Resch, H Treatment with PTH 1-84 in male patients with severe osteoporosis - Results from a prospective 24 month open-label trial
WIEN KLIN WOCHENSCHR. . 2011; 123(17-18):A51-A51.-42. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; OCT 5-8, 2011; Innsbruck, AUSTRIA. [Poster]
Web of Science

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Bittighofer, C; Trubrich, A; Kuhne, F; Waneck, R; Resch, H Teriparatide and antiresorptive combination treatment subsequent to 9 Months of osteoanabolic monotherapy in female patients with severe osteoporosis and prevalent fragility fractures
WIEN KLIN WOCHENSCHR. . 2011; 123(17-18):A51-A51.-42. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; OCT 5-8, 2011; Innsbruck, AUSTRIA. [Poster]
Web of Science

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Kühne, F; Bittighofer, C; Trubrich, A; Waneck, R; Resch, H Teriparatide and Antiresorptive Combination Treatment Subsequent to 9 Months of Teriparatide Monotherapy
J Bone Miner Res. 2011; 26(Supp):-ASBMR ; Sep 16th-20th 2011; San Diego, CA USA. [Oral Communication]

 

Olivia Trummer, Medical University, Austria; Elisabeth Wehr, Medical University, Austria; Verena Schwetz, Medical University, Austria; Daniela Walter, Medical University, Austria; Markus Gugatschka, Medical University, Austria; Wilfried Renner, Medical University, Austria; Astrid Fahrleitner-Pammer, Medical University Graz, Austria; Harald Dobnig, Diagnostikinstitut Dr.B.Fueger, Institute for Endocrine and Bone Diseases, AUT; Thomas Pieber, Medical University, Austria; Barbara Obermayer-Pietsch, Medical University Graz, Austria Allelic Determinants of Vitamin D Insufficiency, Bone Mineral Density and Past and Prospective Bone Fractures
J Bone Miner Res. 2011; 26(Supp):-ASBMR; Sep 16th-20th 2011; San Diego, CA USA. [Poster]

 

Sampl, E; Dobnig, H; Obermayer-Pietsch, B; Dimai, HP; Pieber, T; Fahrleitner-Pammer, A; Development and set-up of a Fracture Liaison Service (FLS)
Osteology. 2011; 1/2011(20):49-49.-Osteology ; 23 - 26.03.2011; Fuerth, Deutschland. [Poster]

 

Trummer, O; Schwetz, V; Walter, D; Wehr, E; Gugatschka, M; Fahrleitner-Pammer, A; Dobnig, H; Renner, W; Pieber, TR; Obermayer-Pietsch, B Vitamin D insufficiency genotypes, bone mineral density and past and prospective bone fractures.
Österreichische Gesellschaft zu Erforschung des Knochens und Mineralstoffwechsels. 2011; -Wissenschaftliche Herbsttagung der ÖGEKM ; NOV 25-26, 2011; Vienna, AUSTRIA. [Oral Communication]

 

Wagner, D; Dimai, HP; Amrein, K; Dobnig, H; Kniepeiss, D; Fahrleitner, A COMBINATION THERAPY WITH IBANDRONATE AND CALCITRIOL IS EFFECTIVE IN PATIENTS FOLLOWING LIVER TRANSPLANTATION (LTX): A THREE YEAR PROSPECTIVE CONTROLLED STUDY
TRANSPL INT. . 2011; 24: 345-345.-15th Congress of the ESOT and 22nd Annual Conference of the BSHI; SEP 4-7, 2011; Glasgow, UK. [Poster]
Web of Science

 

Wagner, D; Dimai, HP; Amrein, K; Pieber, T; Dobnig, H; Stiegler, P; Sereinigg, M; Beham-Schmid, C; Fahrleitner-Pammer, A Paired Bone Biopsies – How Valid Are They? A Prospective Controlled Study!
J Bone Miner Res. 2011; 26(Supp):-ASBMR; Sep 16th-20th 2011; San Diego, CA USA. [Poster]

 

Wagner, D; Dobnig, H; Tscheliessnigg, K; Prenner, G; Wasler, A; Piswagner-Solkner, C; Kniepeiss, D; Fahrleinter, A TESTOSTERONE REPLACEMENT IN CARDIAC TRANSPLANT PATIENTS ON TOP OF BISPHOSPHONATE THERAPY EXERTS MULTIPLE BENEFITS ON BONE MASS, LIBIDO AND SEXUAL ACTIVITY
TRANSPL INT. 2011; 24: 332-332. [Oral Communication]
Web of Science

 

Wagner, D; Fenzl, K; Dimai, H; Dobnig, H; Amrein, K; Kniepeiss, D; Stiegler, P; Fahrleitner-Pammer, A Combination Therapy with Ibandronate and Calcitrol Is Effective in Patients Following Liver Transplantation (LTX): A Three Year Prospective Controlled Study
J Bone Miner Res. 2011; 26(Supp):-ASBMR; Sep 16th-20th 2011; San Diego, CA USA. [Poster]

 

Wagner, D; Telsnig, B; Kniepeiss, D; Jakoby, E; Schaffellner, S; Fahrleitner-Pammer, A; Wasler, A; Roller, R; Tscheliessnigg, K THE ROLE OF SERUM ALBUMIN (SA) IN THE PREDICTION OF MALNUTRITION IN PATIENT AT LEAST ONE HEART TRANSPLANTATION (HTX)
TRANSPL INT. 2011; 24: 270-271. [Poster]
Web of Science

 

Amrein, K; Schnedl, C; Dobnig, H; Fahrleitner-Pammer, A Exceptional bone mineral density gain over 6 years attributable to permanent hypoparathyroidism after thyroidectomy in a 36-year old woman
J Klin Endokrinol Stoffw2010; 3 (Sonderheft 1): -Österreichische Gesellschaft für Endokrinologie; MAY 7-8, 2010; Vienna, AUSTRIA. [Poster]

 

Amrein, K; Amrein, S.; Amegah-Sakotnik A; Pill, V; Fahrleitner-Pammer, A; Dimai, HP; Dobnig, H Physical activity is superior to body mass index in modulating bone mineral density in healthy adults
Journal für Mineralstoffwechsel2010; Sonderheft 2: -Wissenschaftliche Herbsttagung der Österreichischen Gesellschaft für Knochen und Mineralstoffwechsel; NOV 26-27, 2010; Vienna, AUSTRIA . [Oral Communication]
FullText

 

Amrein, K; Dimai, H; Dobnig, H; Fahrleitner-Pammer, A; Postoperative Hypoparathyroidism leading to impressive Increases in Bone Mineral Density over 6 years in a 36 year old woman
JBMR. 2010; 25(Sup1):353-354.-Asbmr; 14-19.Oct; Toronto, Canada. [Poster]

 

Amrein, K; Dobnig, H; Dimai, HP; Fahrleitner-Pammer, A Yearly bone mineral increase of 2% caused by permanent hypoparathyroidism despite TSH-suppressive therapy
Journal für Mineralstoffwechsel2010; Sonderheft 2: -Wissenschaftliche Herbsttagung der Österreichischen Gesellschaft für Knochen und Mineralstoffwechsel ; NOV 26-27, 2010; Vienna, AUSTRIA. [Poster]

 

Amrein, K; Dobnig, H; Dimai, HP; Fahrleitner-Pammer, A Yearly bone mineral density increase of 2% caused by permanent hypoparathyroidism despite TSH-suppressive therapy
www.oegkm.at2010; -Wissenschaftliche herbsttagung der ÖGEKM; 26. - 27. November 2010; Vienna. [Poster]

 

Amrein, K; Sourij, H; Pieber, TH; Dimai, HP; Fahrleitner-Pammer, A; Amrein, ST; Dobnig, H Metabolic bone disease in Vitamin D - deficient critically Ill medical patients
Wissenschaftlicge Herbsttagung der ÖGEKM ; 26.-27. November 2010; Vienna. 2010. [Oral Communication]
FullText

 

Amrein, K; Sourij, H; Pieber, TR; Dimai, HP; Fahrleitner-Pammer, A; Amrein, S; Dobnig, H Metabolic bone disease in vitamin D ¿ deficient critically Ill medical patients
Journal für Mineralstoffwechsel2010; Sonderheft 2: -Wissenschaftliche Herbsttagung der Österreichischen Gesellschaft für Knochen und Mineralstoffwechsel; NOV 26-27, 2010; Vienna, AUSTRIA. [Poster]

 

Dobnig, H; Scharnagl, H; Renner, W; Seelhorst, U; Wellnitz, B; Kinkeldei, J; Bohm, B; Fahrleitner-Pammer, A; Marz, W INFLUENCE OF 25-HYDROXYVITAMIN D STATUS ON SERUM PARATHYROID HORMONE LEVELS VARIES WITH KDOQI CLASSIFICATION OF RENAL FUNCTION AND IS INDEPENDENT OF 1,25 DIHYDROXYVITAMIN D CONCENTRATIONS
OSTEOPOROSIS INT. 2010; 21: 11-11. -IOF World Congress on Osteoporosis 10Th European Congress on Clinical an Economic Aspects of Osteoporosis and Osteoarthritis ; 5-8 May ; Florence, Italy. [Oral Communication]
Web of Science FullText

 

Fahrleitner-Pammer, A Osteoporose - mein Schicksal eine Erkrankung
Bezirksärztetagung Tröpolach ; 16.12.2010; Tröpolach. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A Klinische Risikoerfassung und Eingangsuntersuchungen
DVO Zertifizierungskurs II ; 05. - 06. 11. 2010; Graz. 2010. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A Knochenbruch trotz guter Knochendichte?
Wiener osteoporosetag; 28.10.2010; Wien, Austria. 2010. [Oral Communication]

 

Fahrleitner-Pammer, A Anabolic therapy in the severely osteoporotic patient
Hungarian Rheumatology2010; 51(3):170-170.-8Th Central European Congress of Rheumatology; 23rd - 25th September 2010; Sopron, Hungary. [Oral Communication]

 

Fahrleitner-Pammer, A osteoporose - effizient therapieren
Wokrshop; 26.- 27. februar; Stegersbach. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A Osteoporosetherapie 2010 - wem, was, wann?
Beziksärztefortbildung ; 16. Juni 2010; Salzburg. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A Bone Quality
Wiener Osteoporosetag; 28.09.2010; Wien, Austria. 2010. [Oral Communication]

 

Fahrleitner-Pammer, A Ernaährung und Lebensführung
Zertifizierungskurs zum DVO Osteologen; 23. - 24. April 2010; Graz. 2010. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A Evista- immer noch der einzige SERM in der Osteologie
18. Osteoporoseforum; 27.-29. Mai 2010; St. Wolfgang. 2010. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A Osteoporose Update 2010
Qualitätszirkel Bezirk Feldbach; 08.06.2010; Feldbach. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A Parenterale Osteoporosetherapie
Sommerfortbildung RADSTDT; 03.-06. juni 2010; radstadt. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A Nicht nur Osteoporose sondern auch Schmerzen behandeln!
Interdiziplinärer Workshop: Der Schmerzpatient; 11.-12.Juni 2010; Panhans Semmering. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A Anatomie und Pathophysiologie des Knochens
DVO Grundkurs 1; 23. - 24. April 2010; Graz. 2010. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A Diagnostik der Osteoporose - Zielvorgaben
DVO Zertifizierungskurs II ; 05. - 06. 11. 2010; Graz. 2010. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A Stufentherapie der Osteoporose
Workshop Knochen- Schmerz - Fraktur Heilung; 23. - 24. April 2010; Frauenkirchen. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A Sinn und Unsinn in der Osteoporosetherapie
Osteoporose auch eine Krankheit des Gehirns?; 17.11.2010; Bad Pirawarth. 2010. [Oral Communication]

 

Fahrleitner-Pammer, A Die Rolle von Vitamin D in der Osteoporosetherapie
Fortbildung LKH Wagna; 17.November 2010; LKH WAGNA. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A Nicht ganz Alltägliches aus der osteologischen Praxis
Eröffnungsfortbildung Apparategemeinschaft Graz St. Peter; 05.11.2010; Graz. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A Laboruntersuchungen
DVO Zertifizierungskurs II ; 05. - 06. 11. 2010; Graz. 2010. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A Osteodensitometrieverfahren für Wirbelsäule und proximales Femur
DVO Zertifizierungskurs II ; 05. - 06. 11. 2010; Graz. 2010. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A Enterale versus Parenterale Therapie- ist sie wirklich besser?
Bezirksärztefortbildung; 16. Juni 2010; salzburg. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A Der Knochen im Wandel der weiblichen Hormone
Wintertagung der Österreichischen Gesellschaft für Gynäkologie; 20 - 26. Jänner; Lech. 2010. [Oral Communication]

 

Fahrleitner-Pammer, A Interdisziplinäres Frakturmanagement der osteoporose - Kooperation Klinik und niedergelassener bereich
Wintertagung der ÖGAM ; 16. - 23. 01. 2010; ZUG. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A; Die Bedeutung und Evidenz von Sequenztherapien in der Osteoporose
Tri - nationales Advisoryboard Meeting in Wien; 23. - 24. September 2010; Wien. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A; Erkennen und handeln - Endokrinologie im Alltag
Bezirksärztefortbildung; 15.12.2010; Villack. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A; Vitamin D - das lange unterschätze Hormon
Geriatriekongress ; 08. - 11. März 2010; bad Hofgastein. 2010. [Oral Communication]

 

Fahrleitner-Pammer, A; Der geriatrische Osteoporosepatient
Forum für Geriatrie und Gerontologie ; 08.03. - 11.03.2010; Bad Hofgastein. 2010. [Oral Communication]

 

Fahrleitner-Pammer, A; Osteoporose - kein Schicksal, eine Erkrankung!
Bezirksärztefortbildung Graz Andritz; 28.09.2010; Graz. 2010. [Keynote lecture]

 

fahrleitner-Pammer, A; Parenterale versus enterale Osteoporosetherapie
osteoporose Weekend; 12. - 14. März ; salzburg. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A; Osteoporose - kein Schicksal, eine Erkrankung
Bezirksärztefortbildung St.Peter/Graz; 29. 09.2010; Graz. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A; Modernes Therapiemanagement
Spitalsärztefortbildung LKH Feldbach; 13.01.2011; Feldbach. 2010. [Oral Communication]

 

Fahrleitner-Pammer, A; Osteoporosetherapie - 2010: wo stehen wir heute?
Bezirksäeztefortbildung Klagenfurt; 16.03.2010; klagenfurt. 2010. [Keynote lecture]

 

Fahrleitner-Pammer, A; Knochenqualität und Biochemie
DVO Kurs Osteologe; 23. - 24. April 2010; Graz. 2010. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Ljunggren, O; Langdahl, B; Walsh, B; Barker, C; Lems, W; Karras, D; Rajzbaum, G; Jakob, F; Barrett, A; Marin, F CHANGES IN QUALITY OF LIFE AND BACK PAIN IN WOMEN WITH OSTEOPOROSIS TREATED WITH RHPTH(1-34) (TERIPARATIDE): 36 MONTH RESULTS FROM THE EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS)
OSTEOPOROSIS INT. 2010; 21: 156-157. -IOF World Congress on Osteoporosis tenth European Congress on Clinical and Economic Aspects of Osteoporosis and osteoarthritis; 5-8 may 2010; Florence, Italy. [Poster]
Web of Science FullText

 

Fahrleitner-Pammer, A; Obermayer-Pietsch, B; Wagner, D; Tscheliessnigg, KH; Kniepeiss, D; Iberer, F; Pieber, TR; Piswanger-Sölkner, JC; Dobnig, H Testosterone Replacement in cardiac transplant patients on top of Bisphosphonate therapy exerts multiple benefits on bone mass, Libido and sexual function: A 5 Year prospective study.
Journal für Klinische Endokrinologie und Stoffwechsel. 2010; 1(supp):16-15.-15. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel; 7.-8. Mai; Vienna, Austria. [Poster]
FullText

 

Fahrleitner-Pammer, A; Pieber, TR; Piswanger-Sölkner, JC, Obermayer-Pietsch, BM; Wagner, D; Tscheliessnigg, KH; Dobnig, H; Type-2 diabetes mellitus is a common complication following cardiac transplantation: does developing glycemia prevent catch-up in bone mineral density?
Journal für Klinische Endokrinologie und Stoffwechsel. 2010; 3(1):9-9.-15. Jahrestagung der österreichischen Gesellschaft für Endokrinologie und Stoffwechsel; 7.-8. Mai; Vienna, Austria. [Poster]
FullText

 

Fahrleitner-Pammer, A; Wagner, D Ibandronat im Hochrisikokollektiv
18. Osteoporoseforum ; 27.-29. Mai 2010; St. Wolfgang. 2010. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Wagner, D Ibandronat in Hochrisikopopulationen
Spectrum Osteoporose2010; 2(1):8-8.-18. Osteoporoseforum; 27.-29. Mai 2010; St. Wolfgang. [Oral Communication]
FullText

 

Fahrleitner-Pammer,A; Koochenqualität - zählt siewirklich?
Jahrestagund der DVO ; 05. - 08. März Berlin; Berlin. 2010. [Keynote lecture]
FullText

 

Fahrleitner-Pammer,A; Das eine tun, das andere nicht lassen - das alles können SERMs
OsteoKolleg St. Pölten; 29. April 2010; St. Pölten. 2010. [Keynote lecture]
FullText

 

Fahrleitner-Pammer,A; Management der sekundären Osteoporose
Bezirksärztefortbildung Friesach; 27.April 2010; Graz Umgebung. 2010. [Keynote lecture]

 

Friedl, C; Dobnig, H; Pieber, TR; Piswanger-Sölkner; JC; Stiegler,C; Warnkross, H; Fahrleitner-Pammer, A; Vitamin-D- Status internistischer Akutpatienten: eine prospektive Kohortenstudie
www. osteologie-de.com2010; 19(supp):58-58.-osteologie 2010; 3.-6. März; Berlin, germany. (ISBN: 1019-1021 ) [Poster]

 

Friedl, C; Dobnig, H, Piswanger-Sölkner, JC; Sampl, EM; Fahrleitner-Pammer, a; Eine 55-jährige patientin mit bekannter Osteoporose und unklarer Gewichtszunahme: Morbus Cushing oder doch nicht?
Journal für Klinische Endokrinologie und stoffwechsel. 2010; 3(1):9-9.-15. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel; 7.-8. Mai; Vienna, Austria. [Poster]
FullText

 

Fruhwald, FM; Fahrleitner-Pammer, A; Wagner, D; Haas, J; Erdmann, E; Tavazzi, L; Schoppet, M; Cleland, JGF Prognostic impact of serum osteoprotegerin, NT-pro-BNP and big endothelin levels in patients with heart failure and ventricular dysynchrony. Results from the CARE-HF study.
Eur Heart J2010; 31: 1048-1048.-ESC congress 2010; Aug 28 - Sep 1, 2010; Stockholm, Schweden. [Poster]
Web of Science

 

Karl, W; Dobnig , H; Pieber, TH; Wagner, D; Amrein, K; Dimai, HP; Ferstl-Rohrbacher, A; Gerdova, J; Fahrleitner-Pammer, A Treatment with antiresorptive agents and PTH and the effects on bone turnover in female wistar rats
www.oegekm.at2010; -Wissenschaftliche Herbsttagung der ÖGEKM; 26. - 27. November 2010; Vienna. [Poster]

 

Karl, W; Dobnig, H; Pieber, TR; Dimai, HP; Wagner, D; Amrein, K; Fahrleitner-Pammer, A Treatment with antiresorptive agents and PTH and the effects on bone turnover in femal wistar rats
Abstractbook Joint ZMF and Doctoral Days 2010; 1: P6-P6.-Joint ZMF and Doctiral Days; 05. - 06. 11. 2010; Graz. [Poster]

 

Karl, W; Fahrleitner-Pammer, A; Dandachi, N; Strutz, J; Rapp, N; Pieber, TH; Samonigg, H; Balic, M Breast cancer stem cells and their responsiveness to zoledronic acid and anti-RANKL antibody
www.oegekm.at2010; -Wissenschaftliche Herbsttagung der Ögekm ; 26. - 27. November 2010; Vienna. [Poster]

 

Köhler, G; Bock, G; Fahrleitner-Pammer, A; Mader, J; Pieber, TH Der akute Charcot Fuß wird häufig verspätet diagnostiziert und damit eine adäquate Therapie zu spät eingeleitet ¿ ein Fallbericht
www.oegekm.at2010; -Wissenschaftliche Herbsttagung der Ögekm; 26. - 27. November 2010; Vienna. [Poster]

 

Kuehne, F; Fahrleitner-Pammer, A; Resch, H; Kocijan, R; Muschitz; C; Vitamin D Insufficiency as a possible Explanation for the lack of BMD increase in bisphosphonate pretreated male patients with fractures and PTH 1-84
JBMR. 2010; 25(Supp):205-205.-ASBMR; 14-19.Oct; Toronto, Canada. [Poster]

 

Lems, WF; Ljunggren, O; Langdahl, B; Walsh, B; Barker, C; Fahrleitner-Pammer, A; Karras, D; Rajzbaum, G; Jakob, F; Barrett, A; Marin, F FRACTURE INCIDENCE AND CHANGES IN QUALITY OF LIFE AND BACK PAIN IN WOMEN WITH OSTEOPOROSIS TREATED WITH RHPTH(1-34) (TERIPARATIDE): 36 MONTH RESULTS FROM THE EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS)
Proceedings of Eular 20102010; 1(1012):321-321.-EULAR; 16. - 19.06.2010; Rom - Italy. [Oral Communication]
FullText

 

Lind, A; Dobnig, H; Fahrleitner-Pammer, A; Year-long survival with untreated panhypopituitarism following surgery for acromegaly: A case report
Journal für Klinische Endokrinologie und Stoffwechsel. 2010; 1(supp):14-14.-15. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel; 7.-8. Mai; Vienna, Austria. [Poster]
FullText

 

Muschitz, C; Haschka, J; Kocijan, R; Kühne, F; Putz, M; Fahrleitner-Pammer, A; Thun, M; Gallowitsch, HJ; Rechberger, M; Mayr, H; Resch, H; Vitamin D deficiency as a possible explanation for lack of BMD increase in male patients with fractures and PTH 1-84 therapy.
www.osteologie-de.com2010; 19(supp):55-55.-Osteologie 2010; 3. - 6. März 2010; Berlin, germany. (ISBN: 1019-1021 ) [Poster]

 

Pirker, T; Muschitz, C; Fahrleitner-Pammer, A; Roschger, P; Kocijan, R; Haschka, J; Resch, H; Geschlechtsspezifische Unterschiede in transiliakalen Beckenkammbiopsien bei juvenilen patientinnen mit Frakturen unklarer Genese.
www.osteologie-journal.de2010; 19(1):32-32.-Osteologie 2010; 3.-6. März; Berlin, germany. (ISBN: 1019-1021 ) [Poster]

 

Reid, I; Miller, P; Brown, JP; Kendler, D; Fahrleitner-Pammer, A; Valter, I; Maasalu, K; Bolognese, M; Woodson, G; Bone, HG; Ding, B; Wagman, RB; San Martin, J; Ominsky, MS; Dempster, DW EFFECT OF DENOSUMAB TREATMENT ON BONE HISTOLOGY AND HISTOMORPHOMETRY: THE FREEDOM AND STAND STUDIES
OSTEOPOROSIS INT. 2010; 21: 134-134. -11.-IOF World Congress on Osteoporosis 10Th European Congress on Clinical an Economic Aspects of Osteoporosis and Osteoarthritis ; 5-8 May ; Florence, Italy. [Poster]
Web of Science FullText

 

Sampl, E; Dobnig, H; Obermayer-Pietsch, B; Dimai, HP; Pieber, T; Fahrleitner-Pammer, A Development and set-up of a " Fracture Liaison Service (FLS)" in Styria
Abstract book of the ZMF and Doctorial Joint Days2010; P93-P93.-Joint ZMF and Doctoral Days ; 05. - 06. 11. 2010; Graz. [Poster]

 

sampl, E; Wagner, D; Friedl, C; Dobnih, H; Fahrleitner-Pammer, A; Vitamin D deficiency following billroth II Surgery- How much vitamin d is enough?
15. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel. 2010; 1(supp):29-29.-15. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel; 7.-8. Mai; Vienna, Austria. [Poster]
FullText

 

Schnedl, C; ; Fahrleitner-Pammer, A; Dimai, HP; Schilcher, G; Amrein, K Vitamin D: Rescue for many, threat for some?
Journal für Mineralstoffwechsel2010; Sonderheft 2: -Wissenschaftliche Herbsttagung der Österreichischen Gesellschaft für Knochen und Mineralstoffwechsel ; NOV 26-27, 2010; Vienna, AUSTRIA. [Poster]

 

Stocker, P; Wehr, E; Schweighofer, N; Phuong, U; Fahrleitner-Pammer, A; Dobnig, H; Pieber, T; Obermayer-Pietsch, B; Calcium Sensing Rezeptor (A986S)-Polymorphismus, Frakturrisiko und Knochenultraschall.
www.osteologie-journal.de2010; 19(supp):38-38.-Osteologie 2010; 3. - 6. März 2010; Berlin, germany. (ISBN: 1019-1021 ) [Poster]

 

Wagner, D; Adunka, C; Kaindlbauer, M; Kniepess, D; Schaffellner, S; Jakoby, E; Iberer, F; Roller-Wirnsberger, R; Fahrleitner-Pammer, A; Tscheliessnigg, KH Comparison of Antrophometric Measurements, Laboratory Parameters and Bio Impedance Analysis in the Assessment of Malnutrition in Patients 5, 10 and 15 Years after Liver Transplantation
LIVER TRANSPLANT. 2010; 16(6):S248-S248.-Meeting of the International Liver Transplantation Society; JUN 10-16; Hongkong, CHINA. [Poster]
Web of Science

 

Wagner, D; Dobnig, H; Dimai, HP; Obermayer-Pietsch, BM; Amrein, K; Kniepeiss, D; Iberer, F; Tscheliessnigg, KH; Fahrleitner-Pammer, A Combination Therapy with Ibandronate and calcitriol is effective in patients following liver transplantation (LTX): A three year prospective controlled study.
Abstractbook Joint ZMF and Doctoral Days2010; P7-P7.-Joint ZMF and Doctoral Days 2010; 05. - 06. 11. 2010; Graz. [Oral Communication]

 

Wagner, D; Dobnig, H; Iberer, F; Prenner, G; Kniepeiss, D; Leb, G; Tscheliessnig, KH; Piswanger, C; Fahrleitner, A Combination Therapy with Ibandronate and Calcitrol Is Efffective in Patients Following Liver Transplantation (LTX): A Three Year Prospective Controlled Study
LIVER TRANSPLANT. 2010; 16(6):S248-S248. [Poster]
Web of Science

 

Wagner, D; Dobnig, H; Kniepeiss, D; Iberer, F; Schaffellner, S; Tscheliessnigg, K; Pieber, T; Fahrleitner, A Combination Therapy with Ibandronate and Calcitrol Is Efffective in Patients Following Liver Transplantation (LTX): A Three Year Prospective Controlled Study
AM J TRANSPLANT. 2010; 10: 157-158. [Oral Communication]
Web of Science

 

Wagner, D; Dobnig, H; Kniepeiss, D; Iberer, F; Tscheliessnigg, K; Pieber, T; Obermayer, B; Trauner, M; Fahrleitner, A Vitamin D Deficiency, Hyperparathyroidism and Bone Turnover in Patients Listed for Liver Transplantation (LTX).
AM J TRANSPLANT. 2010; 10: 350-350.-Annual Meeting of the American Society of Transplantation; MAY 2-8; San Diego, California. [Oral Communication]
Web of Science

 

Wagner, D; Kniepeiss, D; Iberer, F; Tscheliessnigg, KH; Pieber, TR; Dobnig, H; Obermayer-Pietsch, B; Fahrleitner-Pammer, a; Vitamin D Deficiency, hyperparathyroidism and Bone turnover in patients listet for Liver transplantation (LTX): Results of a cross-sectional study.
Journal für Klinische endokrinologie und Stoffwechsel. 2010; 1(supp):16-15.-15. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel; 7.-8. Mai; Vienna, Austria. [Poster]

 

Walsh, W; Lems, W; Karras, D; Langdahl, B; Ljunggren, O; Baker, C; Fahrleitner-Pammer, A; Jakob, F; Marin, F Fracture Incidence, Quality of Life and Back Pain in elderly Women with Osteoporosis treated with Teriparatide: 36 months results from the EFOS Study
Journal of Bone and Mineral research 2010; 25(Sup1):332-332.-ASBMR 2010; 14-19.Oct; Toronto, Canada. [Poster]

 

Benedikt,M; Schweighofer, N; Karl, W; Fahrleitner-Pammer, A, Dimai, HP; Dobnig, H; Formation of 1,25-dihydroxyvitamin D from 25-hydroxyvitamin D by human osteoblast-like osteosarcoma cells.
Herbsttagung der ÖGEKM; 21. 11. 2009; Wien. 2009. [Poster]
FullText

 

Dobnig, H; Pilz, S; Scharnagl, H; Renner, W; Seelhorst, U; Wellnitz, B; Fahrleitner-Pammer, A; Bohm, BO; Marz, W 25-hydroxyvitamin D levels and association with all-cause mortality in patients with type 2 diabetes mellitus
DIABETOLOGIA. 2009; 52: 316--44th General Assembly of the European Association for the Study of Diabetes (EASD); SEP 7-11, 2009; Rome, ITALY. [Poster]
Web of Science

 

Dobnig, H; Pilz, S; Scharnagl, H; Renner, W; Seelhorst, U; Wellnitz, B; Kinkeldei, J; Bohm, B; Fahrleitner-Pammer, A; Marz, W Influence of 25-hydroxyvitamin D and 1,25 dihydroxyvitamin D status on serum parathyroid hormone levels varies at different levels of renal function
BONE. 2009; 44(2):S360-S360.-36th European Symposium on Calcified Tissue; MAY 23-27, 2009; Vienna, Austria. Doi: 10.1016/j.bone.2009.03.193 [Poster]
Web of Science FullText FullText_MUG

 

Dobnig, H; Pilz, S; Scharnagl, H; Renner, W; Seelhorst, U; Wellnitz, B; Kinkeldei, J; Böhm, B; Fahrleitner-Pammer, A; März, W Influence of 25-hydroxyvitamin D status on serum PTH levels varies with KDOQI classification of renal function and is independent of 1,25 dihydroxyvitamin D concentration
Journal of Bone and Mineral Society, Suppl.2009; -American Society for Bone and Mineral Research; SEP 11-15, 2009; Denver, USA. [Oral Communication]

 

Fahrleitner-Pammer, A Protelos - eine Alternative zu Bisphosphonaten
Mitarbeiterschulung Servier; 26.01.2009; Stegersbach, Austria. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A Pathophsiologie der Osteoporose
Mitarbeiterschulung Novartis; 13.01.2009; Stegersbach, Austria. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A Warum wir Protelos in der Therapie der Osteoporose brauchen?
Bezirksärztefortbildung Fürstenfeld; 04. Juni 2009; Fürstenfeld. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A Protelos - eine Alternative zu Bisphosphonaten?
Interne Fortbildung LKH Hörgas; 01.Juli 2009; Hörgas. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A ÖGEKM Osteo Kolleg
Osteo Kolleg - Raloxifen, das exklusive Molekül für Frauen; 09.11.2009; Graz. 2009. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A Parenterale Osteoporsetherapie - eine echte option?
www.osteologie-journal.de2009; 18: 3-57.-Osteologie ; 5. - 7. März 2009; Frankfurt. [Oral Communication]

 

Fahrleitner-Pammer, A Diagnostik der Osteoporose
OASE Fachtagung Kärnten; 04.02.2009; Feldkirchen. 2009. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A Workshop Osteoporose
ÖGAM - Wintertagung; 16.01. - 23.01.2009; Lech. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A Sind parenterale Bisphosphonate wirklich besser?
OsteoKolleg GRAZ; 09.02.2009; Graz. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A Parenterale Osteoporosetherapie - wirklich besser?
OsteoKolleg LINZ; 12.03.2009; LINZ. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A, Bone Quality und Mikroarchitektur des Knochens
DVO Zertifizierungskurs; 19. - 20.06.2009; Wien. 2009. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Aktuelles in der Osteologie.
Bezirksärztefortbildung; 1.April 2009; Köflach, Austria. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A; Therapie der Osteoporose
OASE Salzburg; 22.04.2009; Salzburg. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; Therapieupdate Osteoporose
Bezirksärztefortbildung ; 15. Mai 2009; Deutschlandsberg. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A; Ibandronat intravenös: optimales Therapieschema für Arzt und Patient
17. Österreichisches Osteoporoseforum; 8.-9. Mai 2009; St. Wolfgang. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; Osteoporose UpDate 2009
Gynäkologische Sommerschule 2009; 01. Sep. - 02.Sep 2009; Pörtschach, Austria. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A; Neue Studiendaten und klinische Erfahrungen mit Teriparatide.
17. Österreichisches Osteoporoseforum; 8.-9. Mai 2009; St. Wolfgang. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; Die direkte RANK-Ligand Inhibition-Ein neuer Therapieansatz!
17. Österreichisches Osteoporoseforum; 8.-9. Mai 2009; St. Wolfgang. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; Die osteoporotische Fraktur-ein stark unterschätztes Mortalitätsrisiko
Interaktiver Workshop; 22. - 23.09.2009; Langenlois, Austria. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A; Warum wir Protelos in der Osteoporosetherapie brauchen
Herbsttagung der ÖGEKM; 21.11.2009; Wien. 2009. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Klinische Relevanz von PTH
Osteoporoseweekend Hafnersee; 20. - 21. 3. 2009; keutschach, Kärnten. 2009. [Oral Communication]

 

Fahrleitner-Pammer, A; Raloxifen, das exklusive Molekül für Frauen!
Gynäkologen Fachgruppentagung Kärnten; 04.11.2009; Klagenfurt. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A; Vitamin D - das Überraschunh´gshormon der Endokrinologie
Oase Fachtagung; 26.03. 2009; Innsbruck. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; OPG, RANKL, RANK - klinische Bedeutung aus heutiger Sicht.
Osteoporoseweekend Hafnersee ; 20. - 21. 3. 2009; keutschach, Kärnten. 2009. [Oral Communication]

 

Fahrleitner-Pammer, A; Pathophysiologie des Knochens
Mitarbeiterschulung Novartis; 13.01.2009; Stegersbach. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A; Therapieoptionen der Osteoporose
OASE Fachtagung Kärnten; 04.02.2009; Feldkirchen . 2009. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Vitamin D
OASE Salzburg; 22.04.2009; Salzburg. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; Ernährung in der Geriatrie
OASE; 22.04.2009; Salzburg. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; Der lebendige Knochen im Alter
Bezirksärztefortbildung; 21.04.2009; Gniebing/Weissenbach. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A; Vitamin D das Überraschungshormon der Endokrinologie
OASE- Fachtagung Kärnten; 04.02.2009; Feldkirchen. 2009. [Oral Communication]
FullText

 

Fahrleitner-Pammer, a, Differentialtherapie der Osteoporose
OASE Fachtagung Hoechst; 24.03.2009; Hoechst, Vorarlberg. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; Klinische Relevanz von SERMs
Osteoporoseweekend 2009; 20. - 21. 3. 2009; keutschach, Kärnten. 2009. [Oral Communication]

 

Fahrleitner-Pammer, A; Ist die parenterale Therapie wirklich die beste Option?
Fortbildungstage der ÖGAM West; 5. - 8. 12.2009; Radstadt. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A; Spomdylitis, Spondylodiscitis eitrige Rückenmarkserkrankungen
DVO Zertifizierungskurs Modul 3 ; 4. - 5. 12.2009; Krems. 2009. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Renale osteopathie
DVO Zertifizierungskurs Modul 3 ; 4. - 5. 12.2009; Krems. 2009. [Oral Communication]
FullText

 

Fahrleitner-Pammer, A; Optimale Patientenführung mit BONVIVA
Osteoporosewochenende ; 27.03. - 30.03. 2009; Salzburg. 2009. [Keynote lecture]

 

Fahrleitner-Pammer, A; Oase - Vorarlberg Vitamin D - das Überraschungshormon der Endokrinologie
OASE Fachtagung Höchst ; 24.03.2009; Hoechst. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; Therapieoptionen der Osteoporose
Oase Fachtagung ; 26.03. 2009; Innsbruck. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer, A; Piswanger-Soelkner, JC; Obermayer-Pietsch, BM; Friedl, C; Prenner, G; Tscheliessnigg, K; Dobnig, H Testosterone replacement in combination with bisphosphonate therapy in male cardiac transplant patients exerts additional benefits on bone mass: A 5-year prospective study
BONE. 2009; 44(2):S424-S424.-ECTS; June 2009; Vienna; Austria. Doi: 10.1016/j.bone.2009.03.362 [Poster]
Web of Science FullText FullText_MUG

 

Fahrleitner-Pammer, A, Piswanger-Soelkner, JC; Obermayer-Pietsch, BM; Friedl,C; Prenner, G; Tscheliessnigg, KH; Dobnig, H; Testosterone replacement in combination with bisphosphonate therapy in male cardiac transplant patients exerts additional benefits on bone mass: A 5-year prospective study
www.ectsoc.org. 2009; 44(2):S454-S454.-36th European Symposium on Calcified Tissues; may 23rd to 27 th; Vienna. [Oral Communication]

 

Fahrleitner-Pammer, A; Piswanger-Soelkner, JC; Prenner, G; Wagner, D; Tscheliessnigg, KH; Obermayer-Pietsch, BM; Pieber, TR; Dobnig, HP; Testosterone Replacement in Cardiac Transplant Patients on Top of Bisphosphonate Therapy Exerts Multiple Benefits on Bone Mass, Libido and Sexual Activity: A 5-Year Prospective Study
www.endocrinsoc.org2009; -91st Endocrine Sociery; June 8th - 13th 2009; Washington, DC, USA. [Poster]

 

Fahrleitner-Pammer, A *1; Piswanger-Soelkner, JC 2; Roller-Wirnsberger, R 3; Friedl, C 4; Hofbauer, L 5; Dobnig, H 6 Type 2 diabetes mellitus is a common complication following cardiac transplantation: does developing glycemia prevent catch-up in bone mineral density?.
Abstractband of the 31st Annual Meeting of the American Society of Bone and Mineral Research. 2009; JMBR (Suppl2): 482-482.-31st Annual Meeting of the American Society of Bone and Mineral Research; September; Denver Colorado USA. [Poster]

 

Fahrleitner-Pammer,A Diagnose und Differentialdiagnose der Osteoporose
DVO Zerfifizierungskurs; 19.-20.06.2009; Wien. 2009. [Oral Communication]
FullText

 

Fahrleitner-Pammer,A; Raloxifen, das exklusive Molekül für Frauen
Osteo Kolleg Graz; 09.11.2009; Graz. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer,A; RANKL-Inhibition:neue therapeutische Perspektiven bei postmenopausaler Osteoporose
ÖGEKM Osteo Kolleg Klagenfurt; 30.Sep.2009; Klagenfurt. 2009. [Keynote lecture]
FullText

 

Fahrleitner-Pammer,A; Mitarbeiterschulung ROCHE Therpeutics
Roche Herbstmeeting; 29.09. - 01.10; Sregersbach. 2009. [Keynote lecture]

 

Friedl, C; Dobnig, H; Pieber, T; Obermayer-Pietsch, BM; Fahrleitner-Pammer, A; Vitamin-D-Status bei stationären Patienten
Journal für Klinische Endokrinologie und Stoffwechsel2009; 2009(2):7-7.-14. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel; 7.-8. Mai 2009; St. Wolfgang. [Poster]
FullText

 

Friedl, C; Dobnig, H; Pieber, TR; Pilz, S; Piswanger-Sölkner, JC; Stiegler, C; Warnkross, H; Fahrleitner-Pammer, A Vitamin D-Status internistischer Akutpatienten: Eine prospektive Kohortenstudie.
Wissenschaftliche Herbsttagung der ÖGEKM; 21. November 2009; Wien, Österreich. 2009. [Oral Communication]

 

Friedl, C; Dobnig, H; Piswanger-Sölkner, JC; Obermayer-Pietsch, B; Pilz, S; Pieber, TR; Fahrleitner-Pammer, A Eine 55-jährige Patientin mit multiplen Frakturen und unklarer Gewichtszunahme:ein fallbericht aus der endokrinologischen Ambulanz
www.osteologie-journal.de. 2009; Suppl1: 51-52.-Osteologie; Mar 5-7,2009; Frankfurt. [Poster]

 

Ian Reid*1, Claude Laurent Benhamou2, Michael Bolognese3, Jacques Brown4, Hans Chr Hoeck5, Steven Cummings6, Richard Eastell7, Astrid Fahrleitner-Pammer8, J Christopher Gallagher9, Johan Halse10, David Kendler11, Katre Maasalu12, Paul Miller13, Sergio Ortolani14, Ivo Valter15, Beiying Ding16, Rachel Wagman17, Javier San Martin18, David Dempster19 Effects of Denosumab on Bone Histology and Histomorphometry: the FREEDOM and STAND Studies.
2009 Abstracts Thirty-first Annual Meeting of the American Society for Bone and Mineral Research. 2009; JBMR Suppl1(2009):28-28.-31st Meeting of the American Society of Bone and Mineral Research; September; Denver Colorado USA. [Oral Communication]

 

J. Bernard Walsh1, Willem Lems2, Dimitros Karras3, Bente Langdahl4, 5, Clare Barker6, Astrid Fahrleitner-Pammer7, Annabel Barrett8, Ge´rald Razjbaum9, Franz Jakob10, Fernando Marin Fracture Incidence, Quality of Life and Back Pain in Elderly Women with Osteoporosis Treated with Teriparatide: 18-Month Results from the European Forsteo Observational Study (EFOS).
Abstractband of the 31st Annual Meeting of the American Society of Bone and Mineral Research. 2009; JBMR Suppl2: 338-338.-31st Annual Meeting of the American Society of Bone and Mineral Research; September; Denver Colorado USA. [Poster]

 

Karl,W; Dobnig, H; Pieber, TR; Dimai, HP; Ferstl-Rohrbacher, A; Gerdova, J; Muschitz, C; Resch, H; Fahrleitner-Pammer, A From fracture and bone markers to bone histomorphometry and gene expression level - a backbreaking work.
Herbsttagung der ÖGEKM; 21.11.2009; Wien. 2009. [Oral Communication]
FullText

 

Lems, W; Marin, F; Langdahl, B; Karras, D; Barrett, A; Walsh, B; Fahrleitner-Pammer, A; Rajzbaum, G; Barker, C; Jakob, F FRACTURE INCIDENCE, QUALITY OF LIFE AND BACK PAIN IN WOMEN WITH OSTEOPOROSIS PRETREATED WITH BISPHOSPHONATES: 18 MONTH RESULTS FROM THE EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS)
OSTEOPOROSIS INT. 2009; 20: 75-75. [Poster]
Web of Science

 

Lems, WF; Karras, D; Langdahl, BL; Ljunggren, O; Walsh, JB; Barker, C; Fahrleitner-Pammer, A; Barrett, A; Rajzbaum, G; Jakob, F; Marin, F Fracture incidence, quality of life and back pain in women with osteoporosis and concomitant glucocorticoid use treated with teriparatide: 18-month results from the European Forsteo Observational Study
BONE. 2009; 44(2):S448-S449.-ECTS; June 2009; Vienna; Austria. Doi: 10.1016/j.bone.2009.03.421 [Poster]
Web of Science FullText FullText_MUG

 

Lems, WF; Karras, D; Langdahl, BL; Ljunggren, Ö; Walsh; JB; Barker, C; Fahrleitner-Pammer, A; Barrett, A; Rajzbaum, G; Jakob, F; Marin, F Fracture incidence, quality of life and back pain in women with osteoporosis and concmitant glucocorticoid use treated with teriparatide: 18-month results ftom the European Forsteo observational study.
www.ectsoc.org2009; 55(2):448-449.-36th European Symposium on Calcified Tissues; 23. - 27. Mai 2009; Vienna. [Poster]

 

Michaela Benedikt1, Natascha Schweighofer2, Astrid Fahrleitner-Pammer3, Hans Dimai4, Harald Dobnig Formation of 1,25-dihydroxyvitamin D from 25-hydroxyvitamin D by human osteoblast-like osteosarcoma cells.
2009 Abstracts Thirty-first Annual Meeting of the American Society for Bone and Mineral Research. 2009; JBMR Suppl2: 313-313.-31st Annual Meeting of the American Bone and Mineral Society; September; Denver Colorado USA. [Poster]

 

Oase OASE
17. Österreichisches Osteoporoseforum; 8.-9. Mai 2009; St. Wolfgang. 2009. [Keynote lecture]
FullText

 

Pilz S, Tomaschitz A, Stepan V, Obermayer-Pietsch B, Fahrleitner-Pammer A, Protugaller HR, Sourij H, Dobnig H, Pieber TR Graz Endocrine Causes Of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone-to-active-renin ratio in screening for primary aldosteronism
Abstracts der Jahrestagung St. Wolfgang 7.-9. Mai 20092009; 12-12.-14. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel; MAY 7-9, 2009; St. Wolfgang, AUSTRIA. [Poster]

 

Pilz S, Tomaschitz A, Stepan V, Obermayer-Pietsch B, Fahrleitner-Pammer A, Schweighofer N, Protugaller HR, Sourij H, Dobnig H, Pieber R Graz endocrine causes of hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ration in screening for primary aldosteronism
Adrenal tumors and hormone excess; MAY 14-15, 2009; Paris, FRANCE. 2009. [Poster]

 

Schweighofer, N; Schrampf, E; Schweiger, M; Kniepeiss, D; Pieber, TR; Tscheliessnig, KH; Müller, H; Obermayer-Pietsch, B Knochen vs Gefäßsystem, Regulation der Kalzifizierung bei Nierentranplantations-PatientInnen.
Abstractbook der Jahrestagung der ÖGEKM/ÖGES 20092009; -Jahrestagung der ÖGEKM/ÖGES; MAI 7-9, 2009; St. Wolfgang, AUSTRIA. [Poster]

 

Schweighofer, N; Wehr, E; Fahrleitner-Pammer, A; Dobnig, H; Pieber, TR; Renner, W; Obermayer-Pietsch, B Moprhogenese-Gen Meis1 und Knochendichte
Frühjahrsakademie DadorW; APR 22-25, 2009; Braunlage, GERMANY. 2009. [Poster]

 

Schweighofer, N; Wehr, E; Fahrleitner-Pammer, A; Dobnig, H; Pieber, TR; Renner, W; Obermayer-Pietsch, B Morphogenese-Gen Meis1 und Knochendichte
DadorW Frühjahrsakademie 2009; APR 22-25,2009; Braunlage, Germany. 2009. [Poster]

 

Schweighofer, N; Wehr, E; Pöschl, E; Stocker, P; Rohrer, S; Fahrleitner-Pammer,A; Dobnig, H; Pieber, TR; Renner, W; Obermayer-Pietsch,B; Morphogenese-Gen Meis1 undKknochendichte
Osteologie 2009; 18: 23-24.-Osteologie 2009; 5.-7.März 2009; Frankfurt. [Poster]

 

Stocker, P; Wehr, E; Schweighofer, N; Fahrleitner-Pammer, H; Dobnig, H; Pieber, TR; Obermayer-Pietsch, B Senseing polymorphisms of the calcium receptor and its possible clinical relevance
WIEN KLIN WOCHENSCHR. 2009; 121(15-16):A20-A20. [Poster]
Web of Science

 

Tomaschitz, A; Maerz, W; Pilz, S; Scharnagl, H; Renner, W; Seelhorst, U; Wellnitz, B; Boehm, BO; Fahrleitner-Pammer, A; Wiehrauch, G; Dobnig, H Aldosterone-to-Renin Ratio Determines Peripheral and Central Blood Pressure Values Over a Broad Range and Well Below a Cut-off Suggestive of Primary Aldosteronism.
14. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel; Mai 7-9, 2009 ; St.Wolfgang-Salzkammergut, Austria. 2009. [Oral Communication]

 

Wagner, D; Dobnig, H; Kniepeiss, D; Iberer, F; Pieber, TR; Obermayer-Pietsch, BM; Trauner, M; Fahrleitner-Pammer, A Vitamin D deficiency, hyperparathyroidism and bone turnover in patients listed for liver transplantation (LTX): Preliminary results of a cross-sectional study
BONE. 2009; 44(2):S400-S400.-ECTS; June 2009; Vienna; Austria. Doi: 10.1016/j.bone.2009.03.301 [Poster]
Web of Science FullText FullText_MUG

 

Wagner, D; Dobnig, H; Kniepeiss, D; Iberer, F; Pieber, TR; Obermayer-Pietsch, BM; Trauner, M; Fahrleitner-Pammer, A Vitamin D deficiency, hyperparathyroidism and bone turnover in patients listed for liver transplantation (LTX)
www.ectsoc.org. 2009; 44(2):400-400.-36th European Symposium on Calcified Tissue; may 23rd to 27 th; Vienna. [Poster]

 

Wehr, E; Schweighofer, N; Giukiani,A; Graupp, M; Lerchbaumer,B; Rohrer,S; Kopera,D; Fahrleitner-Pammer,A; Dobnig, H; Pieber T; Obermayer-Pietsch, B; Die Rolle des 25-OH-Vitamin D beim Polycystischen Ovarsyndrom
www.osteologie-journal.de2009; Suppl1(18):33-33.-Osteologie; Mar 5-7; 2009; Frankfurt. [Poster]

 

Zhang, J; Goode, KM; Cleland, JGF; Fruhwald, F; Fahrleitner-Pammer, A; Clark, AL; Rigby, A Prognostic values of big endothelin and NT-proBNP in predicting of mortality in patients with heart faliure
European Heart Journal2009; 30(supp):130--Annual congress of the European Society of Cardiology; Aug 29-Sep 2, 2009; Barcelona, SPAIN. [Poster]

 

Zhang,J; Goode, K.M, Cleland J.G.F; Fruhwald, F; Fahrleitner-Pammer, A; Clark, A.L.; Rigby, A; prognostic values of big endothelin and NT-pro BNP in predicting of mortality in patients with heart failure.
http./ESC2009/2009; 2009 30(30):130-130.-European Heart Society; 01.- 04. September ; Barcelona; spain. [Poster]

 

Fahrleitner-pammer, A Touch down Osteoporose - nicht alltägliches aus ser Ambulanz
Österreichische Internisten tagung; 15. - 18. Sep 2008; Graz Austria. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Management der Osteoporose beim geriatrischen patienten
Oase - Fachtagung Burgenland; 19.11.2008; Pinkafeld. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Vitamin D - ein Hormon für jedes Alter
Oase Fachtagung Burgenland; 19.11.2008; Pinkafeld. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Diagnose und Therapie der Osteoporose
Fortbildungswochenende Knochen; 7. - 9. November 2008; Pamhagen Burgenland. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Die cortisoninduzierte Osteoporose.
7. Wiener Osteoporosetag; 11.11. 2008; Wien . 2008. [Oral Communication]

 

Fahrleitner-Pammer, A Differentialtherapie der Osteoporose Mitarbeiterschulung DSA
Mitarbeiterschulung DSA; 06.10.2008; Loipersdorf. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Osteoporosetherapie - eine Entscheidung
Oase Fachtagung NÖ; 20.11.2008; Krems. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Osteoporose - eine stille Erkrankung mit fatalen Folgen
Bezirksärzte Fortbildung ; 22.11.2008; Graz . 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Impulsreferat - Strontiumranelat
Advisoryboard Meeting Servier ; 11.11. 2008; Wien. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Meet the expert - BONVIVA
Herbsttagung der ögekm; 25.10.2008; Wien, AKH. 2008. [Oral Communication]

 

Fahrleitner-Pammer, A Wirkmechanismus von raloxifen
Herbsttagung der ÖGEKM; 25.10.2008; Wien, AKH. 2008. [Oral Communication]

 

Fahrleitner-Pammer, A Hürden bei der Verschreibung von Parathormon
Investigatormeeting der PACE Studie; Hotel SAS Radisson. 24.11.2008; Wien. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Vitamin D - ein Hormon für jedes Alter
OASE Fachtagung Niederösterreich; 20.11.2008; Krems. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Osteoporosetherapie - Präparate im Wandel.
Mitarbeiterschulung; 23.Sep 2009; Blumau, Austria. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Osteoporose-Update 2008
Gynäkologenweekend ; 06-07.sep2008; Donnersbachwald, Austria. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Optimales Therapiemanagement der osteoporose
Spitalsärztefortbildung; 26.03.2008; Hartberg, Austria. 2008. [Oral Communication]

 

Fahrleitner-Pammer, A Die postmenopausale Frau mit osteoporose - eine therapeutische Herausforderung?
Bezirksärztefortbildung; 09.01.2008; Brunn am Gebirge, Österreich. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Frakturen das Spiegelbild der Osteoporose
Unfallchirurgietagung; 16. 10. 2008; graz, UKH. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Differentialtherapie der Osteoporose
Oase Wien; 15.10.2008; Seniorenzentrum Schrutkagasse 1130 Wien. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Bonviva - vertbrale Frakturdaten
Osteoporosewochenende Salzburg ; 06. - 08.03.2008; Salzburg Austria. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Parenterale Bisphosphonate - Differntialtherapeutische aspekte
Gynäkologenfortbildung Kärnten; 28.05.2008; Pörtschach, Austria. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Der lebendige Knochen im Alter
Spectrum Osteoporose2008; 1(1):-Osteoporoseforum; 15.-17. Mai 2008; St. Wolfgang, Austria. [Oral Communication]

 

Fahrleitner-Pammer, A Bonviva Quartalsspritze - eine optimale Therapieoption?
Spectrum Osteoporose. 2008; 1(1):-Osteoporoseforum; 15. - 17.05.2008; St. Wolfgang, Austria. [Oral Communication]

 

Fahrleitner-Pammer, A Vitamin D - das Überraschungshormon der Endokrinologie.
OASE Wien; 15.10.2008; Seniorenzentrum Schrutkagasse 1130 Wien. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Der lebendige Knochen im Alter.
Bezirksärzte Fortbildung; 04.03.2008; Graz, Austria. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Fosamax - Therpie erster Wahl auch noch 2008.
Spitalsärztefortbildung; 28.02.2008; Feldbach, Österreich. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Forsteo - Anwendungdsgebiete, neue Studiendaten
ÖGIM; 15. - 168.Sep 2008; Graz, Austria. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A Meet the Expert - Protelos
Herbsttagung der ÖGEKM; 25.10.2008; Wien AKH. 2008. [Oral Communication]

 

Fahrleitner-Pammer, A Differentialtherapie der Osteoporose - Ein Update!!
Bezirksärztefortbildung ; 22.10.2008; Oberwart. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A; Osteoporose- eine Erkrankung mit schweren Folgen.
Schulung Ordinationsgehilfinnen; 18.10.2008; Vienna Hilton. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A; Update Osteoporse: sicher und effizienzt therapieren
LKH Leoben Ärtefortbildung; 26.11.2008; Leoben. 2008. [Keynote lecture]

 

Fahrleitner-Pammer, A; Bonviva Quartalsspritze, die ideale Therapieform?
Osteologie 2008; 02.-05.04.2008; Hannover, Deutschland. 2008. [Oral Communication]

 

Fahrleitner-Pammer, A; Evista - ein anspruchsvolles Molekül mit vielen Aspekten
Spectrum osteoporose2008; 1(1):-Osteoporoseforum 2008; 15. - 17. Mai 2008; St. Wolfgang , Austria. [Oral Communication]

 

Fahrleitner-Pammer, A; Friedl, C; Obermayer-Pietsch, B.M; Piswanger-Sölkner, J.C; Pilz, S; Dobnig, H; Every nanogram of 25(Oh)D makes a difference: Subgroup analysis of institutionalized patients with vitamin D deficiency in Austria
osteoporosis International2008; 19(supp):S191-s192.-ECCEO; 9-12 APR, 2008; istanbul, Turkey. [Poster]

 

Fahrleitner-Pammer, A; Obermayer-Pietsch, B; Schweiger, M; Prenner, G; Tscheliessnigg, K.H; Piswanger-Sölkner, J.C; Dimai, H.P; Dobnig, H. Replacing testosterone in male cardiac transplant patients exerts multiple benefits on bone mass, libido and sexual activity: A 5-year prospective study.
. 2008; 23: S471 [Poster]
Web of Science

 

Fahrleitner-Pammer, A; Piswanger-Sölkner J.c; Schweiger, M; Prenner, G; Tscheliessnigg, K.H; Obermayer-Pietsch, BM, Dimai, H.P; Dobnig, H. Hypogonadism is a Common Complication following Cardiac Transplantation and Associated with Low Bone Density and High Fracture Incidence
J clin Endocrin Metabol. 2008; 93(5):m356--American Endocrine Society; 12.06. - 16.06.2008; San Francisco, CA, USA. [Poster]

 

Fahrleitner-Pammer, A; Piswanger-sölkner, J.C; Dobnig, H; Eine Testosteron Substitution bei herztransplantierten Männern mit Hypogonadismus zeigt positive Effekte auf den Knochenstoffwechsel, die Libido und das Sexualleben: Eine 5jährige kontrollierte Studie
ÖGIM; 15.-18. Sep 2008; Graz Austria. 2008. [Poster]

 

Fahrleitner-Pammer, A; Piswanger-Solkner, JC; Obermayer-Pietsch, B; Friedl, C; Dobnig, H Testosteron substitution in a men with a heart graft with hypogonadism shows positive effects on bones metabolism, on Libido and sexual life: A 5 years long lasting controlled study
WIEN KLIN WOCHENSCHR. 2008; 120(15-16):A40-A40.-ÖGIM; 17.-21.9.2008; Graz. [Poster]
Web of Science

 

Friedl, C; Dobnig, H; Piswanger-Solkner, JC; Obermayer-Pietsch, B; Fahrleitner-Pammer, A Vitamin D3 and muscular strength: Prospective analyze of 832 occupants of a nursery home in Austria
WIEN KLIN WOCHENSCHR. 2008; 120(15-16):A40-A40. [Poster]
Web of Science

 

Friedl, C; Dobnig, H; Piswanger-Sölkner, JC; Obermayer-Pietsch, BM; Riedmüller, G; Fahrleitner-Pammer, A Every nanogram of 25(OH)D makes a difference: subgroup analysis of institutionalized patients with vitamin D deficiency in Austria.
Endocrine Abstracts 20082008; 16: -10th European Congress of Endocrinology; Mai 3-7; Berlin, Germany. [Poster]

 

Friedl,C; Dobnig, H; Pieber, TR; Pilz, S; Piswanger-Soelkner, JC; Stiegler, C; Warnkross, H; Fahrleitner - Pammer, A; Vitamin D - Status internistischer Patienten
Herbsttagung der ÖGEKM; 21. November 2009; Vienna. 2008. [Oral Communication]
FullText

 

Langdahl, B; Ljunggren, O; Lems, W; Walsh, B; Barker, C; Fahrleitner-Pammer, A; Karras, D; Rajzbaum, G; Jakob, F; Kutahov, A; Marin, F Fracture incidence and changes in quality of life and back pain in women with osteoporosis treated with rhpth(I-34) (teriparatide): 18 month results from the European Forsteo Observational Study (EFOS)
CALCIFIED TISSUE INT. 2008; 82: S158-S158.-ECTS; June 2008; Barcelona. [Oral Communication]
Web of Science

 

Langdahl, B; Ljunggren, Ö; Lems, W; Walsh, B.j; Barker, C; Fahrleitner-Pammer, A; Karras, D; Marin, F; Women with severe Osteoporosis treated with rhPTH(1-34)(teriparatide) improve Quality of life regardles of incident fractures: 18 month results from the European Forsteo Observational Study (EFOS).
. 2008; 23: S347 [Poster]
Web of Science

 

Lems, W; Langdahl, B; Ljunggren, O; Kutahov, A; Karras, D; Walsh, JB; Fahrleitner-Pammer, A; Rajzbaum, G; Barket, C; Jakob, F; Marin, F Fracture incidence, quality of life and back pain in women with osteoporosis pretreated with bisphosphonates: 18 month results from the European forsteo, observational study (EFOS)
ARTHRITIS RHEUM. 2008; 58(9):S737-S738.-72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals; OCT 24-29, 2008; San Francisco, CA. [Oral Communication]
Web of Science

 

Ljunggren, O; Fahrleitner-Pammer, A; Kutahov, A; Walsh, JB; Langdahl, B; Jakob, F; Lems, W; Rajzbaum, G; Barker, C; Karras, D; Marin, F Back Pain is Reduced in Postmenopausal Women with Severe Osteoporosis Treated with rhPTH(1-34) (teriparatide) Regardless of Incident Fractures: 18 Month Results from the European Forsteo Observational Study (EFOS).
J BONE MINER RES. 2008; 23: S347-S347.-30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research; SEP 12-16, 2008; Montreal, CANADA. [Oral Communication]
Web of Science

 

Meilinger, M; Gugatschka, M; Wehr, E; Schweighofer, N; Fahrleitner-Pammer, A; Dobnig, H; Pietschmann, P; Kudlacek, S; Kiesler, K; Friedrich, G; Obermayer-Pietsch, B Körpergewicht beeinflusst bei Hypogonadismus die Knochendichte bei Männern: ein Langzeit-Follow-up.
ÖGES; 15.-17.5.2008; St. Wolfgang, Austria. 2008. [Poster]

 

Meilinger, M; Gugatschka, M; Wehr E; Schweighofer, N; Fahrleitner-Pammer, A; Dobnig, H; Pietschmann, P; Kudlacek, S; Kiesler, K; Friedrich, G; Obermayer-Pietsch, B Hypogonadismus und Knochendichte bei Münnern: Einfluss von Körpergewicht und Calciumzufuhr - ein Follow-up über 4 Jahre
Osteologie. 2008; -DGO; 02.04.2008 - 05.04.2008; Hannover. [Oral Communication]

 

Obermayer-Pietsch, BM; Meilinger, M; Wehr, E; Schweighofer, N; Fahrleitner-Pammer, A; Dobnig, H; Pietschmann, P; Kudlacek, S; Friedrich, G; Gugatschka, M Hypogonadism and bone in men: Impact of body weight in a follow-up over 4 years
CALCIFIED TISSUE INT. 2008; 82: S160-S160.-ECTS; June 2008; Barcelona. [Poster]
Web of Science

 

Pilz, S; März, W; Fahrleitner-Pammer, A; Dimai, HP; Boehm, BO; Dobnig, H Vitamin D deficiency is associated with heart failure and sudden cardiac death: cross-sectional and mortality data of 3299 patients referred to coronary angiography
Endocrine Abstracts2008; (16):P228--European Congress of Endocrinology; MAY 3-7, 2008; Berlin, GERMANY. [Poster]

 

Pilz, S; März, W; Welllnitz, B; Seelhort, U; Fahrleitner-Pammer, A; Dimai, HP; Boehm, BO; Dobnig, H Vitamin D deficiency is associated with heart failure and sudden cardiac death: cross-sectional and mortality data of 3299 patients referred to coronary angiography
Journal für Klinische Endokrinologie und Stoffwechsel2008; 1(1):7-7.-Gemeinsame Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechel und der Österreichichen Gesellschaft zur Erforchung des Knochens und Mineralstoffwechsels; May 15-17, 2008; St. Wolfgang, Austria. [Oral Communication]

 

Pilz, S; März, W; Wellnitz, B; Seelhorst, U; Fahrleitner-Pammer, A; Dimai, HP; Boehm, BO; Dobnig, H Vitamin D deficiency is associated with heart failure and sudden cardiac death: cross-sectional and mortality data of 3299 patient referred to coronary angiography
Abstracts der Jahrestagung in St. Wolfgang2008; 1(1):11-11.-Gemeinsame Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel und der Österreichischen Gesellschaft zur Erforschung des Knochens und Mineralstoffwechsels; MAY 15-17, 2008; St. Wolfgang, Austria. [Oral Communication]

 

Schweighofer, N; Fahrleitner-Pammer, A; Obermayer-Pietsch, B; Dobnig, H Von der Gewebeprobe zur Kopienzahl und darüber hinaus
DAdoW Klausurtagung Osteologie; Feb 15-17; Graz. 2008. [Oral Communication]

 

Tomaschitz, A; Maerz, W; Pilz, S; Scharnagl, H; Renner, W; Boehm, BO; Fahrleitner-Pammer, A; Dobnig, H How does aldosterone renin ratio impact blood pressure levels? A Cross-Sectional Study of 3252 Normo- and hypertensive patients referred to coronary angiography
Endocrine Abstracts (2008) 16 P9 2008; -European Congress of Endocrinology ; 03 May 2008 - 07 May 2008; Berlin, Germany. [Poster]

 

Berger, R; Freemantle, N; Fruhwald, F; Fahrleitner-Pammer, A; Tavazzi, L; Cleland, JGF; Pacher, R The mode of death depends on the severity of disease in patients with heart failure treated with cardiac resynchronisation therapy: a substudy of the CARE-HF trial
Eur Heart J2007; 28(Supp):377--ESC annual meeting; September 1-5, 2007; Vienna, AUSTRIA. [Poster]

 

Berger, R; Fruhwald, F; Fahrleitner, A; Tavazzi, L; Freemantle, N; Cleland, JGF; Pacher, R Influence of Cardiac Resynchronisatioon Therapy on the Prognostic Power of NT-BNP in Patients with Heart Failure Characterised by Cardiac Dyssynchrony: A Substudy of the CARE-HF Trial
JACC2007; 49(Supp):32A--56th Annual Scientific Session of the American College of Cardiology; March 24-27, 2007; New Orleans, USA. [Poster]

 

Brueck, CC; Dobnig, H; Obermayer-Pietsch, BM; Fahrleitner-Pammer, A High serum osteoprotegerin but low bone mass in patients with peripheral arterial disease (PAD)
EXP CLIN ENDOCRINOL DIABETES. 2007; 115: S88-S88.-IOF; June 2007; Montreal Canada. [Oral Communication]
Web of Science

 

Brueck, CC; Rienmuller, R; Riedmueller, G; Benedikt, M; Kovaleva, K; Gerdova, J; Fahrleitner-Pammer, A; Obermayer-Pietsch, B; Dobnig, H Acid-base metabolism is independently correlated to bone turnover
EXP CLIN ENDOCRINOL DIABETES. 2007; 115: S88-S88.-DGE; Sakzburg. [Poster]
Web of Science

 

Dimai, HP; Fahrleitner, A Zoledronat - Fakten aus der Praxis
Österr. Osteoporoseforum; Mai 2007; St. Wolfgang. 2007. [Keynote lecture]

 

Dobnig, H; Stepan, JJ; Burr, DB; Fahrleitner-Pammer, AF; Li, J; Sipos, A; Sato, M; Pavo, I Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate
J BONE MINER RES. 2007; 22: S28-S28.-Asbmr ; September; Honolulu Hawai. [Poster]
Web of Science

 

Fahrleitner-Pammer, A Strontuim Ranelat - ein dualer Therapieansatz.
Beziksärztefortbildung; 12.Apr,2007; Vorau, Austria. 2007. [Oral Communication]

 

Fahrleitner-Pammer, A Differentialtherapie der Osteoporose
Mitarbeiterschulung DSA; 25. - 26.03.2007; Bad St. Leonhardt, Austria. 2007. [Keynote lecture]

 

Fahrleitner-Pammer, A. Teriparatide - rasch, effektiv und Schmerztherapeutikum.
3. Österreichische Schmerztage; 24. - 25.4.2007; voecklabruck, austria. 2007. [Oral Communication]

 

Fahrleitner-Pammer, A; Die postmenopausale Frau - eine therapeutische Herausforderung
bezirksärztefortbildung Innsbruck ; 12.12. 2007; Innsbruck Österreich. 2007. [Oral Communication]

 

Fahrleitner-Pammer, A; Osteoporosetherapie jenseits der grünen Box
Abstractband dér Wiener Klinischen Wochenschrift2007; -Osterreichische Internistentagung 2007; 26.09. - 29.09.2007; Innsbruck, Österreich. [Oral Communication]

 

Fahrleitner-Pammer, A; Bonviva - Quartalsspritze - die optimale Therapieoption der osteoporose?
Kärnter Gynäkolgiefortbildungstage; 15. - 16.06.2007; Pörtschach, Austria. 2007. [Keynote lecture]

 

Fahrleitner-Pammer, A; Bisphosphonate und Nier - Freund oder Feind?
´Deutschsprachige Nephrologie Fortbildung; 17. - 19. 05.2007; Salzburg, Austria. 2007. [Oral Communication]

 

Fahrleitner-Pammer, A; Evista - ein effektiver Schutz vor Frakturen.
Jahrestagung der Orthopädie. 2007; 4(2):21-21.-Jahrestagung der Ortghopädie ; 14. - 16.06.2007; Vienna, Austria. [Keynote lecture]

 

Fahrleitner-Pammer, A; Osteoporose - eine Therpeutische Herausforderung.
Mitarbeiterschulung DSA; 18. - 19.12.2007; Wien, österreich. 2007. [Keynote lecture]

 

Fahrleitner-Pammer, A; Protelos - der lebendige Knochen im Alter
Konferenzband der Gynäkologen 20072007; 2(1):3-4.-bezirksärztefortbildung; 29.11.2007; Bad Waltersdorf; Austria. [Keynote lecture]

 

Fahrleitner-Pammer, A; Parenterale Bisphosphonate - eine neue Option?
bezirksärztefortbildung; 31.01.2007; Hartberg, Austria. 2007. [Keynote lecture]

 

Fahrleitner-Pammer,A; Antiresorptiva und Anabolika - Kollision zweier Welten?
Orthopädísche Wintertagung 2008; 15. - 18. Jänner 2008; Turracherhöhe, AUSTRIA. 2007. [Keynote lecture]

 

Li, J; Burr, DB; Stepan, JJ; Dobnig, H; Fahrleitner-Pammer, A; Sipos, A; Mullamey, T; Westmore, M; Sato, M; Pavo, I Teriparatide improves bone microarchitecture in postmenopausal women previously treated with alendronate
J BONE MINER RES. 2007; 22: S28-S28.-Asbmr; September; Honolulu Hawai. [Poster]
Web of Science

 

Meilinger, M; Schweighofer, N; Forjanics, A; Dobnig, H; Fahrleitner-Pammer, A; Obermayer-Pietsch, B Autoimmune thyroid disease, genetic predisposition and environment - case-control family studies
EXP CLIN ENDOCRINOL DIABETES. 2007; 115: S60-S60. [Poster]
Web of Science

 

Obermayer-Pietsch, B; Gugatschka, M; Groselj-Strele, A; Goessler, W; Dobnig, H; Hoegenauer, C; Fahrleitner-Pammer, A; Renner, W Genetically defined adult-type hypolactasia and calcium balance: High amounts of lactose decrease calcium absorption
EXP CLIN ENDOCRINOL DIABETES. 2007; 115: S7-S7. [Poster]
Web of Science

 

Riedmueller, G; Wascher, TC; Brueck, CC; Gerdova, J; Breuss, B; Obermayer-Pietsch, B; Fahrleitner-Pammer, A; Dobnig, H PTH - a new cardiovascular risk factor?
EXP CLIN ENDOCRINOL DIABETES. ; 115: S87-S88. [Poster]
Web of Science

 

Schweighofer, N; Fahrleitner-Pammer, A; Obermayer-Pietsch, B; Dobnig, H From Bone Biopsy to Copynumber  Absolute Quantitation via Realtime PCR
17th Scientific Meeting International Bone and Mineral Society; Jun 24-29; Montreal, CANADA. 2007. [Oral Communication]
FullText

 

Bonelli, C; Walter, D; Clar, H; Dobnig, H; Fahrleitner-Pammer, A; Obermayer-Pietsch, B; Hip geometry, metabolic and tissue properties associated with COLIA Sp1 genotypes.
keine2006; -33 rd European Meeting of ECTS Prague 2006; 10-14 May 2006; Prague, Czech Republic. [Oral Communication]

 

Dobnig, H; Piswanger-Solkner, C; Maier, L; Obermayer-Pietsch, B; Strele, A; Tiran, A; Brueck, C; Fahrleitner-Pammer, A Prediction of hip- and non-vertebral fractures in nursing home patients: Role of bone ultrasound and bone turnover measurements
BONE. ; 39(5):S22-S22. [Poster]
Web of Science

 

Fahrleitner-Pammer, A; Dobnig, H Treatment of post-transplantation bone disease: Clinical and economic aspects
OSTEOPOROSIS INT. 2006; 17: S3-S3.-Ecceo; 25. - 28. Februar Wien; vienna austria. [Oral Communication]
Web of Science

 

Fahrleitner-Pammer, A; Piswanger-Solkner, C; Obermayer-Pietsch, B; Prenner, G; Tscheliessnigg, KH; Dobnig, H Intravenous Ibandronate effectively prevents bone loss and minimizes fracture risk in patients following cardiac transplantation: A prospective randomized placebo controlled study
BONE. 2006; 39(5):S24-S25.-American Endocrine Society; June 2006; Toronto Canada. [Oral Communication]
Web of Science

 

Lems, W; Rajzbaum, G; Marin, F; Fahrleitner, A; Karras, D; Langdahl, B; Walsh, JB; Ljunggren, O; Cleall, S; Tynan, A Baseline characteristics of subjects enrolled in a teriparatide observational study in Europe.
ARTHRITIS RHEUM. 54(9):S588-S588. [Poster]
Web of Science

 

Obermayer-Pietsch, B; Bonelli, CM; Strele, A; Hodl, AK; Dobnig, H; Fahrleitner-Pammer, A; Kapfhammer, HP; Bonelli, RM Bone mineral density in Huntington's disease is depending on CAG repeats in the neurotrophic Huntingtin gene, but not on weight or medication
BONE. 39(5):S8-S8. [Poster]
Web of Science

 

Schweighofer, N; Fahrleitner-Pammer, A From bone biopsy to copy numbers - Quantitation of bone turnover regulators via real time PCR
BONE. 39(5):S37-S37. [Poster]
Web of Science

 

Schweighofer, N; Fahrleitner-Pammer, A; Obermayer-Pietsch, B; Dobnig, H From Bone Biopsy to Copy Numbers - Quantitation of Bone Turnover Regulators via Real Time PCR.
International Conference on Progress in Bone and Minearal Research; NOV 16-18, 2006; Vienna, AUSTRIA. 2006. [Poster]

 

Walsh, JB; Cleall, S; Fahrleitner, A; Karras, D; Langdahl, B; Lems, W; Ljunggren, O; Marin, F; Raizbaum, G; Tynan, AJ Quality of life and back pain in the European Forsteo observational study - EFOS.
J BONE MINER RES. 21: S305-S305. [Poster]
Web of Science

 

Obermayer-Pietsch, BM; Gugatschka, M; Strele, A; Fahrleitner-Pammer, A; Dobnig, H; Kudlacek, S; Pietschmann, P; Renner, W Osteoporosis and genetic disposition for primary adult lactose intolerance in men
BONE. 36: S252-S252.-2nd Joint Meeting of the European-Calcified-Tissue-Society/International-Bone-and-Mineral-Society; JUN 25-29, 2005; Geneva, SWITZERLAND.
Web of Science

 

Obermayer-Pietsch, BM; Gugatschka, M; Strele, A; Reitter, S; Plank, W; Fahrleitner-Pammer, A; Dobnig, H; Goessler, W; Renner, W Lactose intolerance and skeletal calcium balance - Decreased calcium intake or impaired calcium resorption?
J BONE MINER RES. 20: S391-S391.-27th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research; SEP 23-27, 2005; Nashville, TN.
Web of Science

 

Weber-Mzell, D; Hauer, AC; Gugatschka, M; Fahrleitner-Pammer, A; Dobnig, H; Forjanics, A; Deutschmann, A; Deutsch, J; Obermayer-Pietsch, B Genetic predisposition for primary hypolactasia of the adult type in children and adolescents with recurrent abdominal pain.
Journal of Pediatric Gastroenterology and Nutrition2005; 40(5):703-703.-38th Annual meeting of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; JUN 1-4, 2005; Porto, Portugal. [Poster]

 

Weber-Mzell, D; Obermayer-Pietsch, B; Gugatschka, M; Fahrleitner-Pammer, A; Dobnig, H; Forjanics, A; Deutschmann, A; Deutsch, J; Hauer, AC Genetic predisposition for primary hypolactasia of the adult type in children and adolescents with recurrent abdominal pain (RAP).
sps-Publications2005; 17-17.-The Brush Border Membrane. From Molecular Cell Biology to Clinical Pathology. Perspectives in Pediatric Gastroenterology.; FEB 9-11, 2005; Fulda, GERMANY. [Oral Communication]

 

Weber-Mzell, D; Obermayer-Pietsch, B; Gugatschka, M; Fahrleitner-Pammer, A; Dobnig, H; Forjanics, A; Deutschmann, A; Deutsch, J; Hauer, AC Genetische Prädisposition der primären adulten Hypolaktasie bei Kindern und Jugendlichen mit rezidivierenden abdominalen Beschwerden.
Symposia Abstracts, sps publications, Abstract Nr. 392005; 92-93.-20. Jahrestagung der Gesellschaft für pädiatrische Gastroenterologie und Ernährung; MÄR 10-12, 2005; Basel, Schweiz. (ISBN: 3-936145-24-5 ) [Poster]

 

Dimai, HP; Fahrleitner, A; Piswanger-Soelkner, C; Ramschak-Schwarzer, S; Obermayer-Pietsch, B; Leb, G A new hormonal upstream factor in the RANKL/OPG system? Effects of the thyroid stimulating hormone TSH in humans
J BONE MINER RES 2004 19: S414-S414.
Web of Science

 

Dimai, HP; Piswanger-Soelkner, C; Fahrleitner, A; Ramschak-Schwarzer, S; Wenisch, H; Gugatschka, M; Obermayer-Pietsch, B; Leb, G Another hormonal upstream factor in the OPG/RANKL system? Effects of the thyroid stimulating hormone TSH on bone metabolism
OSTEOPOROSIS INT 2004 15: S16-S17.
Web of Science

 

Fahrleitner-Pammer, A; Maier, E; Eichhorn, T; Graebe, A Postmenopausal women with osteoporosis are compliant and satisfied with daily raloxifene treatment: Results from a six-month Austrian observational study
OSTEOPOROSIS INT 2004 15: S114-S114.
Web of Science

 

Fahrleitner-Pammer, A; Prenner, G; Kniepeiss, D; Tschelissnigg, K; Leb, G; Piswanger-Solkner, CJ; Obermayer-Pietsch, BM; Dobnig, H Combination therapy with ibandronate and calcitriol is effective in patients following liver transplantation: A three year prospective controlled study.
J BONE MINER RES 2004 19: S475-S475.
Web of Science

 

Lercher, P; Wonisch, M; Fahrleitner, A; Scherr, D; Rotman, B; Klein, W The impact of AV optimized RV pacing in patients with implanted cardioverter-defibrillators and reduced left ventricular function
Heart Rhythm 20042004; 1(S1):147--North American Society of Pacing and Electrophysiology, 25th Annual Scientific Sessions 2004; MAY 19-22, 2004; San Francisco, USA. [Poster]

 

Lercher, P; Wonisch, M; Fahrleitner, A; Scherr, D; Rotman, B; Klein, W Die Auswirkungen der rechtsventrikulären Stimulation bei Patienten mit implantiertem Kardioverter-Defibrillator
J Kardiol 20042004; 11: 274--ÖKG 2004; JUN 3-5, 2004; Salzburg, AUSTRIA. [Oral Communication]

 

Obermayer-Pietsch, BM; Bonelli, CM; Walter, DE; Kuhn, RJ; Fahrleitner-Pammer, A; Berghold, A; Stepan, V; Dobnig, H; Leb, G; Renner, W GENETIC DISPOSITION FOR ADULT LACTOSE INTOLERANCE AND RELATION TO BONE PROPERTIES AND FRACTURES DURING LIFETIME
CALCIFIED TISSUE INT. 2004; 74: S128-S128.
Web of Science

 

Roth, M; Fahrleitner, A; Piswanger-Solkner, CJ; Obermayer-Pietsch, B; Tiran, A; Leb, G; Dobnig, H A calcium-raising mechanism lowers PTH levels and bone turnover with preservation of bone mass indices in institutionalized elderly at high risk of fracture
OSTEOPOROSIS INT 2004 15: S126-S126.
Web of Science

 

Roth, M; Fahrleitner, A; Piswanger-Solkner, CJ; Obermayer-Pietsch, B; Tiran, A; Leb, G; Maier, E; Dobnig, H Institutionalized elderly type II diabetics have higher bone mass, lower bone turnover markers and PTH levels compared to non-diabetics: Evidence for decreased calcium sensing by parathyroid glands.
J BONE MINER RES 2004 19: S439-S439.
Web of Science

 

Bonelli, CM; Walter, D; Fahrleitner, A; Solkner, CP; Dobnig, H; Linhart, W; Reitinger, T; Windhager, R; Leb, G; Obermayer-Pietsch, B Congenital hip dysplasia and disturbances of bone and connective tissue in adult female patients
BONE 2003 33: S13-S13.
Web of Science

 

Dimai, HP; Piswanger-Soelkner, C; Fahrleitner, A; Ramschak-Schwarzer, S; Wenisch, H; Gugatschka, M; Leb, G Is bone metabolism affected by the human thyroid stimulating hormone TSH? Preliminary results from a clinical study in patients with TSH-suppressive thyroid hormone therapy
BONE 2003 33: S13-S13.
Web of Science

 

Feigl, G; Weigl, V; Fahrleitner, A; Berghold, A; Mokry, M Development of pituitary insufficiency as a side effect of radiosurgery of pituitary adenomas: the role of the hypothalamus.
12th European Congress of Neurosurgery; SEP 7-12, 2003; Lissabon. 2003. [Oral Communication]

 

Obermayer-Pietsch, BM; Bonelli, CM; Walter, DE; Kuhn, RJ; Fahrleitner-Pammer, A; Berghold, A; Goessler, W; Stepan, V; Dobnig, H; Renner, W; Leb, G Genetic disposition for adult lactose intolerance, calcium metabolism, bone density, and bone fractures
BONE 2003 33: S12-S12.
Web of Science

 

Obermayer-Pietsch, BM; Hartl, U; Bonelli, CM; Fahrleitner Pammer, A; Piswanger-Sölkner, JC; Maritschnegg, P; Leb, G; Dobnig, H Bone Fractures and Age at Fracture Time is associated with Estrogen Receptor Alpha1 Gene Polymorphisms in institutionalized Patients
30th European Symposium on Calcified tissues; MAY 8-12, 2003; Rome, ITALY. 2003. [Oral Communication]

 

Roth, M; Fahrleitner, A; Piswanger-Solkner, C; Obermayer-Pietsch, B; Leb, G; Dobnig, H Diabetes mellitus in institutionalized patients is associated with higher bone mass measured by ultrasonography as well as lower iPTH levels and markers of bone turnover
BONE 2003 33: S14-S14.
Web of Science

 

Bonelli, CM; Walter, D; Fahrleitner, A; Piswanger-Solkner, CJ; Dobnig, H; Linhart, W; Reitinger, T; Windhager, R; Leb, G; Obermayer-Pietsch, BM Congenital hip dysplasia and disturbances of bone and connective tissue in adult female patients
OSTEOPOROSIS INT 2002 13: S61-S61.
Web of Science

 

Dimai, HP; Mueller, T; Fahrleitner, A; Hermann, J Secondary osteoporosis in rheumatoid arthritis: Early onset and effective inhibition of bone resorption after a single infusion of the TNF-alpha antibody infliximab
OSTEOPOROSIS INT 2002 13: S25-S26.
Web of Science

 

Dimai, HP; Mueller, T; Fahrleitner, A; Hermann, J A single infusion of the tumor necrosis factor-alpha antibody infliximab suppresses bone resorption in patients with rheumatoid arthritis.
J BONE MINER RES. 2002; 17: S274-S275.
Web of Science

 

Dobnig, H; Fahrleitner, A; Piswanger-Solkner, CJ; Obermayer-Pietsch, B; Leb, G Prospective evaluation of hip-fracture risk in institutionalized elderly by measurement of ultrasonic velocity at the radius and phalanx.
J BONE MINER RES 2002 17: S188-S188.
Web of Science

 

Fahrleitner, A; Dobnig, H; Leb, G; Dimai, HP; Piswanger-Solkner, C; Bonelli, CM; Obermayer-Pietsch, B Osteoprotegerin serum levels in women: Influence of age, bone mass, bone turnover and fracture status
OSTEOPOROSIS INT 2002 13: S52-S52.
Web of Science

 

Fahrleitner, A; Hofbauer, LC; Viereck, V; Obermayer-Pietsch, B; Leb, G; Dobnig, H Serum osteoprotegerin-level as a novel independent predictor of BMD changes after initiation of bisphosphonate treatment in osteoporotic patients
OSTEOPOROSIS INT 2002 13: S12-S12.
Web of Science

 

Fahrleitner, A; Lauermann, T; Schreiber, B; Lewitschnig, S; Leb, G; Obermayer-Pietsch, B; Dobnig, H; Klima, G Intravenous ibandronate 1 mg every three months is an effective and well tolerated treatment option in patients with osteoporosis
OSTEOPOROSIS INT 2002 13: P42-P42.
Web of Science

 

Fahrleitner, A; Prenner, G; Tscheliessnigg, KH; Leb, G; Piswanger-Solkner, CJ; Obermayer-Pietsch, B; Dimai, HP; Dobnig, H Testosterone supplementation has additional benefits on bone metabolism in cardiac transplant recipients receiving intravenous bisphosphonate treatment: A prospective study.
J BONE MINER RES 2002 17: SU423-SU423.
Web of Science

 

Obermayer-Pietsch, B; Li, W; Fahrleitner, A; Maritschnegg, P; Piswanger, C; Bonelli, C; Roth, M; Leb, G; Dobnig, H FokI-Polymorphisms of the Vitamin D Receptor Gene are associated with 25(OH)vitamin D levels in elderly Residents of Austrian Nursing Homes
29th European Symposium on Calcified tissues; MAY 25-29, 2002; Zagreb, Croatio. 2002. [Oral Communication]

 

Obermayer-Pietsch, B; Li, W; Fahrleitner, A; Maritschnegg, P; Piswanger-Sölkner, CJ; Bonelli, CM; Leb, G; Dobnig, H Calcium-Sensing Rezeptor Polymorphismus und Calciumstoffwechsel im höheren Lebensalter
7.Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel2002; -7.Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel; APR 25-27, 2002; St. Wolfgang , AUSTRIA. [Poster]

 

Obermayer-Pietsch, BM; Li, W; Fahrleitner, A; Piswanger-Solkner, CJ; Bonelli, CM; Leb, G; Dobnig, H Polymorphisms of the vitamin D receptor and the collagen I alpha 1 genes as genetic risk factors for bone fractures in a high risk population in Austrian nursing homes
OSTEOPOROSIS INT 2002 13: S64-S64.
Web of Science

 

Bonelli, CM; Fahrleitner, A; Walter, D; Stepan, V; Piswanger-Solkner, CJ; Dobnig, H; Leb, G; Obermayer-Pietsch, B Osteoporosis and bone metabolism in premenopausal patients with congenital hip dysplasia
BONE 2001 28: S191-S191.
Web of Science

 

Dobnig, H; Fahrleitner, A; Prenner, G; Tscheliessnig, KH; Piswanger-Solkner, C; Leb, G Serum osteoprotegerin is a major determinant of bone density and vertebral fracture status in patients after cardiac transplantation
BONE 2001 28: S97-S97.
Web of Science

 

Fahrleitner, A; Obernosterer, A; Pilger, E; Kudlacek, S; Hoffmann, A; Weber, K; Obermayer-Pietsch, B; Leb, G; Dobnig, H High prevalence of vitamin D deficiency and low bone mass in patients with advanced peripheral arterial occlusive disease
BONE 2001 28: S210-S210.
Web of Science

 

Fahrleitner, A; Prenner, G; Leb, G; Tscheliessnigg, K; Piswanger-Solkner, C; Dobnig, H Combination therapy with ibandronate and calcitriol is effective in patients following liver transplantation.
J BONE MINER RES 2001 16: S287-S287.
Web of Science

 

Mueller, TJ; Hermann, J; Fahrleitner, A; Yazdani-Biuki, B; Dimai, HP Effects of the anti-TNF-antibody infliximab on markers of bone turnover in patients with rheumatoid arthritis.
ARTHRITIS RHEUM. 2001; 44(9): S232-S232.
Web of Science

 

Obermayer-Pietsch, B; Walter, D; Fahrleitner, A; Stepan, V; Kotschan, S; Berghold, A; Leb, G Bone mineral density, fracture status, bone metabolism and genetic background of osteoporosis in 350 mother-daughter pairs
BONE 2001 28: S191-S192.
Web of Science

 

Fahrleitner, A; Prenner, G; Kniepeiss, D; Tscheliessnigg, KH; Stach, L; Piswanger-Solkner, C; Leb, G; Dobnig, H Evidence for continued bone loss after cardiac transplantation - A cross sectional study in 53 patients
OSTEOPOROSIS INT 2000 11: 379-379.
Web of Science

 

Fruhwald, FM; Fahrleitner, A; Maier, R; Watzinger, N; Klein, W Long-term treatment of pulmonary hypertension with inhaled iloprost and its effect on natriuretic peptides
EUR HEART J 2000 21: 596-596.
Web of Science

 

Piswanger, CJ; Fahrleitner, A; Prenner, G; Kniepeiss, D; Tscheliessnigg, KH; Leb, G; Dobnig, H Liver transplantation and prevalence of osteoporosis and secondary hyperparathyroidism: First observations on osteoprotective treatment.
J BONE MINER RES 2000 15: S430-S430.
Web of Science

 

Dobnig, H; Friedl, G; Piswanger-Solkner, C; Berghold, A; Scherubel, C; Fahrleitner, A; Obermayer-Pietsch, B; Leb, G SOS-HIP study: Design of a 3-year hip-fracture prevention trial in institutionalized high-risk patients using ibandronate, calcium and vitamin D.
J BONE MINER RES. 14: 298-298.
Web of Science

 

Fahrleitner, A; Prenner, G; Kniepeiss, D; Tscheliessnigg, KH; Dimai, HP; Leb, G; Dobnig, H Influence of cardiac transplantation (CTX) on laboratory parameters, bone mineral density (BMD) and vertebral fracture rate.
J BONE MINER RES 1999 14: S389-S389.
Web of Science

 

Friedl, G; Roth, M; Timischl, C; Fahrleitner, A; Obermayer-Pietsch, B; Leb, G; Dobnig, H The effect of age on the response of bone to parathyroid hormone in rats.
J BONE MINER RES 1999 14: S308-S308.
Web of Science

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum